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ABSTRACT 
 
Over three decades ago, W.H.O. declared infertility as a public health issue; due to its impact 
on millions of people worldwide. While cases of infertility could be multifactorial (affecting 
both male and female), 50% of cases are due to male factor infertility and this is mostly 
characterised by reduced sperm motility (asthenozoospermia). Assisted Reproduction 
Technology (ART) is the only treatment option available for this condition. Over 20 years 
ago, non-selective phosphodiesterase inhibitors (PDEi), such as pentoxifylline, were shown 
to enhance motility of human spermatozoa; however, contradictory results and stimulation of 
premature acrosome reaction has precluded their clinical use. Advancement in our knowledge 
have now made it clear that human sperm express several different PDEs and these are 
compartmentalised at different regions of the cells. By using type-specific phosphodiesterase 
inhibitors, differential modulation of sperm motility can be achieved without affecting other 
sperm function such as acrosome reaction. Additionally, by enhancing sperm function 
through PDE inhibition, there is a possibility of increasing IVF rates. The objective of this 
thesis is to: (1) examine the effect of phosphodiesterase inhibitors on spermatozoa in order to 
identify compounds that have clinically relevant enhancement of human sperm motility; (2) 
identify the signalling pathway(s) involved in the motility enhancing effects of identified 
compounds by targeting the modulator and mediator of cyclic nucleotides; (3) develop an 
animal IVF model to assess effects of Ibudilast on fertilization; and (4) optimise high 
performance liquid chromatography (HPLC) techniques for routine detection of cyclic 
nucleotides in sperm cells. A two phase drug screening approach was used to systematically 
and comprehensively screen series of compounds in order to identify those that have 
clinically relevant enhancement of human sperm motility. In phase 1, 6 compounds (out of 43 
compounds) were found to have strong effects on poor motility samples, with magnitude of 
response ≥60% increase in percentage total motility. Additionally, these compounds 
significantly enhanced sperm penetration into cervical mucus substitute (p≤0.05), and they 
did not affect sperm acrosomal integrity nor cause externalisation of phosphatidylserine 
(p=0.6 respectively). 63% of IVF samples treated with compounds #26, #37 and #38 had 
significant increase in percentage total motility. For ICSI samples, compounds #26, #37 and 
#38 were the most effective. In respect to total motility, 88%, 81% and 79% of samples 
treated with these compounds showed significant increases in total motility, and 94%, 93% 
and 81% of samples showed significant increases in percentage of progressive cells, 
vi 
 
respectively. Analysis of the signalling pathways, using PKA, sGC and PKG inhibitors, 
showed that chosen PDE inhibitors were working predominantly through PKA signalling 
pathways. Additionally, this study revealed that this pathway is needed for the maintenance 
of basal progressive motility and hyperactivation in human sperm.  Animal IVF studies 
showed that addition of Ibudilast (compound #26) during sperm-oocyte incubation leads to 
higher IVF rates. Lastly, this study used an HPLC system to detect cAMP in boar sperm. This 
was done to explore if HPLC system can be used for high throughput detection of cyclic 
nucleotides in mammalian sperm.   
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Chapter 1.  
                                   General Introduction
2 
 
1.1 Infertility and ART 
 
Infertility remains a global epidemiological issue; and more couples are having trouble 
conceiving naturally.  On average, the conception rate of “normal” fertile couples is 30% per 
month or approximately 85% per year and in circumstances where this rate reduces, couples 
are considered to be infertile. In the clinical sense, infertility is regarded as a disease of the 
reproductive system characterised by the failure to achieve a clinical pregnancy after twelve 
months of regular unprotected sexual intercourse (Cooper et al., 2010). Most cases of 
infertility can be categorised into: disorder of the female genital tract, disorders of ovulation, 
spontaneous abortion and seminal inadequacy. Although there are discrepancies in literature 
regarding the incidence of infertility, depending on what is considered reproductive success 
(e.g. pregnancy, on-going pregnancy and live birth) or definition of infertility (e.g. percentage 
of couples failing to conceive or time to pregnancy), male factor infertility is considered the 
single most common cause of infertility. Excluding regional variation, it is estimated that 3.7 
million people (that is 1:7 couples) are affected in the UK (NICE 2013; HFEA 2013). 
Furthermore, male reproductive dysfunction is predominantly the main diagnosis in patients 
seeking treatment compared to other factors (Figure 1-1) and assisted reproductive 
technologies, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) 
are used to overcome some male factor infertility problems (HFEA 2013). 
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With advances in assisted reproductive technology there has been an increase in success rates 
and there is less social and ethical stigma associated with this procedure. However, its 
economic and health consequences present issues for policy makers and health practitioners 
alike. In vivo, the female reproductive tract has been adapted to ensure the best sperm cells 
with the best genetic material are the ones with the best chance of fertilizing an egg. 
Although procedures such as ICSI and IVF effectively eliminate most male factor infertility 
issues (low sperm count or poor motility) by introducing sperm cells directly into or close to 
the proximity of an egg, they exclude the natural process of sperm selection in the female 
reproductive tract. Additionally, these procedures are now commercially driven and 
indiscriminate use without adequate diagnosis, even though there is no strong research 
evidence, has been associated with increased risk of developmental and congenital diseases 
Figure 1-1: Graph indicating reasons for patients undergoing infertility 
treatment in 2013 in the UK (HFEA, 2013). Data shows male factor infertility 
as one of the most common cause of infertility. 
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(Funke et al., 2010, Davies et al., 2012). Therefore, it’s only with better understanding of 
different mechanisms, such as initiation of motility, capacitation, acrosome reaction, 
penetration and fusion with eggs, which regulates or is involved in sperm functions that male 
infertility could be appropriately diagnosed and treated. 
Spermatozoa undergo complex developmental/ maturation processes as a result of interaction 
with the microenvironment in which they are produced and migrate. Immediately after 
ejaculation, mammalian sperm are unable to fertilize an oocyte. In vivo, the ability for 
fertilization is acquired in the female reproductive tract after further maturational process 
termed ‘capacitation’ (Austin, 1951, Chang, 1951). The process of sperm capacitation is still 
not completely understood; however, it involves plasma membrane reorganization resulting 
in increased membrane permeability, alkalization of sperm cytoplasm due to ion fluxes and 
activation of second messenger systems (A.P. Harrison and Gadella, 2005, Abou-haila and 
Tulsiani, 2009, Bou Khalil et al., 2006, Cross, 2004). After capacitation, spermatozoa must 
be able to bind the extracellular matrix of the egg (zona pellucida (ZP)) which leads to 
exocytosis of acrosomal content (induction of acrosome reaction) and finally, penetration and 
fusion with the vitelline membrane of an egg. 
Although not fully characterised, many of the signal transduction pathways associated with 
sperm capacitation and acrosome reaction have been identified. It is widely acknowledged 
that extracellular calcium ions play a crucial role in the process of capacitation and acrosome 
reaction in mammalian spermatozoa (see section 1.3.2.1 and 1.5). In addition to this, there is 
evidence for increased intracellular cyclic nucleotides level (see section 1.3.3.1), activation of 
protein kinase A (PKA) (see section 1.3.3.3) and an increase in protein tyrosine 
phosphorylation (see section 1.3.3.3).  
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1.2 Spermatogenesis 
Spermatogenesis is a complex, hormonally regulated, process of male germ cell proliferation 
and differentiation in the seminiferous tubules. This process is initiated at puberty and it is 
controlled by the pulsatile hypothalamic release of gonadotropin-releasing hormone (GnRH), 
follicle stimulating hormone (FSH) and luteinizing hormone (LH), which influence both the 
endocrine and paracrine stimulation of spermatogenesis. Within the testis, LH stimulates 
Leydig cells to synthesise testosterone, which with FSH, acts on Sertoli cells and other 
peritubular cells to release factors that fuel spermatogenesis(de Kretser et al., 1998). 
The duration of spermatogenesis is estimated to be within 74 days in humans (Johnson, 1986) 
(41 days in boars (Franca et al., 2005)) and it involves three distinct phases, that is, 
spermatocytogenesis, spermatidogenesis and spermiogenesis. Spermatocytogenesis is a 
proliferative or a mitotic phase where non-differentiated spermatogonia give rise to two 
daughter cells (type A and B spermatogonia). While type A spermatogonia remain as stem 
cells, type B spermatogonia proliferate by mitosis to yield primary spermatocytes which go 
on to form secondary spermatocytes (meiosis I) (Phillips et al., 2010). The latter then 
proceed(s) to form round spermatids, in a process referred to as spermatidogenesis, during 
meiosis II. This cell division leads to conversion of diploid chromosomes in spermatocytes to 
haploid chromosomes in spermatids. Lastly, spermatids undergo dramatic transformation, 
during spermiogenesis, into streamlined spermatozoa adapted for fertilization (Figure 1-2).  
This transformation involves profound nuclear condensation and the movement of the 
nucleus to the periphery of the cell, formation of acrosomal cap which overlays the nucleus, 
and development of the flagellum responsible for sperm motility. The acrosome is derived 
from the Golgi apparatus and it contains secretory granules which are released during the 
fertilization process. It should be mentioned, however, that there are characteristic species-
specific differences regarding the size, and shape of mammalian spermatozoa. 
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After transformations that occur through spermiogenesis, the functionally incompetent but 
anatomically “complete” spermatozoa are released into the long convoluted tubule known as 
the epididymis. The structure to function and biochemical characteristics of the epididymis 
have been highlighted in many reviews (Cooper, 2010). The human epididymis is segmented 
into eight sections (efferent ducts, anterior caput, posterior caput, anterior corpus, mid corpus, 
posterior corpus, anterior cauda, posterior cauda and ductus deferens) with distinct gene 
expression patterns and secretions into the intraluminal space by epididymal epithelial cells 
(Sullivan et al., 2011, Cornwall, 2009). Although it is widely accepted that it is during the 
passage through the epididymis that mammalian spermatozoa mature and acquire progressive 
motility and potential to fertilize the oocyte (Yeung et al., 1993, Yeung et al., 1997), others 
have argued for the redundancy of the epididymis on the basis of observation that 
spermatozoa from the proximal region of the tract has the potential to fertilize an oocyte both 
in vivo and in vitro (Bedford, 1994). Additionally, the relatively rapid transit that sperm 
undergo, in some cases, along the excurrent duct in men also argues against the notion of 
complex remodelling of sperm during its epididymal transit. Conversely, it has to be stated 
that the study questioning the relevance of epididymis was done in men that had undergone 
vasovasostomy, had a congenital lack of a vas deferens, or had an obstruction along the 
excurrent duct (Bedford, 1994). It has been postulated that the vas deference can possibly 
adapt to take on some of the function of the epididymis after re-anastomosis; overall, both 
proteomics and genomics analyses have given support to the fact that human epididymis does 
have a significant role in the functional maturation of spermatozoa (Cooper, 1993, Dacheux 
et al., 2006, Dacheux et al., 2009). 
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Figure 1-2: The process of spermatogenesis.  
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Animal studies have shown that a combination of low pH (<6.5) (Carr et al., 1985, Carr and 
Acott, 1984), low concentrations of sodium (Na+) and high concentrations of potassium (K+) 
(Cooper, 2010) or the presence of viscous mucoproteins in the epididymis (Mitra et al., 2010) 
(depending on species) are the primary mechanisms for maintaining the quiescence of mature 
spermatozoa prior to ejaculation. Upon ejaculation, spermatozoa become motile when they 
mix with the constituents of seminal plasma; this results in initiation of progressive motility. 
Sperm motility at this time is characterised by relatively low-amplitude, symmetrical tail 
bending when compared with the high amplitude, asymmetrical tail bending characteristic of 
hyperactivation (see section 1.4), which is observed close to the site of fertilization (Suarez 
and Pacey, 2006, Suarez, 2008). Although progressively motile, the cells are functionally in 
an inactive state without capacity to fertilize an oocyte. 
1.3 Sperm Capacitation 
Over six decade ago, two independent studies performed by Austin and Chang (Chang, 1951, 
Austin, 1951) showed that sperm cells need a period of incubation in the female reproductive 
tract to acquire the capacity to effectively fertilize an oocyte. The morphological and 
biochemical changes that occur between sperm deposition in the female reproductive tract 
and fertilization occurring is termed ‘capacitation’ (Austin, 1952). Although there is debate 
over which processes are encompassed by capacitation, some investigators stress the 
separation of capacitation and acrosome reaction (Chang, 1984). It is widely accepted that the 
capacitation process involves an increase in protein tyrosine phosphorylation, the acquisition 
of acrosomal responsiveness, and alterations in flagellar motility; which may be involved in 
the penetration of the zona pellucida. Despite the discovery of capacitation over 60 years ago, 
we have only recently begun to underpin, through in vitro studies, the molecular and 
biochemical modification that leads to capacitation. In many species, alterations in 
intracellular pH and calcium level are observed. Capacitation is also associated with 
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bicarbonate-sensitive increase in cAMP level, a nucleotide that is involved in the regulation 
of sperm motility, due to the presence of soluble adenylyl cyclase (sAC) (Figure 1-3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1-3: Intracellular signalling pathways involved in regulating sperm capacitation: 
Incubation of un-capacitated sperm under capacitating conditions gives rise to changes in 
the permeability of the sperm to Ca2+ and HCO3
− via a change in membrane ﬂuidity or 
membrane destabilization.  These changes in membrane properties are thought to occur 
by the loss of cholesterol from the membrane; this loss may be accelerated by the 
presence of serum albumins, which can bind cholesterol. As a consequence of the 
increase in Ca2+ and HCO3
− permeability, cAMP metabolism is altered. This could occur 
by the Ca2+ and/or HCO3
− induced activation of adenylyl cyclase (AC), resulting in an 
increase in intracellular cAMP. The increase in cAMP then results in the activation of 
protein kinase A (PKA) which leads to phosphorylation of serine/threonine 
phosphorylation (Ser/Ther-P), activation of sperm tyrosine kinase(s) and/or inactivation 
of phosphoprotein phosphatases (PTP), the net result being an increase in protein tyrosine 
phosphorylation. As a consequence of an increase in protein tyrosine phosphorylation, 
events leading to capacitation and/or hyperactivation of motility are initiated.  
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1.3.1 Cholesterol Efflux and Initiation of Capacitation 
Early events in the process of capacitation involve a major reorganization of the plasma 
membrane and the removal of cells from the decapacitating factors found in the seminal 
plasma. Seminal plasma contains decapacitating factors, such as semenogelin, that have 
regulatory influences on preventing sperm capacitation while maintaining the cells in a state 
of preparedness for capacitation (Cross, 1998, Mitra et al., 2010). For human spermatozoa, 
removal of unesterified cholesterol is a must before they can become responsive to an inducer 
of the acrosome reaction such as progesterone (Zarintash and Cross, 1996, Khorasani et al., 
2000). It was suggested, although still debatable, that cholesterol regulates sperm function by 
preventing the exposure of specific antigens, such as the mannose-ligand, on the surface of 
plasma membrane (Martínez and Morros, 1996, de Lamirande et al., 1997b, Cross, 1998). 
The extraction of cholesterol has been proposed to cause mannose receptors to migrate into 
the phospholipid bilayer.  
In a study examining the levels of cholesterol and phospholipids of fertile and unexplained 
infertile men, the cholesterol/phospholipid ratio in sperm of patients with unexplained 
infertility was found to be about twice that of fertile donors (Sugkraroek et al., 1991). 
Furthermore, sperm of normozoospermic men who failed to fertilize eggs in vitro were also 
found to be characterised by abnormally high cholesterol content or by a slow loss, or even 
an increase, in cholesterol during in vitro incubation (Benoff et al., 1993). The efflux of 
cholesterols from the plasma membrane changes membrane potentials, and increases 
membrane permeability and fluidity, this then allows an influx of ions; leading to the 
activation of secondary messengers such as cyclic adenosine monophosphate (cAMP) 
(Visconti et al., 1999a, Visconti et al., 1999b). 
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1.3.2 Ion Fluxes through Sperm Ion Channels  
As mentioned above, efflux of cholesterol alters the fluidity and permeability of the plasma 
membrane and this leads to influx of ions (especially Ca2+ and HCO3
- ions) into the 
intracellular domain of the cells. This influx of ions, mediated through the activation of ion 
channels, causes elevation of intracellular pH and initiation of signal transductions. 
1.3.2.1 Calcium, CatSper Channel and Ca2+Stores 
Increase in intracellular Ca2+ ion is one of the main biochemical changes that occurs during 
sperm capacitation. There is accumulating evidence to suggest the prerequisite need of Ca2+ 
ion to modulate several events, including hyperactivation (Suarez, 2008), chemotaxis and 
acrosome reaction (Kirkman-Brown et al., 2002), in many species. As a result of new 
approaches and advances in the field, the mechanism by which Ca2+-permeable channels 
participate in fertilization due to their distinctive localisation at different segments of the  
sperm cell are being elucidated (Darszon et al., 2005, Ren and Xia, 2010, Kirichok and 
Lishko, 2011, Kirichok et al., 2006). Since calcium is involved in many of the sperm cell 
processes; calcium homeostasis is crucial to sperm function in order to prevent premature 
initiation of signalling. The spatial distribution of these channels might have a physiological 
function of fine-tuning cell response to calcium influx; since different steps of fertilization 
have distinctive Ca2+ requirements (Marin-Biggiler et al., 2003, Bedu-Addo et al., 2008). 
A sperm specific, pH sensitive ion channel has been localised in the principal piece region of 
human and mouse sperm tail (Quill et al., 2001, Ren et al., 2001, Navarro et al., 2008). The 
CatSper channels (CatSper1-4 Cationic channel of sperm), are putative transmembrane Ca2+ 
ion –channels with at least three auxiliary subunits: CatSperβ, CatSper δ, and CatSper γ 
(Chung et al., 2011, Liu et al., 2007, Wang et al., 2009). CatSper is synergistically activated 
by elevation of intracellular pH and extracellular progesterone (Lishko et al., 2011, Strünker 
et al., 2011, Nishigaki et al., 2014). Advances in mature sperm electrophysiology, through 
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whole-cell patch clamp technique, is elucidating the role of CatSper in influencing sperm cell 
behaviour (Kirichok and Lishko, 2011). CatSper has been identified as the only active 
calcium conductance present in mouse and human spermatozoa. The importance of this 
channel in relation to sperm function was confirmed by the generation of CatSper knockout 
mice. As a result of reduced ability to constitutively transport extracellular Ca2+ into the cells, 
sperm from these animals exhibit impaired motility and inability to hyperactivate, 
consequently, the animals were infertile because their sperm cells were unable to penetrate 
the zona pellucida of the oocyte. Also, studies have identified CatSper 1 and 2-mutations in 
human sperm and they revealed that the disruption to this gene is associated with male 
infertility (Hildebrand et al., 2010, Avenarius et al., 2009, Smith et al., 2013).  
In a recent study by Tateno et.al the significance of Ca2+ was highlighted. In this study, by 
exposing mouse sperm to Ca2+ ionophore (20 μM), a compound that introduces a hydrophilic 
pore into the membrane, Tateno et.al suggested that short elevation of intracellular Ca2+ 
overcomes other necessary signalling pathways (Tateno et al., 2013). Although the results of 
this study are interesting, because A23187-treated spermatozoa recovered motility, showed 
hyperactivation, and were able to fertilize cumulus-intact eggs independent of cAMP-PKA 
pathway activation, the treatment conditions do not mimic in vivo conditions regarding 
calcium levels in the female reproductive tract and it betrays the time-dependence process of 
capacitation. It has to be made clear, however, that this observation has only been recorded in 
the mouse model.  
In addition to extracellular Ca2+ influx via CatSper, evidence from human and animal studies 
showed that Ca2+ intracellular storage organelles are alternative sources of Ca2+ within the 
cells (Alasmari et al., 2013b, Costello et al., 2009, Bedu-Addo et al., 2008). Although the 
endoplasmic reticulum, which serves as Ca2+ store in somatic cells, is lost in sperm during 
spermatogenesis, the acrosome and the membranous organelles found at the sperm 
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neck/midpiece, serve as Ca2+ stores in sperm. Studies have shown that neck/midpiece Ca2+ 
store mobilisation is required to sustain sufficient Ca2+ elevation during CatSper channel 
mediated Ca2+ tail to head propagation (Olson et al., 2010). Mobilisation of stored Ca2+ in the 
neck/midpiece region of sperm is achieved through activation of two major intracellular 
receptor-operated Ca2+ channels: inositol triphosphate receptors (IP3Rs) and ryanodine 
receptors (RYRs) (Ho and Suarez, 2001, Park et al., 2011). A recent study by Alasmari et. al., 
using a combination of incubation conditions and pharmacological agent (activator and 
inhibitor of CatSper),  showed  that mobilisation of  Ca2+ store at the sperm neck region 
induces a functionally different effects in human sperm and this is different to effects 
observed during CatSper activation. This study concluded that Ca2+ signalling as a result of 
Ca2+store mobilisation stimulates flagellar activity and supports  hyperactivation in human 
sperm (Alasmari et al., 2013b). The results from this study further highlight the complexity of 
signalling in human sperm and how distinct functions and behaviours are achieved through 
the activation and regulation of different pathways. 
1.3.2.2 Bicarbonate Ions 
Numerous studies have also shown that capacitation and many other sperm functions are 
bicarbonate (HCO3
-) dependent (Lee and Storey, 1986, Boatman and Robbins, 1991, Shi and 
Roldan, 1995, Okamura et al., 1985).  While a speciﬁc carrier protein responsible for the 
transport of bicarbonate into the sperm cell has not been unequivocally identiﬁed, the ability 
of 4,4-diidothiocyanatostilbene-2,2-disulfonic acid (DIDS), a well-known inhibitor of anion 
transporters, to inhibit the actions of HCO3
– on various sperm functions suggests that sperm 
contain functional anion transporters (Okamura et al., 1988, Visconti et al., 1999c, Spira and 
Breitbart, 1992). In the female reproductive tract spermatozoa are exposed to higher 
bicarbonate levels, due to tubal epithelia secretions (Wang et al., 2003, Liu et al., 2012, Zhou 
et al., 2005), and this may influence the process of capacitation and hyperactivation. The 
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main functions attributed to the transmembrane movement of HCO3
– are increase in 
intracellular pH, which might enhance the activity of transmembrane protein such as CatSper 
channel, and regulation of cAMP metabolism through stimulation of a unique type of 
adenylyl cyclase (sAC) (Visconti et al., 1999c). 
1.3.3 Signal Transduction 
1.3.3.1 cAMP and cGMP 
Increase in the intracellular level of both HCO3
- and Ca2+ leads to stimulation of adenylyl 
cyclase (AC) activity in sperm. Ten isoforms of AC have been identified in mammalian cells 
and adenylyl cyclase in sperm has been the subject of multiple studies. There are conflicting 
data about the nature of the mammalian sperm adenylyl cyclase. In fact, despite some studies 
describing the presence of the classical membrane adenylyl cyclase (mAC) (Leclerc and 
Kopf, 1995, Baxendale and Fraser, 2003, Harrison, 2003), recent findings demonstrate the 
prevalent expression of a distinct soluble adenylyl cyclase (sAC) (Chen et al., 2000, Litvin et 
al., 2003, Sinclair et al., 2000), localised to the flagellar region, which does not possess a 
transmembrane domain, is insensitive to forskolin and G protein regulation and is selectively 
activated by HCO3
- (Hess et al., 2005). Stimulation of sAC generates a rapid and sustained 
increase in intracellular cyclic AMP levels which specifically activate protein kinases in 
different cellular compartments. 
The role of cyclic adenosine 3', 5’ monophosphate  to indirectly influence mammalian sperm 
motility through activation of PKA is well established. In contrast, potential roles for cyclic 
GMP (cGMP) in mammalian sperm are less clearly defined. Cyclic GMP is produced from 
GTP as a result of a catalytic reaction by guanylyl cyclase (GC). GC is expressed both in 
soluble (sGC) and membrane (mGC) isoforms. The soluble isoform of guanylyl cyclase 
(sGC) contains a prosthetic heme group which has affinity for diffusible gases such as nitric 
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oxide (NO) and carbon monoxide (Wedel and Garbers, 2001). Consequently, NO can activate 
GC and thereby stimulates cGMP production. Indeed, human sperm has been found to 
contain nitric oxide synthase and endogenous production of nitric oxide has been suggested 
to be beneficial to human sperm motility through the activation of cyclic GMP/protein kinase 
G signalling pathway (Lewis et al., 1996, Miraglia et al., 2011). However, the beneficial 
effects of NO are only seen at a low concentration; with higher concentration having an 
adverse effect on spermatozoa as a result of NO acting as a free radical that cause direct 
oxidative damage to sperm cells (Rosselli et al., 1995, Zini et al., 1995). 
In a study by Willipinski-Stapelfeldt et. al, the mean concentration of cGMP (0.1µM) was 
found to be 100-fold lower than that of cAMP in non-stimulated cells (107 cells). This result 
suggests that cAMP-dependent pathway might predominantly regulate motility and it further 
affirms the consideration that the cGMP-dependent pathway plays a comparatively minor 
role in normal mammalian sperm motility (Willipinski-Stapelfeldt et al., 2004). Additionally, 
reports on mammalian sperm cyclic nucleotide-gated ion channels that respond to cGMP 
(Ren et al., 2001, Weyand et al., 1994, Wiesner et al., 1998) and the identification of novel 
ion channels that are expressed specifically in sperm (Quill et al., 2001) raise the possibility 
that such proteins represent important target molecules for cGMP in human sperm. 
1.3.3.2 Phosphodiesterase and Phosphodiesterase Inhibitors 
Since cyclic nucleotides play a major role in mammalian sperm motility, regulating their 
levels are crucial (1) in order to prevent unwanted fluctuation in sperm motility, (2) to 
prevent premature hyperactivation, capacitation or acrosome reaction. The required 
equilibrium is achieved in mammalian spermatozoa by regulating the synthesis of cyclic 
nucleotides, through sAC and sGC, and degradation through phosphodiesterases. Cyclic 
nucleotide phosphodiesterases (PDE) are a family of enzyme that hydrolyses, cAMP and 
cGMP, to inactive 5′AMP and 5′GMP respectively. Mammalian PDEs are subdivided into 11 
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families, comprising 21 different gene products, with each member exhibiting a substantial 
difference in primary structure, tissue distribution and substrate specificity: some hydrolysing 
only cAMP (PDEs 4, 7 and 8), or cGMP (PDE 5, 6 and 9) and some hydrolysing both cAMP 
and cGMP (PDE 1, 3, 10 and 11) (Figure 1-4) (Francis et al., 2011).  Therefore, the 
expression profile of PDEs within a given cell may determine the type of cyclic nucleotide 
hydrolysed in that cell or its subcellular regions. Besides, many of the PDE forms expressed 
in mammalian tissues are closely related to different physiological functions and pathological 
conditions. Hence, selective targeting of specific PDEs is a therapeutic means of treating 
some disease states (Gazzaruso et al., 2008, Vardi and Nini, 2007, Lipworth, 2005).   
Currently, little is known about the presence, activity and subcellular localisation of specific 
PDE families in human spermatozoa. There is evidence for the presence of more than one 
isoform of PDEs in spermatozoa. A study by Richter et. al, reports the presence of mRNA 
transcripts of 6 types of PDE in ejaculated human spermatozoa (PDE 1A/B/C. 2, 3A/B, 
4A/B/C, 5 and 8). However, since spermatozoa are considered to be transcriptionally and 
translationally quiescent, the role of these mRNAs in ejaculated spermatozoa is unclear 
(Richter et al., 1999). On the other hand, use of PDE inhibitors (PDEi) and the resultant 
stimulation of hyperactivation, capacitation and acrosome reaction has confirmed a role for 
PDEs in the control of sperm functions (Visconti et al., 1995b, Leclerc et al., 1996a, Fisch et 
al., 1998). PDE activity has been found in the head and flagellum of human spermatozoa 
respectively. Using selective inhibitors of PDE 1 and 4, MMPX and Rolipram, Fisch et al 
have reportedly identified these PDEs in human spermatozoa and they suggest they play a 
role in the acrosome reaction and motility respectively (Fisch et al., 1998). The expression of 
PDE 1 and 4 has also been reported in mouse spermatozoa (Yan et al., 2001, Geremia et al., 
1984, Rossi et al., 1985) and rat spermatozoa (Geremia et al., 1982, Naro et al., 1996). Using 
the inhibitor of PDE3 and PDE5 (Milrinone and Sildenafil), Lefièvre et al. has also suggested 
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the presence of these PDE’s in ejaculated human spermatozoa; although PDE5 was said to be 
present at very low levels (Lefièvre et al., 2000, Lefièvre et al., 2002a). 
Although it is known that cyclic nucleotides, such as cAMP, are essential for sperm 
functions, the concept of modulating sperm cAMP level through inhibition of PDE activity 
are recently being explored for the treatment of male factor infertility. Pentoxifylline (PTX), 
a non-specific inhibitor of PDE, has been used clinically to stimulate human sperm motility. 
In a clinical study (Yovich et al., 1990), a strong correlation between PTX and fertilization 
rate was observed. Using spermatozoa pre-incubated (30min) with PTX prior to 
insemination, a significant increase in fertilization rate was observed; 20.4% in control group 
vs 47.4% in PTX treated group (Yovich et al., 1990). Also, when PTX was added to sperm 
cells during IUI sperm preparation in a group of asthenozospermic and 
oligoasthenozoospermic patients (101 cycles) a significant (p<0.05) increase in pregnancy 
rate was observed in PTX treated group (27.5%, 40 cycles) in comparison to control group 
(11.5%, 61 cycles) (Negri et al., 1996). Nevertheless, the concentration required to induce a 
motility enhancing effect (1-10mM) has raised concern regarding the use of non-specific 
PDE inhibitors. At this concentration range, others have also reported that the use of non- 
specific PDE inhibitor enhances induced acrosome reaction (Tasdemir et al 1993).  Since 
acrosome reaction represents an important step in sperm-oocyte interaction, premature 
induction is considered detrimental; the fertilizing ability of sperm decreases when the 
acrosome reaction has taken place prior to oocyte penetration, even if there is enhancement of 
motility as a result of PTX treatment (Buffone, et al 2008).  
Finally, since inhibition of PDEs still represents a potential mechanism by which sperm 
cellular processes can be modulated, identification of PDE inhibitor with type specificity is of 
crucial importance in order to eliminate the possibility of other PDEs being inhibited and in 
turn causing detrimental effects. 
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Figure 1-4: Schematic representation of the structure of the 11 cyclic nucleotide 
phosphodiesterase (PDE) families. The family name is reported on the side of each 
structure, and the number in parenthesis denotes the number of genes composing the family 
(Francis et al., 2011).  
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1.3.3.3 PKA and Tyrosine Phosphorylation 
A consequence of increase in intracellular cAMP level is the activation of cAMP-dependent 
kinase (PKA). The presence and activity of PKA has already been reported in bovine 
(Garbers et al., 1973), mouse (Visconti et al., 1997) and human sperm (Lefièvre et al., 
2002b). Its activity has been reported to be crucial in almost every aspect of sperm function 
that has been analysed so far (Baker, 2011, Taylor et al., 2004). The activation of PKA 
holoenzyme occurs due to cAMP binding to the regulatory subunit of PKA and this leads to 
dissociation of the catalytic (C) subunits. Two isoforms (type I and type II) of this 
holoenzyme are present in sperm cells and type II isoforms are the dominant form of these 
isoenzyme in elongating spermatids while type I are considered to be selectively decreased 
during spermatids development (Landmark et al., 1993, Oyen et al., 1990). RII holoenzyme is 
considered to be held firmly to the flagellum by the A kinase anchoring proteins (AKAPs) 
that serve as scaffolds for PKA. AKAPs localise PKA to specific sites in the cell by docking 
to the N-terminus of the regulatory subunits, thus creating microenvironments for PKA 
signalling that allows for rapid but selective phosphorylation and dephosphorylation of 
targeted proteins (Burton et al., 1999, Taylor et al., 2004). 
However, a study by Burton et al. 1999, produce data to suggest that delocalization of PKA 
by disrupting the RIIα subunit of PKA does not affect mouse sperm motility or fertilizing 
ability. This result is rather unexpected, because one would have thought delocalization of 
PKA would lead to erratic activation which might compromise motility or fertility (Burton et 
al., 1999). The catalytic subunits of PKA have been, nonetheless, demonstrated to be 
important for the enzymatic activity of PKA. Using PKACα knockout mice, (Skalhegg et al., 
2002), showed that these mice had little to no PKA activity in their sperm and although they 
have normal spermatogenesis there is defective progressive motility. Since this observation 
implies that PKACα is the key to the kinase activity of PKA, other catalytic subunits of PKA 
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have been probed.   PKAαII, a catalytic subunit, among others; has been identified to be 
responsible for triggering hyperactivated motility by affecting downstream pathways which 
involve up-regulation of tyrosine phosphorylation in the flagellar region of the sperm cell 
(Nolan et al., 2004b, Baker et al., 2009). PKAαII knockout mice are infertile and this is 
consistence with the presume significant role of hyperactivated motility in penetration of the 
oocyte, in addition; no increase in tyrosine kinase cascade was observed in the PKAαII 
knocked out mouse sperm (Nolan et al., 2004b, Baker et al., 2009).  
Although there is consensus that PKA activity is associated with increase in protein tyrosine 
phosphorylation (Leclerc et al., 1996a, Leclerc et al., 1996b, Visconti et al., 1995a, Aitken et 
al., 1998a), the events occurring between the early activation of PKA (Lefièvre et al., 2002b, 
Visconti et al., 1997) and protein tyrosine phosphorylation are not fully elucidated. As PKA 
is a serine/threonine kinase, it cannot play a direct role in tyrosine phosphorylation and 
therefore must activate tyrosine kinases indirectly (Leclerc et al., 1996a). Studies by Baker et 
al., 2006 and 2009 have implicated two intermediate tyrosine kinases (SRC and c-Abl) that 
respond to PKA activation (Baker et al., 2006, Baker et al., 2009). Both SRC and c-Abl have 
been localised within mouse sperm flagellum, where most capacitation-dependent tyrosine 
phosphorylation occurs (Baker et al., 2006, Baker et al., 2009). Additionally, as cells became 
hyperactivated, autophosphorylation on SRC and c-Abl could be detected in the sperm tail 
and this event could be suppressed with the PKA inhibitor, H89 (Baker et al., 2009). 
However, with the complexity of the cAMP induced tyrosine phosphorylation, that is (1) 
response in terms of the subcellular structures phosphorylated (fibrous sheath, axoneme, 
mitochondrial membranes) and (2) the differential timing of these events, the involvement of 
more than two species of intermediate tyrosine kinase cannot be ruled out (Lin et al., 2006, 
NagDas et al., 2005, Petrunkina et al., 2003). 
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1.4 Hyperactivation 
First observed in hamster sperm (Yanagimachi 1970), hyperactivation (hyper-activated 
motility) is characterised by a high amplitude, asymmetrical flagellar waveform. This form of 
motility pattern has been observed in all eutherian mammalian sperm examined, including 
humans (Burkman, 1984). In most species, these waves develop only on one side of the tail, 
producing asymmetrical flagellar beating and circular or figure-of-eight swimming 
trajectories. Hyperactivation can be observed in situ in transilluminated murine oviducts 
around the time of ovulation and near the site of fertilization (Suarez and Osman, 1987, 
Suarez, 1987). However, hyperactivation has not been observed directly within the human 
oviduct and detailed reports on the swimming patterns of sperm recovered from the human 
oviduct are lacking. Hyperactivated sperm are more efficient at penetrating highly 
viscoelastic media and because sperm do encounter mucus in the oviduct and must also pass 
through the matrix of the cumulus oophorus and the zona pellucida, it is believed that this 
form of motility enables sperm to serves this key function of penetration in vivo (Suarez and 
Pacey, 2006, Pacey et al., 1995). Mouse sperm have been observed to use the deep flagellar 
bends exhibited during hyperactivated motility to turn around within pockets of mucosa and 
escape out into the central lumen (Suarez and Osman, 1987). Also in mouse, only sperm 
exhibiting hyperactivated movement in the oviduct were observed to detach from the 
epithelium (Demott and Suarez, 1992). Human sperm observed detaching from oviductal 
epithelium in vitro showed a greater incidence of hyperactivation than sperm that had not yet 
attached to epithelium (Pacey et al., 1995) 
1.4.1.1 Role of cAMP/PKA and Calcium ion in Hyperactivation 
Despite the importance of hyperactivation to fertilization, little is known of the biochemical 
pathways regulating its expression. The majority of what is known about protein targets that 
are involved in hyperactivation are identified while using demembranated sperm cells. There 
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is evidence that cAMP pathways are involved in signalling the onset of hyperactivation 
(White and Aitken, 1989, Yanagimachi, 1994). Treatment of sperm cells with membrane 
permeable analogues of cAMP or phosphodiesterase inhibitors has been found to enhance 
hyperactivated motility in hamster (White and Aitken, 1989); human (Calogero et al., 1998), 
and monkey sperm cells (Yeung et al., 1999) in vitro. In a recent study, by Yu et al, the 
importance of cAMP pathway in hyperactivation was further emphasized. Male rats that had 
their sAC knockdown by electroporation-mediated shRNAs showed a significant reduction in 
hyperactivation rate. Thus, interfering with sAC expression indirectly regulated the level of 
sperm protein phosphorylation and in turn reduced hyperactivation rate was observed (Yu et 
al., 2013). 
Additionally, it has been demonstrated that Ca2+ signalling involving extracellular Ca2+ is 
critical for hyperactivation. When Ca2+ blockers were added to hyperactivated hamster sperm 
to inhibit hyperactivation, most sperm failed to penetrate the zona even though they remained 
motile and underwent acrosome reactions (Stauss et al., 1995). Increased cytoplasmic 
concentrations of free Ca2+ have also been detected in the flagellae of hyperactivated sperm 
(Ho and Suarez, 2001, Suarez et al., 1993). Put together, this indicates that the predominant 
source of Ca2+ for hyperactivation is through extracellular source. Indeed, male mice that are 
null mutants for CatSper-1, -2, -3 or -4, the main transmembrane channel that transports Ca2+ 
into the intracellular domain, are infertile and the infertility has been correlated to a failure to 
hyperactivate (Ren et al., 2001, Jin et al., 2007, Qi et al., 2007, Quill et al., 2003)  
Demembranated sperm have been used to identify calmodulin (CaM) as the intermediate 
messenger protein that transduces calcium signals during hyperactivation. When calmodulin 
was extracted from bull sperm during demembranation, motility was not reactivated unless 
exogenous CaM was added back to the cell. Addition of 1µM Ca2+ with CaM causes 
hyperactivation in reactivated demembranated sperm. When peptide inhibitors of calmodulin 
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kinase II (CaMKII) were added with the CaM, hyperactivation was reduced by 75%; 
whereas, W-7 or a peptide inhibitor of myosin light chain kinase added with the CaM did not 
inhibit hyperactivation. When KN-93, an inhibitor of CaMKII, was added to intact sperm, 
caffeine-induced hyperactivation was inhibited without impairing normal motility. CaM and 
CaMKII were immunolocalized to the flagellum in bull and mouse sperm (Ignotz and Suarez, 
2005, Schlingmann et al., 2007). A study by Marin-Briggiler identified the presence of 
CaMKIV in the flagellum of human sperm using a monoclonal antibody, however, 
monoclonal antibody against CaMKII did not detect its presence in human sperm (Marin-
Briggiler et al., 2005). It has to be noted, however, that a non-detection of CaMKII as well as 
CaMKI cannot completely negate their presence in human sperm. 
1.5 Sperm-Oocyte Interaction  
The key purpose of capacitation is to ensure that spermatozoa are in the appropriate state to 
fertilize oocytes, by finely controlling the rate of the changes necessary to prime spermatozoa 
and by activating all the mechanisms needed for the acrosome reaction. The acrosome 
reaction (AR) is an exocytotic event that is considered to be essential for fertilization 
(Yanagimachi, 1994). During initiation of the acrosome reaction, a sperm’s plasma 
membrane fuses with the underlying outer acrosomal membrane leading to their fenestration 
and vesiculation, to release the acrosomal contents (Yudin et al., 1988, Yanagimachi, 1994). 
The release of the acrosomal contents, coupled with the thrust provided by the hyperactivated 
beating of its flagellum enables a sperm to penetrate the ZP (Yanagimachi, 1994). Although 
the release of the acrosomal content is crucial to fertilization, because sperm that fail to 
initiate the acrosome reaction cannot penetrate the zona pellucida and hence are denied 
access to the egg plasma membrane (Yanagimachi, 1994), there is debate as to when the 
acrosome reaction actually takes place during sperm-oocyte interaction.  
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For many years it was believed that binding of sperm to the zona pellucida triggers acrosome 
reaction; consequently only sperm cells reaching the egg with an intact acrosome are able to 
fertilize an oocyte (Florman and Storey, 1982, Gupta and Bhandari, 2011, Saling and Storey, 
1979). On the contrary, several studies have also suggested that AR occur before binding to 
the ZP in several mammalian species (Bedford, 2011). In a recent studies using mice as a 
model (Jin et al., 2011, Inoue et al., 2011), it was shown that most fertilizing mouse 
spermatozoa begin their AR prior to making contact with the ZP during in vitro fertilization. 
Additionally, acrosome reacted spermatozoa recovered from the perivitelline space of mice 
were able to fertilize other oocytes (Inoue et al., 2011). These observations challenge the 
model that suggested that acrosome intact sperm needs to bind to the ZP and then acrosome 
react before they can fertilize an oocyte. However, it is important to state that the physiology 
of sperm-oocyte interaction may be species-specific and what applies to mice may not be the 
same for human gametes, therefore, further studies are required to determine the exact role of 
the zona pellucida on the acrosome status of human sperm and when exactly the acrosome 
reaction should take place in order to achieve fertilization. 
The primary in vivo initiator of AR is believed to be a glycoprotein constituent of ZP, 
designated ZP3 (or ZPC) (Wassarman, 1999, Kopf, 2002), although a number of other 
endogenous agents including progesterone (Osman et al., 1989), prostaglandin (E1) (Schaefer 
et al., 1998) and acetylcholine (ACh) (Bray et al., 2002) have been identified to be capable of 
triggering acrosomal exocytosis in vitro.  Induction of AR by these endogenous agents leads 
to a rapid increase in intracellular calcium. ZP3 induce AR by activating  non-selective cation 
channels that lead to membrane depolarization and opening of voltage-sensitive Ca2+ 
channels (Florman et al., 1992, Florman et al., 1989). Similar to ZP3, progesterone can 
induce acrosome exocytosis in human sperm, however, this effect is dependent on the 
presence of extracellular calcium (Blackmore et al., 1990, Blackmore et al., 1991). Calcium 
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has been suggested to directly play a role in the fusion events in sperm membrane. Using ram 
spermatozoa, Watson et al., 1995 studied the temporal and spatial location of intracellular 
calcium during acrosome reaction. Calcium was identified by a pyroantimonate-osmium 
fixation technique and as fusion developed, Ca2+ was evident on the outer acrosomal 
membrane. At later stages, Ca2+ is localised in both post acrosomal dense lamina and on outer 
acrosomal membrane under the equatorial segment (Watson et al., 1995). These findings 
suggest that Ca2+ may be implicated in the fusion process. 
In addition to Ca2+ influx, activation of protein kinases (such as PKA) has been reported 
during sperm acrosome reaction (Lefièvre et al., 2002b). Evidence supporting the 
involvement of PKA during AR also demonstrates increase in adenylyl cyclase activity and 
cAMP production during this process. When capacitated spermatozoa were pre-treated with 
inhibitors of PKA (KT5720), PKC (Calphostin C) and PKG (KT5823), before induction of 
acrosome reaction by solubilized ZP, a significantly lowered percentage of acrosome reacted 
cells was observed in comparison to control (Bielfeld et al., 1994). Also, no significant 
stimulation of the acrosome reaction occurred when kinase stimulators were added to 
spermatozoa which had been pre-treated with inhibitors of the kinases (Bielfeld et al., 1994). 
These findings suggest that protein kinases may be involved in AR. Thus, any compound(s) 
that increases the intracellular availability of cyclic nucleotides may indirectly induce 
acrosome reactions since increase in cyclic nucleotide will lead to increased protein kinase 
activity.  
Indeed, treatment of sperm cells with some PDE inhibitors have been suggested to promote 
acrosome reaction (Fisch. et al., 1998). Using 8-MeOM-IBMX, a PDE 1 inhibitor, Fisch and 
colleagues reported a significant stimulation of sperm acrosome reaction in human sperm. 
However, in the same study, Rolipram (a PDE4 inhibitor) was found to induce a significant 
improvement in sperm motility but in contrast to 8-MeOM-IBMX, Rolipram did not affect 
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the acrosome (Fisch et al., 1998). Nonetheless, there is conflicting data regarding the effect of 
Sildenafil (a PDE 5 inhibitor) on inducing the acrosome reaction. In 2000, Lefièvre, et al 
reported that Sildenafil increases sperm motility, capacitation, protein tyrosine 
phosphorylation but not the acrosome reaction, in contrast, Glenn et al demonstrated that 
Sildenafil induced a significant increase in the percent of acrosome reacted sperm (Lefièvre 
et al., 2000, Glenn et al., 2007). From these results, it can be concluded that differential 
activation by type-specific phosphodiesterase inhibitors might account for the observation 
recorded in these studies (Fisch et al., 1998). In addition, since PDE1 is predominantly 
localised in the sperm head (Lefièvre et al., 2002a) the effect of 8-MeOM-IBMX in relation 
to the induction of acrosome reaction will make sense. In view of the potential to induce 
acrosome reaction, it is important to evaluate the effect of PDE inhibitors in order to 
determine if they affect acrosomal status of human sperm cells. 
1.6 Computer Assisted Motility Analysis  
With the development of computer assisted sperm analyser (CASA), the movement 
characteristics of hundreds of spermatozoa can be objectively assessed, in real time, within 
minutes. With negative phase contrast optics, the system identifies sperm in the field of view 
based on the pertinent settings of sperm head size (length and width) and illumination 
(Mortimer, 1997). Motility parameters are measured by tracking the sperm head as opposed 
to the flagellum; because head movement reflects the beating of the flagellum. For each 
spermatozoon tracked, the system reconstructs a trajectory using the centremost point or the 
brightest region of the sperm head as a reference point and this generates huge information on 
series of kinematic values. The kinematic values proffers information about the distance 
travelled in within a set time period, and is therefore a direct reflection of sperm velocity 
(Figure 1-5).  
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The curvilinear velocity (VCL) is a measure of the overall distance that the sperm head 
travelled in any direction. This is dependent on the frequency of tail beating, and the 
wavelength and amplitude of the flagellar movement (Suarez and Dai, 1992). Average path 
velocity (VAP) is the length of the general trajectory, that is, the distance the sperm head 
travels in the average direction of its movement (Mortimer, 2000).  The straight-line velocity 
(VSL) is the shortest distance between the start and end of the sperm trajectory; it therefore 
describes the displacement of the sperm (Mortimer, 2000). Using the ratio of the velocity 
values, linearity (LIN): (VSL/VCL) x 100, and straightness (STR): (VSL/VAP) x 100, 
additional information that further enhances the distinction between types of motility is 
generated by the CASA system.  The amplitude of lateral head displacement (ALH) is the 
width of the side to side movement of the sperm head and it largely corresponds to the degree 
of bending initiated at the sperm neck (Oehninger and Kruger, 2007). Lastly, combination of 
VCL, ALH and LIN is used to define cells with hyperactivated motility. For human 
Figure 1-5: Schematic representation of the different velocities as measured by the computer 
assisted sperm analysis (CASA) systems.  VSL = straight-line velocity, VAP = average path 
velocity, and VCL = curvilinear velocity. See text for more explanation concerning these 
parameters. 
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spermatozoa, cells analysed at 60Hz and with VCL ≥150µm/s, ALH ≥7µm and linearity 
≤50% are categorised as hyperactivated spermatozoa (Mortimer et al., 1998). 
 
Although CASA systems have their limitations, because cells swimming too tightly are 
difficult to track, it has distinct advantage over manual (eye) motility assessment. As 
mentioned above, it can determine cell velocity with high degree of accuracy, which is 
impossible to achieve by eye, and assessment of hundreds of spermatozoa in less than a 
minute is an added advantage over old methods, such as video micrograph; which are time 
consuming and laborious. Numerous investigators have also addressed whether or not CASA 
measurements could be useful in providing prospective indications regarding sperm 
fertilizing capacity (Barratt et al., 1993, Irvine et al., 1994, Larsen et al., 2000, Verstegen et 
al., 2002). In a study by Donnelly and colleagues, sperm velocity measurements of human 
spermatozoa were shown to correlates with penetration of zona-free hamster eggs and human 
oocytes in vitro (Donnelly et al., 1998). In addition, VCL, VAP and VSL values were 
reportedly higher in samples that achieved ≥50% fertilization compared with ≤50% 
fertilization. In another study investigating the relationships between CASA estimates and 
fertilization rates in vitro, Hirano and colleagues showed that there were significant 
differences in VCL (p < .005), average path velocity (VAP) (p < .005), and Rapid (p < .05) 
between prepared samples (swim-up) of 108 “good” and 28 “poor” fertilization groups 
(Hirano et al., 2001). In conclusion, CASA systems have high levels of precision and 
reliability and they are a great tool to objectively compare sperm motility (based on different 
treatment conditions) and to improve our knowledge and ability to manipulate spermatozoa. 
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1.7 Aims and Objectives 
The aim of this study is to examine the effect of second generation phosphodiesterase 
inhibitors on sperm functionality. The main hypothesis is that phosphodiesterase are involved 
in regulation of sperm functions and by inhibiting phosphodiesterase activity sperm 
functions, such as motility, can be modulated. In the first set of experiments, 43 compounds 
with reported phosphodiesterase inhibitor activity will be screened. Identified compounds 
will then be subjected to further testing with specific reference to (1) Effects on quantitative 
motility, including assessments of penetration into artificial cervical mucus substitutes (2) 
The potential negative effects of these compounds e.g. induction of the acrosome reaction (3) 
Effects of these compounds on patients samples under clinical conditions of treatment. . It is 
hypothesised that by using a two phase drug discovery screening approach compounds that 
have motility enhancing effects on human spermatozoa, without affecting other sperm 
function negatively, can be identified.   In the second set of experiments, studies will be done 
to investigate the effects of promising compounds on cyclic nucleotides levels and the 
potential biological pathway effecting enhancement of motility. Finally, an animal model will 
be developed to assess if increase in motility translates to higher fertilization rate, and high 
performance liquid chromatography (HPLC) techniques will be optimised for routine 
detection of cyclic nucleotides in sperm cells 
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Chapter 2.  
                                Materials and Methods
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2.1 Ethical Approval   
 
Written consent was obtained from each patient (APPENDIX 3) in accordance with the 
Human Fertilization and Embryology Authority (HFEA) Code of Practice (version 8) under 
local ethical approval (08/S1402/6) from the Tayside Committee of Medical Research Ethics 
B. Similarly, volunteer sperm donors (healthy men randomly selected from the general public 
[usually students] with no known fertility problems) were recruited in accordance with the 
HFEA Code of Practice (version 8) under the same ethical approval.     
2.2 Semen Samples  
 
Semen samples from donors and patients were collected by masturbation into a sterile plastic 
container after 2-4 days of sexual abstinence. The samples were used for analysis after 
liquefaction of the semen at 37°C for approximately 30 minutes and within 1 hour of 
production.  Normozoospermic donors were recruited for this study after an initial semen 
analysis based on W.H.O. 2010 criteria for sperm concentration (≥ 15 million/ml) and 
motility (≥ 40% total motility and ≥ 32% progressive motility) (W.H.O., 2010). Semen 
samples obtained from patients were assessed for the semen profile by clinical embryologists 
according to W.H.O. criteria (W.H.O., 2010). Patients were selected for IVF or ICSI 
according to clinical indications and semen quality.   
2.3 Media  
 
A modified Synthetic tubal fluid (Mortimer, 1986) was used as capacitating media (CM): 
1.8 mM CaCl2,5.4 mM KCl, 0.8 mM MgSO4.7H2O,116.3 mM NaCl, 1.0 mM NaH2PO4, 5.55 
mM D-glucose, 2.73 mM sodium pyruvate, 25 mM sodium lactate, 26 mM sodium 
bicarbonate and 3mg/ml BSA. The non-capacitating medium (NCM) was similar to CM but 
without  sodium bicarbonate (NCM): 1.8 mM CaCl2, 5.4 mM KCl, 0.8 mM MgSO4.7H2O, 
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116.3 mM NaCl, 1.0 mM NaH2PO4, 5.55 mM D-glucose, 2.73 mM sodium pyruvate, 41.75 
mM sodium lactate, 25 mM HEPES and 3mg/ml BSA. BSA was added to NCM to prevent 
cells from sticking on the glass slides when taking motility reading on CASA. The osmolality 
of buffers was adjusted to 290-320 mOsm/kg and pH 7.4 was adjusted using 1M NaOH 
solution. TBST (Tris-Buffered Saline and Tween 20) consists of 20 mM Tris, 136 mM NaCl 
and Tween20 (0.1% final conc.). Swim-up media was composed of 97.8mM NaCl, 4.69mM 
KCl, 0.2mM MgSO4, 0.37mM KH2PO4, 2.04mM CaCl2, 21mM HEPES, 21.4mM Lactic 
acid, 2.78mM glucose and 0.33mM Na-pyruvate.  
2.3.1 Density Gradient Centrifugation (DGC) 
2.3.1.1 Donor Sperm Preparation 
Semen samples were produced at home after 2-4 days of sexual abstinence and collected in 
sterile 60ml containers. The samples were used for analysis after liquefaction of the semen at 
37°C for approximately 30 minutes and within 1 hour of production.   An initial assessment 
of sperm concentration and motility was carried out in order to determine the quality of the 
individual semen sample using CASA by placing 4µl of the raw sample on a 20µm depth 
Hamilton-Thorne slide with a 22mm by 22mm coverslip. Two different sperm populations 
were isolated using a 40-80% discontinuous density gradient procedure. Maximally 2 ml of 
semen was loaded after 30 min of liquefaction at 37˚C on the top of a colloidal silica 
suspension (Percoll) made of 80% and 40% layered (2ml each). The density gradient was 
centrifuged at 300g for 20 min at room temperature. The high quality cells form a pellet in 
the 80% fraction and the poor motility population are at the interface of 40-80%; respectively 
called 80% and 40% fraction. Depending on experiment to be undertaken, either the 40% 
fraction or the pellet (80% fraction) was then taken by a Pasteur pipette and placed into 15ml 
conical bottom falcon tube containing 5mls of NCM. Sperm cell fractions were washed in 
NCM by centrifugation for 10 min at 500g and the sperm pellets were resuspended using a 
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NCM or CM at ~20-25x106 cells/ml. The cells resuspended in CM are incubated at 37OC in a 
5% CO2 humidified atmosphere for 3hrs in order to initiate sperm capacitation (Mansour et 
al., 2008, Giojalas et al., 2004). 
2.3.1.2 Patient Sperm Preparation 
Patient samples were produced at the Assisted Conception Unit (ACU) and allowed to 
liquefy in a 37°C incubator within 30 minutes allowing the sperm to become freely motile. 
Sperm preparation for IVF/ICSI/IUI treatment was carried out at the ACU by an 
embryologist and any sample surplus to clinical use (Raw semen sample or IVF/ICSI sample 
used in patient treatment) was used in this study. An initial assessment of sperm 
concentration and motility (as above) were carried out to determine the quality of individual 
samples. The samples were prepared as for donor samples, however commercially available 
media was used for sperm preparation. The 40-80% discontinuous density gradients were 
made using PureSperm (Nidacon, Mölndal, Sweden) diluted with Cook Sydney IVF Gamete 
Buffer, a HEPES buffered solution (Cook Sydney IVF Limited, National Technology Park, 
Ireland, UK). Samples were centrifuged at 300g for 20 minutes. The supernatant was 
discarded, and the pellet washed by centrifugation at 500g for 10 minutes in 4 ml of Cook 
Gamete Buffer. The pellets were resuspended in media depending on whether they were for 
IVF or ICSI/IUI. IVF samples were suspended in pre-equilibrated 1ml Cook Sydney IVF 
Fertilization medium (IVF FM), a bicarbonate buffered medium similar to CM (see media 
above) and ICSI/IUI samples were resuspended in Cook Gamete Buffer similar to NCM (see 
media above).  IVF samples were then incubated at 37°C with 6% CO2 for at least 3 hours in 
order for the samples to capacitate whereas ICSI samples were left at room temperature until 
the time for injection procedure. Following insemination (IVF) or injection (ICSI) the 
remaining portion of the sample was analysed for change in motility and kinematic 
parameters as a result of compound treatment.  
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Figure 2-1: Density gradient preparation: Semen samples were collected by masturbation 
into a sterile plastic container after 2-4 days of sexual abstinence. The samples were 
allowed to liquefy for approximately 30 minutes at 37°C. After liquefaction, 2 ml of 
semen was loaded on top of a colloidal silica suspension (Percoll) made of 80% and 40% 
layered (2ml each). The density gradient was centrifuged at 300g for 20 min at room 
temperature. Depending on experiment, either the 40% fraction or the pellet (80% 
fraction) was then taken by a Pasteur pipette and placed into 15ml conical bottom falcon 
tube containing 5mls of NCM (wash buffer). Sperm cell fraction were washed in NCM by 
centrifugation for 10 min at 500g and the sperm pellet were resuspended using a NCM or 
CM  
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2.3.2 Direct Swim-Up 
 
Direct swim-up technique was used to isolate motile spermatozoa on the basis of their ability 
to swim out of seminal plasma into culture medium. 1ml of liquefied semen was gently 
dispensed at the bottom of a 50ml falcon tube containing 5ml of HEPES buffered swim-up 
media (see 2.3 above for media composition). To increase the surface area of the interface 
between the semen layer and the culture medium, tube was incubated at 45o angle for 1hr at 
37oC in a non- CO2 incubator. After incubation, in order not to contaminate the interface, 3ml 
of the top layer was removed into a new 15ml falcon tube. This was then left at room 
temperature for 1-2hr to form a pellet; and the isolated spermatozoa were resuspended in 
capacitating media or non-capacitating media respectively.  
2.4 Assessment of Sperm Motility 
 
Sperm kinematic were analysed using CASA Hamilton-Thorne HTM-CEROS (version 12), 
which provides individual kinetic characteristics of tracked spermatozoon. At the end of each 
incubation or treatment, aliquot (3µl) of samples were loaded onto pre-warmed 20µm depth 
chamber slide (Conception Technologies) that allow lateral head displacement of 
spermatozoa. This was then placed onto MiniTherm stage warmer (37oC) attached to a 
standard (negative) phase contrast microscope under a low field illumination with x10 
objective. System parameter settings for these analyses were 30 frames at 60 frames per 
second (Hz); minimum contrast 80; minimum size 3 (pixels); upper and lower gates of 0.39 
and 1.4 for intensity, and 0.85 and 4.24 for size, and the default values for non-motile cells 
were 6 pixels and 160 for size and intensity respectively. To ensure error was reduced during 
data acquisition, the playback option was used after each analysis to check cell trajectory 
analysed. Sixteen randomly selected microscopic fields, from two sections of the chamber 
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slide, were examined for each sample. Spermatozoa with average path velocity (VAP) > 
25µm/s and straightness (STR) ≥80% are considered progressive while those with curvilinear 
velocity (VCL) >150 µm/s, amplitude of lateral head displacement (ALH) >7.0 µm, and 
decrease in linearity [(VSL/VCL) x100] LIN <50% are defined as hyperactivated (Mortimer, 
2000, Mortimer et al., 1998). 
 
2.5 Statistical Analysis 
 
Statistical analysis of the effects of different compounds was conducted using analysis of 
variance (ANOVA), and t-test using SPSS 20.0 (Statistical Package for Social Science) 
software, a p-value <0.05 was considered significant. Kolmogorov-Smirnov test was used to 
confirm assumption of normality. Data that were not normally distributed were transformed. 
Homogeneity of variance was tested using Levene’s test. 
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Chapter 3.  
 
Identification of compounds with clinically relevant enhancement 
of human sperm motility  
38 
 
3.1 Introduction 
 
The functional characteristic of spermatozoa is their motility capabilities that allow them to 
penetrate cervical mucus, migrate through the uterus into the fallopian tube and to penetrate 
the oocyte. Among other key semen parameters, such as sperm concentration and 
morphology, sperm motility significantly correlates with fertilization rate in vitro (Liu et al., 
1991, Aitken et al., 1982). In addition, it is one of the key criteria in deciding which type of 
assisted reproductive technology should be performed. Impairment in sperm motility, sperm 
dysfunction, is the single most common cause of infertility (Irvine, 1998, Hull et al., 1985) 
and increasing number of couples are resorting to assisted reproductive technology in order to 
achieve a clinical pregnancy. Depending on the severity of sperm dysfunction, in male factor 
infertility, subjects are allocated to different forms of ART. In mild cases of sperm 
dysfunction, intrauterine insemination (IUI) is considered a more favourable and cost 
effective form of ART while in vitro fertilization (IVF) for moderate and intracytoplasmic 
sperm injection (ICSI) for severe case of sperm dysfunction (Van Voorhis et al., 2001, 
Barratt et al., 2011). 
Currently, there is no clinically approved drug that can be added to spermatozoa in vitro or 
taken by a man in order to improve fertility. Since the early 1970’s, however, many research 
groups have targeted different signal transduction mechanism regulating sperm motility so as 
to increase the fertilizing potential of sperm cells in vitro (Fakih et al., 1986, Hatakeyama et 
al., 2008, Wald, 2008). The cyclic AMP/protein kinase A (cAMP/PKA) pathway is now 
widely thought to have a role in the biochemical mechanism controlling sperm function with 
respect to regulation of motility. Most experimental evidences demonstrating a role for 
cAMP/PKA pathway in regulation of motility are based on observed increase in motility and 
concomitant elevation in intracellular cAMP after inhibition of cAMP catabolic enzymes by 
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phosphodiesterases inhibitors (Aitken et al., 1998b, Battistone et al., 2013, Baxendale and 
Fraser, 2005, Calogero et al., 1998, Leclerc et al., 1996a, Visconti et al., 2002). Non-specific 
phosphodiesterase inhibitors such as caffeine, 3-isobutyl-1-methylxanthine (IBMX), di-
methylxanthine (theophylline) and pentoxifylline (PTX) have been shown to stimulate sperm 
motility and kinematic parameters in cases of severe male factor infertility (Rees et al., 1990, 
Yovich et al., 1990).  
Following reports of motility enhancing effects of methylxanthines; clinical interest in the use 
of these compounds gained popularity in human assisted reproduction. A landmark study 
demonstrated a significant enhancement of fertilization rates when using non-specific PDE 
inhibitor (PTX) (Yovich et al., 1990) and 77 pregnancies were achieved (Yovich, 1993).  
Two IUI studies reported higher pregnancy rates following stimulation with PTX combined 
with IUI but the data were not part of a controlled study (Stone et al., 1999, Negri et al., 
1996). In 1992, another study found both PTX and caffeine to significantly enhance sperm 
motility; however, detrimental effects on other sperm function (such as increased incidence 
of induced acrosome reaction) were reported (Tesarik et al., 1992).  Since acrosome reaction 
is considered an important step in sperm-oocyte interaction, premature stimulation of the 
acrosome reaction is not a desirable effect and it counteract the motility enhancing benefits of 
these compounds. In view of the detrimental effects of non- specific PDE inhibitor and the 
widespread use of ICSI, which subsequently became the treatment of choice in male factor 
infertility, interest in sperm stimulation therapies for IVF/IUI has waned.  
It is now clear that there are multiple forms of PDEs with different kinetic and regulatory 
properties and the regulation of intracellular cyclic nucleotides is therefore largely specified 
by the exact nature and localisation of the expressed PDEs (Francis et al., 2012). Also, human 
spermatozoa have been found to express several different PDEs and these are 
compartmentalised at different regions of the cells (Lefièvre et al.2002). Thus, using type-
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specific PDE inhibitors that enhance motility without compromising other sperm function; it 
might be possible to overcome the limitations (e.g. premature stimulation of acrosome 
reaction) found when using non-specific PDE inhibitors. Surprisingly, in view of the plethora 
of existing and new-generation PDEIs (Francis et al., 2012) there are very few studies 
examining inhibition of specific PDEs on human sperm.  Fisch and colleagues (Fisch et al., 
1998) examined the biological activity of PDE1 and PDE4 in the sperm of 30 sub fertile men. 
PDE4 inhibition (via Rolipram) selectively increased the percentage of motile cells at 2 hrs 
and 24 hours of incubation and the most significant effect was noted on those samples with 
the lowest concentration of motile cells.  PDE1 inhibitors (8-MeIBMX) selectively activated 
the acrosome reaction but this was not the case with inhibition of PDE4.   The data on the 
role of PDE5 is controversial, probably because PDE5 represents only a very small fraction 
of the PDE activity (Lefieve et al., 2002). Biological effects have only been observed using 
relatively high concentrations of PDE 5 specific inhibitors. Induction of the AR (presumable 
due to increase [above a critical threshold] in cGMP) is frequently reported (Glenn et al., 
2007). 
 
3.2 Aims and Experimental Design 
 
The aim of this chapter is to use drug screening approach to systematically and 
comprehensively screen a series of compounds with reported phosphodiesterase inhibitor 
activity, in order to identify key candidates that could be added to human spermatozoa in 
vitro to enhance sperm motility. To achieve this, the experiments were done in two phases. 
Phase 1 involves blind screening of 43 compounds with reported phosphodiesterase activity. 
Compounds that resulted in ≥ 60% increase in total motility were selected for further 
screening: motility and longevity, fertilizing ability and DNA/chromatin damage (Figure 
3-1and Figure 3-2).   
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Figure 3-1 : Schematic diagram of overall experimental design: 43 compounds were identified and 
selected at the Drug Discovery Unit (DDU), University of Dundee. Effect of compounds on the 
kinematic parameter of human spermatozoa was assessed using CASA. Compounds that have 
robust and effective stimulation on sperm motility were selected for further testing to determine 
their effect(s) on sperm function. 
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Figure 3-2: Procedure performed to screen different phosphodiesterase inhibitors in Phase 1. 
Three to four donors were used to isolate sperm cells with poor motility by density gradient 
centrifugation. Following the sperm preparation, spermatozoa were pooled together and 100 µl 
was used to assess quantitative sperm motility with 100 µM final concentrations of compound(s) 
for 20 min in NCM.  
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3.3 Experimental Procedures 
 
3.3.1 Semen Preparation 
 
The sperm samples were from healthy donors and the semen was prepared as described in 
Chapter 2.  
3.3.2 Motility Analysis 
 
Motility was recorded using CASA as described in Chapter 2.  
 
3.3.3 Treatment of Spermatozoa with Compounds 
 
In this study, forty three compounds (Table I) were initially tested before six were selected 
for further screening. The number of compounds tested at a given time was subject to the 
total volume of spermatozoa in suspension on a given day. Sperm sample (99µl) cultured 
under non-capacitating condition (including ICSI samples), were treated with 1µl (final 
concentration 100µM) of compounds and were incubated at 37oC for 20min in a non- CO2 
incubator. However, for sperm under capacitating conditions, after incubation at 37OC in a 
5% CO2 humidified atmosphere for 3hrs, aliquots (99µl) of cell suspension were transferred 
into pre-warmed (labelled) Eppendorf tubes and treated with 1µl of compounds; to give a 
final concentration of 100µM compound(s) and 1% DMSO (control). Immediately after 
treatment, the mixtures were incubated at 37OC in a 5% CO2 humidified atmosphere for 
20min. Change in motility parameter was analysed after 20min using CASA. In brief, 3µl of 
sample were loaded onto two section of a chamber slide (pre-warmed and maintained at 
37OC) and video recording of 16 (randomly selected (minimum of 800 cells)) microscopic 
fields of sperm sample was made over 2min using negative phase contrast microscopy. 
Sperm were tracked and analysed using Hamilton-Thorne HTM-IVOS CASA system.  
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Table I: List of Compounds tested 
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3.3.4 Evaluating the Effect of PDEi(s) on Rate of Sperm Capacitation 
 
The effect of PDEi(s) on rate of sperm capacitation was determined by the ability of 
capacitated sperm to undergo induced acrosome reaction after treatment with calcium 
ionophore (10µM) (Liu and Baker, 1998). Semen collected from healthy donor was 
fractionated by density gradient (Percoll) (see 2.3.1.1 above) and spermatozoa in the 80% 
interface were washed in 1x concentrated NCM by centrifuging at 500g for 10min. CASA 
analysis was perfumed and samples were standardised at 20-25x 106cells/ml after they were 
resuspended in CM. Aliquot of 297µl were incubated with 3 µl of compound (100µM), and 
1% DMSO (control)) for 2hrs at 37oC in 5% CO2 humidified atmosphere. To determine 
capacitation status, aliquot of 50µl were treated with 0.5µl calcium ionophore, A23187 at 
10µM final concentration, or 0.5µl of 1% DMSO (control) for 15min at time 0, 1hr and 2hr 
respectively. Acrosome reacted sperm were identified using fluorescein-labelled Pisum 
sativum agglutinin (PSA). Following incubation with calcium ionophore, 17µl aliquot were 
pipetted onto clean glass slides and allowed to air dry. To permeabilize the plasma and outer 
acrosomal membranes, slides were fixed in 100% methanol at room temperature for 20-
30min, were gently washed twice with 100µl TBST (Tris-Buffered Saline and Tween 20) and 
were then labelled with 80µl 1µg/ml FITC-PSA (Sigma L0770) for 30min at room 
temperature in a dark moist chamber (Cross NL, 1986). Slides were then washed with TBST 
to remove excess FITC-PSA and mounted with hydromount (National Diagnostics NS-106). 
AR assays were evaluated with a ﬂuorescence microscope (excitation ﬁlter 450–490 nm, 
emission ﬁlter 520 nm). The AR patterns (bright ﬂuorescence: acrosome intact; no 
ﬂuorescence or only ﬂuorescence of the equatorial segment: acrosome reacted) were 
evaluated in at least 200 cells per condition. Negative (no stimulation) and positive (A23187 
10μM) controls were included in all experiments. 
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3.3.5 Sperm Penetration Assay 
 
Methyl cellulose (1% concentration) was used to assess sperm functional ability to penetrate 
into viscous media (Ivic et al., 2002). Sperm cells were previously treated with compound(s) 
(as described in 3.3.3) and glass tubes filled with 1% methyl cellulose was placed vertically 
in the sperm solution. Glass tubes (5 cm X 0.8 cm X 2 mm; Vitrocom, NJ, USA) were loaded 
with methyl cellulose by capillary action (4,000 cP Sigma M-0512) and one extremity was 
sealed with Cristaseal™ (Hawksley, Sussex, UK). The tubes were incubated with the sperm 
cells at 37°C for 1h 15min, and then the other end of the tube was sealed after incubation. 
The number of sperm cells was scored at 1cm using CASA with a 20X objective. The 
microscope was adjusted manually to obtain the correct focus at each plane to obtain the 
number of cells migrated. The results are expressed as a penetration index (that is, number of 
spermatozoa observed with treatment/the number of spermatozoa without treatment).  
3.3.6 Assessment of Sperm Damage 
 
The Annexin-V–FLUOS Staining Kit (Roche, Meylan, France) was used to detect 
phosphatidylserine (PS) translocation from the inner to the outer leaflet of sperm plasma 
membrane. Annexin V is a phospholipids-binding protein that has high affinity for PS but 
lacks the ability to pass through an intact sperm membrane (van Heerde et al, 1995). 
Therefore, any binding between annexin V and PS needs to occur on the outer surface of the 
sperm plasma membrane, indicating that the membrane integrity has been compromised. 
Following the instructions of the manufacturer, for each assay, 106 cells were washed after 
20mins incubation with compounds, and then diluted in 100μl of annexin V buffer. Five 
microlitres of annexin V–FITC were added to the sample. The tubes were incubated for 15 
min at room temperature in the dark; 900 μl of binding buffer and 6μM propidium iodide (PI) 
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were then added to each tube. Fluorescence microscopy analysis was conducted within 
10mins. 
3.4 Results 
3.4.1 Effects of Vehicle Control (DMSO) on Sperm Motility 
 
All the 43 commercially available compounds used in this study were solubilized in 100% 
Dimethyl sulfoxide (DMSO) and 1% final concentration of DMSO has been reported to have 
no detrimental effects on human spermatozoa (de Lamirande and Gagnon, 2002, Wang et al., 
2013). To investigate this, capacitated spermatozoa isolated by direct swim-up were exposed 
to 1%, 0.5% and 0.2% finial concentration of DMSO for 20 min respectively. Direct swim-up 
method allows isolation of highly motile sperm so the effect(s) of this solvent on total and 
progressive motility of human spermatozoa will not be compromised by less motile cells.  As 
shown in Figure 3-3A and 3B, the percentages of total and progressively motile cells are not 
significantly different from control (Capacitating Media: CM). The mean values of other 
motility parameters such as VCL (p=0.683), VAP (p=0.800), VSL (p=0.713) and 
hyperactivation (p=0.847) were not affected (data not shown).  
  A B 
Figure 3-3: Effect(s) of different dimethyl sulfoxide (DMSO) concentrations on human 
sperm motility: Population of highly motile human spermatozoa was isolated by direct 
swim up. Cells were incubated under capacitating conditions at 37OC in a 5% CO2
humidified atmosphere for 3hrs; they were then treated with DMSO (final 
concentration 1%, 0.5% and 0.2%) or without DMSO (CM: capacitating media) and 
left to incubate for 20min at 37oC in a 5% CO2 humidified atmosphere. (A) Percentage 
total motility (B) Percentage progressive motility. p=0.831 and 0.507 respectively, n=3 
(3 different sample from 3 individuals) mean ±SEM (Data not shown: VAP: p=0.800, 
Hyperactivation: p=0.847 VSL: p=0.713 and VCL: p=0.683). One way-ANOVA 
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3.4.2 Effects of Compound(s) on Sperm Motility 
 
The initial phase 1 investigation involves the use of poor motility fraction from pooled 
samples from normozoospermic donors (see Figure 3-2). In order to identify compounds that 
have significant effect on total motility, cells were incubated under non-capacitating 
conditions. Response to treatment were categorised as moderate responder (20-60% increase 
in total motility) and strong responder (> 60% increase total motility) respectively 
(APPENDIX 1: Figure 1 and 2). Six compounds (#1, #26, #30, #36, #37 and #38) were 
considered to have strong effect on total motility (Figure 3-4A), therefore they were selected 
for further analysis.  
Further testing (phase 2) on individual donor sample in non-capacitating conditions (n=6: 
poor motility fraction) showed significant increase in total and progressive motility for all 
selected compounds (except for #26 total motility) (Figure 3-4B). Evaluation of the effect(s) 
of these compounds under capacitating conditions (n=7 individual sample; poor motility 
fraction) (Figure 3-4C) showed similar significant increase in total and progressive motility 
that was comparable to what was observed when compounds were used in non-capacitating 
conditions (Figure 3-4B).  
49 
 
0
10
20
30
40
50
DMSO  #1  #26  #30  #36  #37  #38 DMSO  #1  #26  #30  #36  #37  #38
%
Cells in capacitating conditions
    
 
 
 
 
  
 
  
  
  
  
C 
Cells in non-capacitating conditions 
0
10
20
30
40
50
%
Cells in non-capacitating conditions
Total Motility Progressive Motility 
Total Motility Progressive Motility 
B 
* 
** 
* 
** ** 
** * 
*** 
****
** 
*** 
*** *** 
*** *** 
*** * 
* 
* * 
** 
Figure 3-4: Effect(s) of compound(s) on sperm motility: Human spermatozoa were 
treated for 20min at 37
o
C with 100µM of Compound. (A) Strong responder (#1, #26, 
#30, #36, #37 and #38) and Mild responder (#7, #13, #15). 100% increase equal 2 
fold increase in motility compare to 1% DMSO (i.e.: DMSO=15%-- treatment 30%). 
Green line indicates threshold for strong responder while red line is the threshold for 
background. Red: most promising compounds; n=3 (3 separate analysis on pooled 
sample) mean ±SEM. (See APPENDIX 1: (Fig 1a-d) for other compound tested). (B) 
Effect(s) of selected compounds on percentage of motile and progressively motile cell 
under non capacitating condition. (* p≤ 0.05, ** p≤0.001 and ***p≤0.0001 in 
comparison to control) n=6 (6 different samples from 6 individuals) mean ±SD. (C) 
Sperm cells with poor motility from poor fraction were incubated at 37OC in a 5% 
CO2 humidified atmosphere for 3hrs; they were then treated with 100µM of 
compound and left to incubate for 20min at 37
o
C in a 5% CO2 humidified 
atmosphere. (* p≤ 0.05, ** p≤0.001 and ***p≤0.0001 in comparison to control) n=7 
(7 different sample from 7 individuals) mean ±SEM.  
 
A 
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3.4.3 Preservation of compound(s) effects during prolong co-incubation and removal                                 
 
Figure 3-4B and C shows the effects of selected compounds on total and progressive motility 
after a period of 20min incubation with capacitated and non-capacitated cells respectively. 
When non-capacitated cells were incubated with compounds over a continues period of up to 
180 min, a significant increase in percentage total and progressive motility was generally 
observed when compared with control (Table II). For total motility (TM), cells incubated in 
compound #37 and #38 were significantly different to control at each time point (Table IIA). 
Cells incubated in compound #36 were significantly different from control at T20, T60, T90, 
and T120. Cells incubated in compound #26 and #30 were significantly different from control 
at T20, T60, T90. Cells incubated in compound #1 only showed a significant difference at 
T20, T60. The effects of the compounds on total motility were not significantly different 
from each other, except at T20 where cells incubated in compound #37 were  significantly 
different from #30 (p =0.023). The effects of the compounds are not significantly different 
over time (e.g. TM: #37 at time T20 is not different from T180). The percentage progressive 
motility of cells incubated with compounds are significantly different from control at each 
time point (Table IIB). Cells incubated with compound #38 had a significantly higher 
progressive motility to those incubated in compound #1 (p<0.05) at all time points, 
compound #30 at  4 time points (T20, T60, T120, and T180) and compound #36 at 1 time 
point (T90). Cells incubated in compound #37 had significantly higher progressive motility to 
compound #1 at all time points except T180 and were significantly higher than those 
incubated in compounds #30 and #36 at T20 and T90 respectively. There is no significant 
difference between compound #26, #37 and #38 in terms of percentage of cells with 
progressive motility. 
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n=5 (5 different samples from 5 individuals). * p<0.05, ** p<0.01 and *** p<0.001 with respect to 
control. T20=Incubation for 20min. (A) For total motility, compound #37 and #38 are sig. different to 
control at each time points. Compound #36 is sig. different from control at time point T20, T60, T90, and 
T120. Both compound #26 and #30 are sig. different from control at time point T20, T60, T90. Compound 
#1 is only sig. different at T20, T60. The effects of the compounds on total motility are not sig. different 
from each other, except at T20 where compound #37 is sig. different from #30 (p=0.23). The effects of 
compounds are not sig. different over time. (B) For progressive motility, all compounds are sig. different 
from control. Compound #38 is sig. different to compound #1 (p<0.05) at all-time point, compound #30 at  
4 time points (T20, T60, T120, and T180) and compound #36 at 1 time point (T90). Compound #37 is sig. 
different to compound #1 at all-time point except T180 and its sig. different to compound #30 and #36 at 
T20 and T90 respectively.    
Table II: Effects of compound on sperm motility with continuous co-incubation (180min) in non-capacitation conditions 
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3.4.4 Persistence of Compound(s) Effect after Drug Removal 
 
In order to mimic clinical procedure in which compounds are washed off, before IVF 
insemination or intrauterine insemination (IUI), spermatozoa were exposed to compounds for 
20min followed by washing off (NCM) and were incubated for up to 300 min. The 
percentage total and progressive motility were significantly higher in compound treated cells 
compared to control (Table III). 
Specifically for total motility (Table IIIA),  cells incubated in  compound #1, #26, #36, #37 
and #38 showed a significant increase in comparison to control, at each time points except at 
W20 (compound #38)  and W20 and W60 (compound #1).  There was no significant 
difference in cells incubated in compounds before (T20) and after (W0-W300) wash off (i.e. 
W0-W300).  Cells incubated in compound #30 only showed a significant increase in % of 
motile cells at T20, W40 and W300 respectively.  
Specifically for progressive motility, cells incubated in all compound showed a significant 
increase at T20 (Table IIIB). After washing, cells incubated in compound #36 and #37 
showed a significant increase at each time point and compound #26 and #38 are not 
significantly different from control only at W20. Cells incubated in compound #30, however, 
do not show any significant difference to control. Cells incubated in compound #1 were only 
significantly different at W0, W40, and W180-W300. 
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  Total Motility (% ± SEM)A  Progressive Motility (% ± SEM)
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DMSO #1 #26 #30 #36 #37 #38 
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T20 20± 1 35± 0*** 38± 2** 36± 2** 37± 1*** 42± 2*** 40± 2***  8± 1 21± 1*** 24± 3** 20± 3** 24± 1*** 27± 2*** 28± 2*** 
W0 18± 1 29± 3* 28± 3* 26± 4 28± 3* 30± 2** 31± 3**  7± 1 18± 3* 16± 3* 14± 3 18± 3* 19± 2** 19± 3** 
W20 21± 3 28± 2 33± 4* 24± 3 31± 3* 36± 5* 33± 5  10± 2 17± 3 20± 4 11± 3 20± 3* 24± 3* 22± 5 
W40 18± 2 29± 2** 30± 4* 30± 4* 27± 3* 33± 4* 36± 2**  7± 1 18± 3* 19± 4* 14± 3 17± 3* 23± 4** 24± 2*** 
W60 18± 2 28± 4 32± 4* 25± 3 29± 3* 35± 2** 32± 4* 
 
7± 1 16± 4 19± 3* 13± 3 19± 3** 23± 3** 22± 3** 
W120 18± 2 26± 3* 35± 4** 25± 4 33± 6* 34± 4** 34± 5* 
 
8± 2 15± 2 22± 4* 12± 4 21± 4* 21± 3** 23± 5* 
W180 17± 2 30± 3* 32± 4* 24± 3 29± 3* 34± 3** 33± 4** 
 
7± 2 18± 3* 21± 5* 12± 3 20± 3** 22± 3** 23± 3** 
W240 18± 2 30± 2** 31± 4* 24± 4 29± 4* 34± 3** 31± 4*  9± 1 17± 3* 20± 4* 12± 3 21± 4* 24± 3** 22± 4* 
W300 15± 1 27± 2** 30± 4* 26± 4* 28± 4* 33± 3** 32± 5* 
 
6± 2 15± 3* 19± 4* 13± 4 19± 4* 21± 3** 22± 4* 
                                  
                 
 
  
n=4 (4 different samples from 4 individuals). * p< 0.05, ** p<0.01 and *** p<0.001 with respect to control. 
(T20=Incubation for 20min, W= Compound washed off/Removed (min)). (A) Compound #1, #26, #36, #37 and #38 
significantly increase % motile cells, in comparison to control, at each time points except compound #38 at W20 and 
compound #1 at W20 and W60. There is no difference between compounds before (T20) and after (W0-W300) 
compounds were washed off (i.e. W0-W300).  Compound #30 only causes sig. increase in % of motile cells at T20, 
W40 and W300 respectively. (B) At T20, all compounds show sig. increase in % of progressive motility. After 
washing off the compounds, compound #36 and #37 showed sig. increase in % of progressive motility at each time 
point and compound #26 and #38 are not sig. different from control only at W20. Compound #30, however, does not 
show any sig. difference to control after washing off. Compound #1 is only sig. different at W0, W40, and W180-
W300 respectively. 
Table III: Effects of compound on sperm motility after compound was removed after 20min of treatment   
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3.4.5 Kremer Penetration Test 
 
Using methylcellulose as cervical mucus substitute, the effect of selected compound(s) on 
functional ability of the cells to migrate into/within viscous environment was tested. There 
were significantly higher numbers of cells at 1cm when sperm were incubated in the 6 
compounds compared to vehicle control (Figure 3-5). Cell incubated in compounds #26 and 
#38 showed significantly higher response than #1 and #36. Additionally, cell incubated in 
compounds #38 showed significantly higher response than those incubated in #30, while cells 
incubated in compound #37 are not significantly different to other compounds (Figure 3-5). 
Figure 3-5: Penetration of compound treated and untreated spermatozoa into viscous media: Sperm cells with 
poor motility were treated with or without 100µM final concentration of Compound(s) (1% DMSO-Control, 
500 µM IBMX-Positive control). Treated cells were allowed to penetrate into methylcellulose solution (1cm) 
for 1hr 15min (Kremer test). (* p≤ 0.05, ** p≤0.001 and ***p≤0.0001 in comparison to control), n= 8 (8 
different samples from 8 individuals) mean ±SEM. Both compound #26 and #38 are sig. different from #1, #36 
and IBMX (p≤0.05). Compound #38 is also sig. different from #30 (p≤0.05) while #37 is not different from 
other compounds.  
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3.4.6 Acrosome Reaction and Externalisation of Phosphatidylserine (PS) 
 
In order to characterise the effects of selected compound(s) on induced acrosome reaction, 
cells were incubated with compounds and then treated with 10µM (final concentration) 
calcium ionophore (A23187).  Figure 3-6B shows that there was no significant induction of 
the acrosome reaction after continuous incubation with any of the compounds (p=0.6) 
compared to vehicle controls (1% DMSO). Also, Figure 3-6A shows that there is no 
significant difference in externalisation of phosphatidylserine between DMSO treated or 
compound treated cells.  
3.4.7 Effects of Compound(s) on Sperm Movement Characteristics of Patient Samples 
Incubated in Non-capacitating Media (NCM) 
 
As seen in Table IV, 23 patients were analysed and patients were attending for either routine 
andrology assessment or IVF/ICSI and a portion of their semen sample was examined 
following density gradient centrifugation and analysed. It wasn’t always possible to examine 
all 6 compounds due to limitations in number of sperm available. While each patient is an 
individual there are some general trends. In 3/8 patients with high motility (W.H.O. normal) 
there was no response (or a negative response) to the compounds (#1, #26, #30 #37 and #38). 
There was a noticeable number who showed a significant increase in progressive motility to 
some, but not all compounds. In contrast, in patients with low progressive motility there were 
a higher proportion of patient samples that responded positively compare to those in the 
normal category.  In patient samples with low total motility and low progressive motility, 
there was a positive response, either by increase in total motility and/or progressive motility 
to some, but not all compounds. In this category, only 1 patient showed no response to any 
compound (RS 760).   
  
56 
 
0
5
10
15
DMSO  #1  #26  #30  #36  #37  #38
%
 A
cr
o
so
m
e 
R
ea
ct
ed
0
5
10
15
DMSO  #1  #26  #30  #36  #37  #38
%
 E
xp
o
se
d
AR: Acrosome reacted 
NAR: Non-acrosome reacted 
 
 
 
 
Figure 3-6: Effect(s) of selected compounds on the expression of phosphatidylserine (PS) and 
percentage of acrosome reacted spermatozoa: Human spermatozoa (sperm fraction with poor 
motility) were treated with 100µM of Compound.  (A) Sperm cells were labeled with 
fluorescein isothiocyanate-labeled annexin V. Arrow shows cell with no externalization of 
phosphatidylserine (n=4 (4 sample from 4 individuals); p=0.6. mean ±SEM). (B) 
Permeabilized spermatozoa were labeled with pisum sativum lectin (n=4 (4 samples from 4 
individuals); p=0.6 mean ±SD).  
 
A 
B 
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Table IV: 
Summary 
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3.4.8 Effects of Compound(s) on Sperm Movement Characteristics of IVF Samples 
Incubated in IVF Media. 
 
In this category, a portion of prepared patient sample (n=32) that was used for treatment was 
obtained for research purposes and analysed. Capacitated human spermatozoa from IVF 
patients were exposed to compounds for 20min (Table V). It wasn’t always possible to 
examine all 6 compounds due to limitations in the number of spermtozoa available. Using 
W.H.O. 2010 normal limit (40% total motility and 32% progressive motility), 27 out of 32 
patients have normal total and progressive motility, 4 were borderline (having either total or 
progressive motility within normal limit) and 1 patient has lower total and progressive 
motility (Table V).  While each patient is an individual there are some general trends: 
compounds #37, 38 and 26 were the most effective in increasing the percentage total motile 
cells (#26 and #37 [20/32] = 63% and #38 [17/27] =63% of patients) followed by #30 [12/26] 
=46%, #36 [8/22] = 36% and #1 [2/14] =14% respectively Table V.  In respect to progressive 
motility, compound #26 and #30 are the most effective; with ≥50% of samples treated with 
these compounds having increase in percentage of progressive cells [16/32] =50%  and. 54% 
[14/26] respectively. 41% [13/32] of IVF samples treated with compound #37 and #38 have 
increase in percentage progressive motility, while 29% [4/14] and 18% [4/22] of samples 
treated with compound #1 and #36 have increase in percentage of progressively motile cells 
respectively. 
As for samples in non-capacitating media (Table IV), the most significant effects of 
compounds were in IVF samples with borderline/low motility (Table V).   
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3.4.9 Effects of Compounds on Average Swimming Velocity of IVF Samples 
 
In Table V, effect of compounds on total and progressive motility was analysed for each 
patient sample. Here the effect of compounds on sperm velocity is analysed for each 
treatment conditions. At a concentration of 100µM, there is a statistically significant increase 
in VAP (that is, the average velocity of sperm cells over a smoothed cell path) when 
compared to control (1% DMSO); except for compound #1 treated samples (Figure 3-7A). 
Although there is no significant difference between other compounds, the most pronounced 
effects were in #26, #30 and #38 treated cells: the average VAP in DMSO was 60 ±2 µm/s, 
while that in #26 treated cells was 75 ±2 µm/s, (p≤0.0001) and 77 ±2 µm/s (p≤0.0001), 73 ±2 
µm/s (p≤0.0001) for #30 and #38 treated cells respectively.    
With regards to VSL (the average velocity on a straight-line between the start and the end 
point of the track), a statistically significant increase was seen with all compounds except 
with compound #1 treated samples (Figure 3-7B).  Once again, the greatest improvements 
were achieved with compound #26 (64 ±2 µm/s, p≤0.0001), #30 (68 ±2 µm/s, p≤0.0001) and 
#38 (62 ±1 µm/s, p≤0.0001): the average VSL in control was (52 ±2 µm/s).  
For curvilinear velocity (VCL; the actual velocity along the trajectory), a statistically 
significant increase was observed for compound #26 (112 ±3 µm/s vs 93 ±3 µm/s), #30 (118 
±3 µm/s vs 93 ±3 µm/s), #36 (111 ±3 µm/s vs 93 ±3 µm/s), #37 (115 ±3 µm/s vs 93 ±3 
µm/s), and #38 (121 ±3 µm/s vs 93 ±3 µm/s) (Figure 3-7C). In compound #26 treated 
samples, 49% of cells had VCL ≥120 µm/s, and a noticeable higher percentage of cells 
treated with compound #30 (46%), #36 (38%), #37 (41%) and # 38 (50%) also had higher 
VCL values (≥120 µm/s) in comparison to control (Figure 3-8).  
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Figure 3-7: Effects of compounds on swimming velocities of spermatozoa from IVF samples. 
(A) Average path velocity (VAP).  (B) Straight-line velocity (VSL). (C) Curvilinear velocity. 
(DMSO, #26, #37, #38 n=32; #30 n=26; #36 n=22; #1 n=14) mean:  ±SEM (* p≤ 0.05, ** 
p≤0.001 and ***p≤0.0001. One way ANOVA) 
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Figure 3-8:  The effects of compounds (five compounds only) on cell frequency distribution of VCL following 20min 
incubation of capacitated spermatozoa from IVF samples. (A) Compound #26 n=32. (B) Compound #30 n=26. (C) 
Compound #36 n=22. (D) Compound #37 n=32. (E) Compound #38 n=32.  Control (1% DMSO n=32), mean ±SEM. 
On average 230 cells were counted 
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D 
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3.4.10 Effects of Compound(s) on Sperm Movement Characteristics of ICSI Samples 
Incubated in IVF Buffer. 
 
In this category, a very small volume of prepared patient samples were obtained for research 
purpose; therefore analysis is limited (n=16). Human spermatozoa from ICSI patients were 
exposed to compounds for 20min (Table VI). It wasn’t always possible to examine all 
compounds due to limitations in number of sperm available. 
Using W.H.O. 2010 normal limit (40% total motility and 32% progressive motility), 6 out of 
16 patients have normal total and progressive motility, 4 were borderline (having either total 
or progressive motility within normal limit) and 6 patient has lower total and progressive 
motility (Table VI).  Specifically for total motility, [14/16] =88%, [9/11] =81% and [11/14] 
=79% of samples incubated with compound #26, #38 and #37 showed a significant increase 
in total motility respectively.  While for compound #30 and #36, [7/12] =58% and [4/6] 
=67% cases showed increase in total motility (Table VI). In one case, compound #36 causes a 
decrease in total motility (RS1160). Compound #1 was only tested once in this category 
because (1) it does not cause statistically significant effect(s) on IVF patient samples; (2) 
small volumes of patient samples were available for analysis (Table VI). 
In respect to progressive motility, compound #26 and #37 are the most effective; with ≥90% 
of samples treated with these compounds having increase in percentage of progressive cells 
[15/16] =94%  and [13/14] =93% respectively. Great than 80% of ICSI samples treated with 
compound #36 [5/6] =83% and #38 [9/11] 81% have increase in percentage progressive 
motility, while 75% [9/12] of samples treated with compound #30 have increase in 
percentage of progressively motile cells (Table VI). 
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Table VI: 
Summary 
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3.4.11 Effects of Compounds on Average Swimming Velocity of ICSI Samples 
 
The effect of compounds on sperm velocity of ICSI samples was analysed for each treatment 
conditions. At a concentration of 100µM, there is a statistically significant increase in VAP 
(that is, the average velocity of sperm cells over a smoothed cell path) when compared to 
control (1% DMSO) (Figure 3-9A). Although there is no significant difference between other 
compounds, the most pronounced effects was in #26, #37 and #38 treated cells: the average 
VAP in DMSO was 43 ±3 µm/s, while that in #26 treated cells was 63 ±3 µm/s, (p≤0.0001) 
and 59 ±3 µm/s (p≤0.001), 59 ±4 µm/s (p≤0.0001) for #37 and #38 treated cells respectively.    
With regards to VSL (the average velocity on a straight-line between the start and the end 
point of the track), a statistically significant increase was seen with all compounds (Figure 
3-9B).  Once again, the greatest improvements were achieved with compound #26 (54 ±2 
µm/s, p≤0.0001) and #38 (52 ±4 µm/s, p≤0.0001): the average VSL in control was (33 ±2 
µm/s).  
For curvilinear velocity (VCL; the actual velocity along the trajectory), a statistically 
significant increase was observed for compound #26 (97 ±5 µm/s vs 70 ±5 µm/s), #30 (87 ±8 
µm/s vs 70 ±5 µm/s), #36 (92 ±7 µm/s vs 70 ±5 µm/s), #37 (94 ±4 µm/s vs 70 ±5 µm/s), and 
#38 (88 ±6 µm/s vs 70 ±5 µm/s) (Figure 3-9C). In compound #26 treated samples, 28% of 
cells had VCL ≥120 µm/s, and a higher percentage of cells treated with compound #30 
(20%), #36 (26%), #37 (23%) and # 38 (22%) also had higher VCL values (≥120 µm/s) in 
comparison to control (Figure 3-10). 
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Figure 3-9: Effects of compounds on swimming velocities of spermatozoa from IVF 
samples. (A) Average path velocity (VAP).  (B) Straight-line velocity (VSL). (C) 
Curvilinear velocity. (DMSO and #26, n=16; #30 n=12; #36 n=6; #37 n=14 and #38 
n=11) mean:  ±SEM (* p≤ 0.05, ** p≤0.001 and ***p≤0.0001. One way ANOVA) 
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Figure 3-10: The effects of compounds (five) on cell frequency distribution of VCL 
following 20min incubation of spermatozoa from ICSI samples. (A) Compound #26 n=16. 
(B) Compound #30 n=12. (C) Compound #36 n=6. (D) Compound #37 n=14. (E) 
Compound #38 n=11.  Control (1% DMSO n=32), mean ±SEM. On average 200 cells were 
counted. 
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3.5 Discussion 
 
The aim of this chapter was to use a two phase drug screening approach to identify 
compounds that have effective stimulation of human sperm motility and to characterise the 
effects of these compounds on other sperm function. The data presented in this chapter 
demonstrated that several compounds that have robust and effective stimulation of sperm 
motility, are non-toxic to the cells, initiate a functional improvement as judged by Kremer 
testing and importantly have a positive response on a significant proportion of patient 
samples under clinical conditions  have been successfully identified. 
In phase 1, 43 commercially available compounds with reported PDEI activity were screened 
for their effects on sperm motility using CASA. In order to reduce variability and increase the 
number of cells available for simultaneous examination of multiple compounds (usually 3-5 
in each run), pooled samples from 3-4 different donors were utilised. Cells in the 40% 
fraction (those with poor motility) were used as putative surrogates for patient samples. 
Previous studies have suggested that these cells have a similar profile, in terms of motility, 
morphology and DNA status, to men with sperm dysfunction/male infertility (Glenn et al., 
2007, O'Connell et al., 2003). The initial screening was performed with non-capacitating 
media as (1) these are the conditions normally used for IUI (Bjorndahl et al., 2010), (2) there 
is no bicarbonate stimulation of soluble adenylyl cyclase (sAC) under this condition. Twenty 
minutes of sperm incubation fits with clinical procedures for preparing cells. 
From experiment analysing the effects of the compounds on sperm motility of pooled donor 
samples, 6 compounds were found to cause ≥60% increase in percentage total motility 
(Figure 3-4A; APPENDIX 1 Figure 1). When these six compounds were analysed on 
individual donor samples, in non-capacitating and capacitating media/conditions, a similar 
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profile of result marked by a significant increase in total and progressive motility was 
observed (Figure 3-4B and C).  
Clinical use of the compounds would involve washing and effective removal prior to use. 
Table III demonstrates that stimulation of total motility was maintained over time however 
progressive motility was not consistently affected using compounds #1 and #30. Continual 
incubation (Table II) suggests that the positive effect on total motility of compounds #1 and 
#26 and #30 were not maintained throughout incubation. For progressive motility, particular 
stimulation with compound #38 and #37 was observed (Table II). 
The objective of phase 1 was to allow a large number of compounds to be screened relatively 
quickly to identify potential key targets for further study. Phase 2 consisted of a more detailed 
assessment based around guidelines for the testing of compounds that can potentially be 
considered safe for use (Mortimer et al., 2013).  Phase 2 involved sperm function testing with 
a view to the use of the compounds in ART e.g. IUI. For sperm to reach the oocyte it is 
essential that they can migrate into and within viscous environment found in the female 
reproductive tract. Modified Kremer testing demonstrated that the stimulation in motility was 
functional i.e. higher numbers of cells penetrated the viscous media (Figure 3-5). 
The purpose of using PDE inhibitors is to improve the quality of sperm from infertile 
patients, in turn increasing the fertilization potential of these couples. It is therefore important 
that sperm are both morphologically and physiologically sound to function well in order to 
fertilize the oocyte. Here, the effects of compounds on A23187 induced acrosome reaction 
and externalisation of phosphatidylserine (PS) was considered. At 100µM final 
concentration, the compounds did not appear to have a significant negative effect as there 
was no significant induction of the acrosome reaction. Additionally, there is no significant PS 
exposure suggesting that the compounds relatively do not stimulate induction of apoptosis. 
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This is contrary to what is normally reported. For example, non-specific PDE inhibitor: 
pentoxifylline (PTX) has been reported to significantly induce acrosome reaction even 
though it significantly stimulates human sperm motility (Tasdemir et al., 1993, Yovich et al., 
1990). One reason for previous association between PDE inhibitors and acrosome reaction 
might be the concentration of non-selective PDE inhibitors used. For these non-specific 
inhibitors, motility enhancing effects are only achieved at 1-10mM concentration and these 
reportedly cause significant premature stimulation of acrosome reaction (Fisch et al., 1998).  
The fundamental clinical question is to reproduce what happens in donor samples (40% 
fraction with poor motility) in patient samples. To address this, a spectrum of diagnostic and 
treatment samples under non-capacitating and capacitating conditions (Tables IV, V, and VI). 
In general, in samples with good motility e.g. IVF, there was a minimal effect on total 
motility but, in some cases, a notable effect on progressive motility. Nevertheless, these 
compounds significantly enhance the swimming velocity of good motility populations 
(Figure 3-7) and in most cases ≥ 40% of motile cells had VCL ≥120 µm/s (Figure 3-8). 
In samples with lower motility there was a significant effect on both total and progressive 
motility. These clinical data give some indications as to the possible therapeutic use and 
effectiveness. Generally there appears to be limited benefit for samples with good motility as 
expected and consistent with previous data using PTX (Nassar et al., 1999). In cells incubated 
under non-capacitating conditions 65% and 74% of the samples responded to compound #26 
with regards to total and progressive motility. From the limited data available compounds #1 
and 30 were less effective. In samples incubated under capacitating conditions (Table V) 
compounds #37, #38 and #26 were the most effective in increasing the percentage total 
motile cells (~ 63% of samples)  and, as for samples in non-capacitating media, the most 
significant effects were in samples with borderline/low motility.  Only relatively few ICSI 
samples were examined (Table VI) however, in the overwhelming majority of cases cells 
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showed an increase in progressive motility and total motility and a considerable higher 
number of cells had higher VCL.  
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Chapter 4.  
Protein kinase A pathway is critical for basal progressive motility 
and induction of hyperactivated motility in human sperm 
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4.1 Introduction: 
 
Mature spermatozoa are transcriptionally and translationally silent, which means all sperm 
functions such as motility, capacitation and acrosome reaction are achieved without activation 
of genes or production of new proteins (Kiani and Rassoulzadegan, 2013, Braun, 2001, Ward 
and Zalensky, 1996, Ward and Coffey, 1991). As a result, spermatozoa rely heavily on 
receptor / ion channel mediated cell signalling and post- translational modification of proteins 
(such as protein phosphorylation) in order to perform their numerous functions (Florman et 
al., 1992, Florman et al., 1998, Ren et al., 2001, Quill et al., 2001, Darszon et al., 2005, 
Lishko et al., 2010, Kirichok and Lishko, 2011, Wassarman, 2002). Detailed studies of sperm 
capacitation and motility have revealed that modulation of second messenger and kinase 
activities are central to the signalling pathways that regulate many sperm functions (Tash, 
1989, Brokaw, 1987, Salicioni et al., 2007, Leclerc and Goupil, 2002, Breitbart, 2003, 
Battistone et al., 2013). 
Indeed, modulation of intracellular cyclic nucleotide level, particularly cyclic AMP (cAMP), 
is necessary to activate spermatozoa and is a prerequisite for sperm hyperactivation by 
mediating flagellar beat frequency (Leclerc et al., 1996a). Soluble adenylyl cyclase (sAC) is 
the principal enzyme that produces cAMP in mammalian spermatozoa and this atypical 
enzyme is activated by bicarbonate and calcium (Carlson et al., 2007, Xie et al., 2006). Most 
evidence has placed cAMP-dependent protein kinase (PKA) as the major downstream effector 
of cAMP signal in human sperm. Activation of cAMP-dependant protein kinase (PKA) leads 
to phosphorylation of serine or threonine residues on proteins, leading to phosphorylation of 
tyrosine residues on other proteins to affect mammalian sperm hyperactivation (Baker et al., 
2006, Krapf et al., 2010, Baker et al., 2009) 
74 
 
 While compelling experimental evidence has implicated cAMP to be a crucial second 
messenger that affects human sperm motility, in contrast, there are still controversies 
regarding the role of cGMP in sperm motility. Using cGMP-dependant phosphodiesterase 
(PDE) inhibitor (Sildenafil), some studies have demonstrated a stimulatory effect on sperm 
motility (Lefièvre et al., 2000, Cuadra et al., 2000). At a lower concentration of Sildenafil (0.4 
– 40nM), Cuadra et al., 2000 reported a significant increase in curvilinear velocity, amplitude 
of lateral head displacement (ALH), and hyperactivation. Similar results were reported by 
Lefièvre, et al., 2000, albeit, a higher concentration of Sildenafil was used (10-200µM). 
Additionally, in this study, increase in intracellular cAMP was also reported suggesting 
cAMP pathway may perhaps be involved in the motility stimulating effect observed for 
Sildenafil (Lefièvre et al., 2000).  
In contrast, when investigating the effect of Sildenafil (0.26 µM to 1.58µM) on motility, 
viability, membrane integrity, and functional capacity of human spermatozoa (healthy donors 
and clinically infertile men), Burger and colleagues found no statistically significant effect of 
Sildenafil on sperm viability, sperm motility, and sperm progressive motility after incubation 
of spermatozoa with various doses of Sildenafil (Burger et al., 2000). Similarly, evaluation of 
the effect of Sildenafil by Andrade and colleagues, on either unwashed or washed 
spermatozoa of 10 men, demonstrated that 420 µM Sildenafil did not affect sperm motility 
either in unwashed or washed sperm (Andrade et al., 2000). 
Recently, soluble guanylyl cyclase (sGC) has been identified in human sperm using immune-
blotting technique (Willipinski-Stapelfeldt et al., 2004) and like in many other cells types, 
nitric oxide (NO), a free radical, has been suggested to activate this enzyme. NO has been 
reported to affect sperm motility in a dose-dependent fashion. At low concentration, NO is 
found to improve or maintain sperm motility probably through the stimulation of cGMP 
production (Donnelly et al., 1997, Lewis et al., 1996), whereas at higher concentrations of 
75 
 
NO, sperm motility and viability are adversely affected;  this is most likely due to free radical 
ability of NO and direct oxidative damage to the sperm membrane  (Rosselli et al., 1995, 
Weinberg et al., 1995, Balercia et al., 2004). 
 
4.2 Aims and Experimental Design 
 
In Chapter 3, several compounds with reported phosphodiesterase inhibitor activity were 
identified, and they were found to have effective stimulation of human sperm motility, thus, 
the aim of this chapter is to identify the causal signalling pathway(s) involved in the motility 
enhancing effects of these compounds. Since most molecular techniques (such as transfection 
and protein over-expression) cannot be applied to sperm cells, the use of specific inhibitors of 
signalling pathways was adopted. Attention was concentrated on PKA, sGC and PKG 
pathways, which represents key modulator and mediator of cyclic nucleotides in human 
sperm.  
Widely reported chemical inhibitors of PKA (H89: 50µM) (Aitken et al., 1998a, Luconi et al., 
2004), sGC (ODQ: 10µM) (Miraglia et al., 2011) and PKG (KT5823: 10µM) (Teves et al., 
2009) were used in this study (Figure 4-1). The working hypothesis is that, by inhibiting 
pathways upstream or downstream of the supposed signalling pathway(s) used by the 
compounds (PDEi), it is possible to modulate their motility enhancing effects. Under the 
experimental conditions (Figure 4-2), concentration of chemical inhibitors does not affect 
sperm viability (as indicated in total and progressive motility studies). In order to minimize 
possible experimental variations, treatment was performed using the same semen pool. To 
fully categorise the signalling pathway(s) involved in motility enhancing effects of the 
compounds identified in Chapter 3, experiments were performed both in capacitating and non-
76 
 
capacitating conditions. For experiments performed under non-capacitating conditions, sperm 
cells were pre-incubated (15 min) in the absence or presence of chemical inhibitors 
(NCM+H89, NCM+ODQ and NCM+KT5823 respectively); in order to ensure inhibition of 
PKA, sGC and PKG, prior to exposure to compounds (PDEi). Direct exposure of cells to 
capacitating media could theoretically lead to immediate activation of targeted pathways, thus 
similar pre-incubation (as above) was done for experiments performed under capacitating 
conditions; however, pre-incubated cells were then resuspended in capacitating media 
containing chemical inhibitors, incubated for 3hrs, before exposure to compounds (PDEi). 
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Figure 4-1: Diagram of signalling pathway targeted by chemical inhibitors: (A) 
PKA activity is inhibited by H89 (as indicated by ) while (B) sGC and PKG 
activity were inhibited by ODQ and KT5823 respectively. If compounds (PDEi) 
were working through PKA; inhibiting its activity with H89 will blunt or abolish 
the motility enhancing effects of compounds. However, if activities of compounds 
are independent of PKA activation, compounds will still be effective in enhancing 
sperm motility in the presence of H89. The same principle applies to both sGC and 
PKG. 
A B 
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↑ PKA ↓
Δ Motility
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4.3 Materials and Methods 
 
4.3.1 Chemicals  
 
Compound(s) were purchased from TOCRIS Bioscience (Bristol, UK), Sigma-Aldrich 
(Dorset, UK) or Santa Cruz Biotechnology (Heidelberg, Germany) by the Drug Discovery 
Unit (DDU) at the College of Life Sciences (University of Dundee, UK). Stock solutions of 
chemical inhibitors, PKA (H89, 100mM), sGC (ODQ 10mM) and PKG (KT5823 10mM), 
and compounds (PDEi, 10mM) were prepared in DMSO and were kept at 4oC until used. The 
final concentration of DMSO in the suspensions did not exceed 1% v/v in all treatment 
conditions. 
 
Figure 4-2: Experimental Overview of PKA inhibitor (H89): For each sample, washed 
sperm cells 100µl was taken and split into four 25µl aliquots. To evaluate the role of 
PKA, 25µl sample aliquot was resuspended in NCM (with DMSO added as vehicle 
control) and another in NCM containing H89 (50µM) (NCM+H89); both sample were 
incubated for 15min at 37oC prior to 20min exposure to compounds (PDEi). In parallel, 
the other two 25µl aliquots of washed sperm cells was either resuspended  in CM (with 
DMSO added as vehicle control) and incubated for 3hrs under capacitating conditions or 
in NCM+H89, incubated for 15min at 37oC, pelleted by centrifugation (300g for 5 min) 
before final re-suspension in CM+H89 and incubation for 3hrs under capacitating 
conditions. After 3hrs under capacitating conditions, sperm cells were exposed to 
compounds (PDEi) for 20min.  Change in motility was analysed using CASA. Exact 
experimental conditions were used for ODQ (10µM) and KT5823 (10µM) respectively. 
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4.3.2 Media and Sperm Preparation 
 
All chemicals were purchased from Sigma-Aldrich. Two different media were used (1) Not 
supporting sperm capacitation [NCM]: 1.8 mM CaCl2, 5.4 mM KCl, 0.8 mM MgSO4.7H2O, 
116.3 mM NaCl, 1.0 mM NaH2PO4, 5.55 mM D-glucose, 2.73 mM sodium pyruvate, 41.75 
mM sodium lactate, 25 mM HEPES and 3mg/ml BSA. (2) supporting capacitation [CM]: 1.8 
mM CaCl2, 5.4 mM KCl, 0.8 mM MgSO4.7H2O,116.3 mM NaCl, 1.0 mM NaH2PO4, 5.55 
mM D-glucose, 2.73 mM sodium pyruvate, 25 mM sodium lactate, 26 mM sodium 
bicarbonate and 3mg/ml BSA (Alasmari et al., 2013a, Tardif et al., 2014).  Semen samples 
were obtained from healthy donors and population of highly motile sperm cells were isolated 
using a 40-80% discontinuous density gradient procedure. Briefly, 2 ml of semen was loaded 
after 30 min of liquefaction at 37˚C on the top of a colloidal silica suspension (Percoll®) made 
of 80% and 40% layered (2 ml each). The density gradient was centrifuged at 300g for 20 
min.  Highly motile sperm cell forms a pellet at the bottom of the conical tube within the 80% 
fraction of the discontinuous density gradient. These cells were recovered and were washed in 
non-capacitating media (NCM) by centrifugation for 10 min at 500g and the sperm pellet was 
resuspended in 100µl NCM. 
4.3.3 Motility Assessment and Compound(s) Treatment 
 
Washed sperm cells (in 100µl NCM) were split into four treatment conditions. 25µl aliquots 
(each) was resuspended in 1ml of NCM (with 0.02% DMSO as vehicle control) and in 1ml of 
NCM containing chemical inhibitors (H89: 50µM, ODQ: 10µM, KT5823:10µM final 
concentration) and these were incubated under non-capacitating conditions (37oC) for 15 min. 
In parallel, another 25µl aliquot of washed sperm cells was either resuspended in CM+ 
(DMSO 0.02%) and incubated for 3hrs under capacitating conditions or resuspended in 
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NCM+H89, incubated for 15min at 37oC, pelleted by centrifugation (300g for 5 min) before 
final re-suspension in CM containing chemical inhibitors (H89: 50µM, ODQ: 10µM, 
KT5823:10µM final concentration) and incubation for 3hrs under capacitating conditions 
(37oC and 5% CO2 humidified atmosphere). After respective incubation times (15 min for 
cells under non-capacitating conditions and 3hrs for cells under capacitating conditions), 
sperm cells were exposed to compounds (PDEi) for 20min. Change in sperm motility was 
evaluated using a computer assisted sperm analyser (CASA) (CEROS machine [version 12] 
Hamilton -Thorne Research, Beverly, MA) attached to an external microscope. Sperm motion 
characteristics were assessed under a negative phase contrast objective as previously 
described in Chapter 2 (Alasmari et al., 2013a, Tardif et al., 2014).  
4.3.4 STATISTICAL ANALYSIS 
 
All data are presented as means ± SEM. The statistical analysis was carried out using 
GraphPad Prism 6 (GraphPad Software, California, USA). The data were analysed by two-
way ANOVA on paired observations. Where differences were detected, Sidak’s and Turkey’s 
multiple comparisons test was used to determine which values differed significantly. 
Differences were considered significant at a P < 0.05. Thus, by using two-way ANOVA, the 
effects of pre-treatment of cells with or without chemical inhibitors (H89, ODQ and KT5823), 
in addition to the effects of PDEi inhibitors can be statistically evaluated. Differences between 
cells with or without chemical inhibitor (H89, ODQ and KT5823) are indicated by asterisk 
(*), while difference within a treatment group are represented by different letters (a-c) and 
hashtags (#) respectively. 
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4.4 Results: 
 
4.4.1 H89 Inhibits Progressive Motility but does not Affect Total Motility under Non-
capacitating Conditions 
 
To validate a role for cAMP-PKA pathway in effecting the motility enhancing effects of 
compound #26, #30, #36, #37 and #38, the effects of PKA antagonist (H89, 50µM) on motile 
human sperm were examined. Sperm cells were pre-incubated for 15 min, under non-
capacitating conditions, with or without 50µM final concentration of H89, before exposure 
(20 min) to 100µM final concentration of compound(s) (1% DMSO: Vehicle Control and 
500µM IBMX: Positive Control) (see Figure 4-2).  A two-way factorial ANOVA was 
conducted on percentage total and progressive motility, with pre-incubation conditions (with 
or without H89) and treatment conditions (PDEi treatment or DMSO) as factors. In agreement 
with previous reports (Aitken et al., 1998a), H89 at 50µM has no significant effect on total 
sperm motility (Figure 4-3A). Thus, when sperm cells are exposed to compounds, total 
motility did not differ with or without H89 pre-incubation, p = 0.3635 (compare white vs 
black bar chart: Figure 4-3A). 
With respect to progressive sperm motility, a significant inhibitory effect was observed 
(Figure 4-3B). Comparing the effect of pre-incubation of cells with or without H89 showed a 
significant (p < .0001) difference between H89 treated and untreated cells. This result indicate 
that the percentage of progressively motile sperm was significantly higher for cells treated 
with compounds but without pre-incubation with H89 than for cells treated with compounds 
and with initial pre-incubation with H89 (compare white vs black bar chart: Figure 4-3B). A 
post hoc analysis using Sidak’s procedure (α level = 0.05), comparing NCM+(DMSO 0.02%) 
vs NCM+H89, revealed significant difference in progressive motility for each incubation 
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conditions (DMSO (1%) and #37: * p ≤ 0.05); (#36: ** p ≤ 0.01); (#26, #30, #38 and IBMX: 
*** p ≤ 0.001) respectively (compare white vs black bar chart: Figure 4-3B). 
Reviewing effects of compounds on the basis of treatment conditions (that is, effect of 
compound on sperm cells in NCM+DMSO) showed that overall, PDEi treated cells have a 
significantly (p = .0053) higher % of progressively motile cells than control (1% DMSO) 
(Figure 4-3B). A post hoc analysis using Tukey’s procedure (α level = 0.05), comparing effect 
of compounds on sperm cells in NCM+DMSO, revealed a significant increase in percentage 
of progressively motile cells in comparison to control (1% DMSO); (as indicated by letter b 
#37 p ≤ 0.01), (as indicated by letters b #26, #30, #36, #38 and IBMX: p ≤ 0.001) (compare 
white bar chart: Figure 4-3B). In contrast, for cells pre-incubated in H89 (NCM+H89), there 
is no significant increase in percentage of progressively motile cells between control and 
compound(s) treated cells (p >0 .05) (as indicated by hashtag #: compare black bar chart: 
Figure 4-3B). These results indicated that pre-incubation of sperm cells in H89 (50µM) 
abolish the motility enhancing effects of the compound(s). 
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Figure 4-3: Inhibition of PKA with H89 (under non capacitating condition). (A) Total motility is not 
significantly different between H89 (50µM) pre-treated cells (NCM+H89) and those in 
NCM+DMSO. (B) Progressive motility is reduced (P < 0.05) in H89 (50µM) pre-treated cells in 
comparison to cells in NCM+DMSO for each compound tested. Addition of compounds did not 
recover progressive motility. Values shown were measured 20min after addition of compounds to 
cell pre-incubated (15min) in NCM+H89 and NCM+DMSO respectively. ±SEM n=5-7 (independent 
experiments): Two Way ANOVA: Differences between cells pre-treated with or without (H89) are 
indicated by asterisk (*p≤0.05 **p≤0.01 ***p≤0.001 while difference in a treatment group are 
represented by different letters (a-b for those in NCM+DMSO: those with different letters differed 
significantly) and hashtags (# for those in NCM+H89) respectively. 
Progressive Motility 
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4.4.2 Inhibition of PKA Activity by H89 Affects Sperm Swimming Velocities under 
Non-capacitating Conditions. 
 
 
In Figure 4-3 A and B, the effect of compounds on total and progressive motility of cells pre-
incubation with or without H89 was analysed. Here the effect of PDEi on sperm velocities is 
analysed for each treatment conditions. In respect to VAP (that is, the average velocity of 
sperm cells over a smoothed cell path), there is a statistically significant interaction between 
compound treatment and the H89 pre-incubation state of the cells. This would suggest that the 
effect of compounds depended on PKA activity status of the cells (Figure 4-4A).  Comparing 
NCM+DMSO vs NCM+H89 revealed a significant difference in VAP as a result of 
incubation conditions (#26, #30, #36, #37 #38 and IBMX *** p ≤ 0.001), with sperm cells in 
NCM+DMSO having higher VAP than those in NCM+H89 respectively (compare white vs 
black bar chart: Figure 4-4A).  
 
A simple effects analysis of treatment conditions indicated that overall, the mean VAP for the 
PDEi treated samples were significantly (****p<0.0001) different from control sample in 
cells pre-treated in NCM+DMSO. A post hoc analysis using Tukey’s procedure (α=0.05) 
revealed that the mean VAP of all PDEi treated cells was significantly higher than the mean 
VAP for control (1% DMSO); (as indicated by letter b #37: p ≤ 0.01) (as indicated by letter b 
#26, #30, #36, #38 and IBMX: p ≤ 0.0001). No significant difference in VAP was found when 
the PDEi treated cells where compared with each other (compare white bar chart: Figure 
4-4A). However, for sperm cells incubated in NCM+H89, there is no significant difference (p 
>0 .05) in mean VAP between control and PDEi treated cells (as indicated by hashtag #: 
compare black bar chart: Figure 4-4A).  
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Figure 4-4: Inhibition of PKA with H89 (under non capacitating condition). (A) Average path velocity (B) Straight-line 
velocity and (C) Curvilinear velocity are reduced (P < 0.05) in H89 (50µM) pre-treated cells in comparison to cells in 
NCM+DMSO. Values shown were measured 20min after addition of compounds to cell pre-treated (15min) in 
NCM+H89 and NCM+DMSO respectively. ±SEM n=5-7 (independent experiments): Two Way ANOVA: Differences 
between cells pre-treated with or without (H89) are indicated by asterisk (*p≤0.05 **p≤0.01 ***p≤0.001). While 
difference in a treatment group are represented by different letters (a-c for those in NCM+DMSO: those with different 
letters differed significantly) and hashtags (# for those in NCM+H89) respectively. 
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With regards to VSL (the average velocity on a straight-line between the start and the end 
point of the track), there is also a statistically significant interaction between compound 
treatment and H89 pre-incubation state of the cells (Figure 4-4B).  Comparing NCM+DMSO 
vs NCM+H89 revealed a significant difference in VSL as a result of incubation conditions 
(#26, #30, #36, #37 #38 and IBMX **** p ≤ 0.0001), with sperm cells in NCM+DMSO 
having higher VSL than those in NCM+H89 respectively (compare white vs black bar chart: 
Figure 4-4B).  
Comparing the effects of compounds on the basis of treatment conditions indicated that the 
mean VSL for the compounds were significantly (****p<0.0001) different for sperm cells in 
NCM+DMSO.  A post hoc analysis using Tukey’s procedure (α=0.05) showed that the mean 
VSL of all PDEi treated cells was significantly higher than the mean VSL for control (1% 
DMSO); (as indicated by letter c #37: p ≤ 0.001) (as indicated by letter b and c #26, #30, #36, 
#38 and IBMX: p ≤ 0.0001).  When cells treated with PDEi were compared, the average VSL 
of compound #26 was significantly different from #37 (as indicated by letter b vs c: p ≤ 0.05); 
other compounds were not significantly different from each other (compare white bar chart: 
Figure 4-4B). For sperm cells pre-incubated in NCM+H89, there is no significant difference 
(p >0 .05) in mean VSL between control and compound treated cells (as indicated by hashtag 
#: compare black bar chart: Figure 4-4B).  
 
For curvilinear velocity (VCL; the actual velocity along the trajectory), sperm cells in 
NCM+DMSO have higher VCL than those in NCM+H89 (#37: ** p ≤ 0.01) (#36: *** p ≤ 
0.001) (#26, #30, #38 and IBMX **** p ≤ 0.0001) respectively (compare white vs black bar 
chart: Figure 4-4C).  Also when effect of PDEi on cells incubated in NCM+DMSO was 
compared, there is a significant increase in average VCL in comparison to control (as 
indicated by letter b, #37: p ≤ 0.05), (as indicated by letter b, #36 and IBMX: p ≤ 0.01), (as 
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indicated by letter b, #30: p ≤ 0.001), (as indicated by letter b, #26 and #38: p ≤ 0.0001) 
respectively. No significant difference was found when PDEi treated cells were compared 
with each other (compare white bar chart: Figure 4-4C). The mean VCL of sperm cells 
incubated in NCM+H89, are not significantly different (p >0 .05) to control (as indicated by 
hashtag #: compare black bar chart: Figure 4-4C). 
4.4.3 Capacitating Conditions Restore H89 Inhibited Progressive Motility 
 
Figure 4-3 and Figure 4-4 imply that compound(s) are effective in enhancing progressive 
motility and velocities of sperm cells under non-capacitating conditions. However, 15 min 
pre-incubation of cells with H89 (a PKA inhibitor) abolished the motility enhancing effects of 
compound(s) under these conditions. Therefore, in this section the effects of H89 on sperm 
incubated under capacitating conditions is assessed. To achieve this, sperm cells were pre-
incubated with inhibitor (H89) in non-capacitating media for 15 min, to ensure PKA 
inhibition prior to exposure to CM, before resuspending the cells in capacitating media that 
contains H89 (50µM) (CM+H89) and incubation for 3hrs.  After 3hrs incubation, cells from 
each incubation conditions were exposed to compounds for 20 min (see Figure 4-2). 
Similar to what was observed under non-capacitating conditions (Figure 4-3A above), 
exposure of sperm cells to H89 have no significant (p >0 .05) effect on total sperm motility 
(compare white vs black bar chart: Figure 4-5A). Comparison of treatment conditions (that is, 
sperm cells in CM+DMSO only or CM+H89 only), also indicates that there is no significant 
difference in total motility between control and compound treated samples; CM+DMSO: p = 
0.8721 (compare white bar chart: Figure 4-5A), CM+H89: p =0.9981 (compare black bar 
chart: Figure 4-5A) respectively. However, contrary to the inhibitory effect of H89 on 
progressive motility of sperm cells under non- capacitating conditions, H89 has no significant 
(p >0 .05) effect on progressive motility when sperm cells were incubated under capacitating 
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Figure 4-5: Capacitating conditions overcomes H89 mediated PKA inhibition of 
progressive motility. (A) Total motility and (B) Progressive motility are not significantly 
(p>0.05) different between H89 (50µM) pre-treated cells (CM+H89) and those in 
CM+DMSO. Values shown were measured 20min after addition of compounds to cells in 
CM+H89 and CM+DMSO respectively. ±SEM n=5-7 (independent experiments): Two 
Way ANOVA: Difference in a treatment group are represented by different letters (a-c for 
those in CM+DMSO: those with different letters differed significantly) and hashtags (# 
for those in CM+H89) respectively. 
conditions (compare white vs black bar chart: Figure 4-5B). This result implies that 
resuspending cells in capacitating media (CM+H89) restores progressive motility inhibited by 
H89 under non-capacitating conditions. Multiple comparison tests indicates that there is no 
significant (indicated by letter a: p >0.05) difference in progressive motility when control and 
PDEi treated samples are compared, however, cells treated with compound #36 have 
significantly higher (*p ≤ 0.05) progressively motile cells than cells treated with compound 
#26 (indicated by letter b vs c: compare white bar chart: Figure 4-5B). For cells incubated in 
CM+H89, there is no significant difference between control and PDEi treated samples: p 
=0.8493 (as indicated by hashtag #: compare black bar chart: Figure 4-5B). 
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4.4.4 H89 Causes a Reduction in Sperm Swimming Velocities under Capacitating 
Conditions 
 
Analysis of sperm velocities showed a general trend: sperm cells incubated in CM+DMSO 
have higher velocities than those incubated in CM+H89 for VAP, VSL and VCL respectively. 
Particularly for VAP, when comparing CM+DMSO vs CM+H89, there is a statistically 
significant difference in mean VAP for each treatment condition, (DMSO(1%), #36 and #38: 
* p ≤ 0.05), (#26 and #30: ** p ≤ 0.01), except for #37 and IBMX respectively (compare 
white vs black bar chart: Figure 4-6A). Multiple comparison tests of cells incubated in 
CM+DMSO indicates that there is no significant (indicated by letter a: p >0.05) difference in 
VAP when control and PDEi treated samples are compared, however, cells treated with 
compound #30 are significantly (*p ≤ 0.05) different to those treated with IBMX (indicated 
by letter b vs c: compare white bar chart: Figure 4-6A). For cells incubated in CM+H89, there 
is no significant difference between control and compound treated samples: p =0.9437 (as 
indicated by hashtag #: compare black bar chart: Figure 4-6A). 
 
With regards to VSL, comparing CM+DMSO vs CM+H89, there is a significant difference in 
VSL as a result of incubation conditions, (DMSO(1%), #26, #37 and #38* p ≤ 0.05), (#30 and 
#36 ** p ≤ 0.01), except IBMX (compare white vs black bar chart: Figure 4-6B). The effects 
of compounds on the basis of treatment conditions indicated that, for cells in CM+DMSO, 
there is no significant (indicated by letter a: p >0.05) difference in VSL when control and 
PDEi treated samples are compared, however, cells treated with #30 are significantly (*p ≤ 
0.05) different to those treated with IBMX (indicated by letter b vs c: compare white bar 
chart: Figure 4-6B). For cells incubated in CM+H89, there is no significant difference 
between control and PDEi treated samples: p =0.9676 (as indicated by hashtag #: compare 
black bar chart: Figure 4-6B). 
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For curvilinear velocity, sperm cells in CM+DMSO have higher VCL than those in CM+H89 
(DMSO, #36, #37 and IBMX: * p ≤ 0.05), (#26 and #38: ** p ≤ 0.01), (#30: *** p ≤ 0.001) 
respectively (compare white vs black bar chart: Figure 4-6C). However, when the effect of 
PDEi on cells incubated in CM+DMSO was compared with control samples, there is no 
significant (p=0.0787) increase in mean VCL (indicated by letter a: compare white bar chart: 
Figure 4-6C). The mean VCL of sperm cells incubated in CM+H89, are also not significantly 
different (p=0.8852) to control (as indicated by hashtag #: compare black bar chart: Figure 
4-6C). 
 
4.4.5 Inhibition of PKA Activity by H89 Leads to Reduction in Percentage of Sperm 
Cells with Hyperactivated Motility under Capacitating Conditions 
 
The effect of compound(s) on hyperactivated motility of cells incubated with or without H89 
was examined under capacitating conditions. Figure 4-7 shows that incubation of cells in 
CM+H89 causes a significant decrease in percentage of hyperactivated cells; with cells 
incubated in CM+DMSO having  higher percentage of hyperactivated cells for each treatment 
conditions (DMSO(1%) and IBMX: * p ≤ 0.05), (#36 and #37: ** p ≤ 0.01), (#26, #30 and 
#38: *** p ≤ 0.001) respectively. Multiple comparison tests of cells incubated in CM+DMSO 
indicates that there is no significant (p=0.0758) difference in percentage of hyperactivated 
cells when control and PDEi treated samples are compared (indicated by letter a: compare 
white bar chart: Figure 4-7). For cells incubated in CM+H89, there is no significant difference 
between control and compound treated samples: p =0.8373 (as indicated by hashtag #: 
compare black bar chart: Figure 4-7). 
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Figure 4-6: Inhibition of PKA with H89 (under capacitating condition). (A) Average path velocity (B) Straight-
line velocity and (C) Curvilinear velocity are reduced (P < 0.05) in H89 (50µM) pre-treated cells in comparison 
to cells in CM+DMSO. Values shown were measured 20min after addition of compounds to cell CM+H89 and 
CM+DMSO respectively. ±SEM n=5-7 (independent experiments): Two Way ANOVA: Differences between 
cells pre-treated with or without (H89) are indicated by asterisk (*p≤0.05 **p≤0.01 ***p≤0.001), while 
difference in a treatment group are represented by different letters (a-c for those in CM+DMSO: those with 
different letters differed significantly) and hashtags (# for those in CM+H89) respectively. 
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  Hyperactivation 
Figure 4-7: Inhibition of PKA with H89 (under capacitating condition) results in decrease in 
hyperactivation. Percentage of hyperactivated cells is reduced (P < 0.05) in H89 (50µM) pre-
treated cells (CM+H89) in comparison to cells in CM+DMSO for each compound tested. 
Values shown were measured 20min after addition of compounds to cells in CM+H89 and 
CM+DMSO respectively. ±SEM n=5-7 (independent experiments): Two Way ANOVA: 
Differences between cells pre-treated with or without (H89) are indicated by asterisk 
(*p≤0.05 **p≤0.01 ***p≤0.001), while difference in a treatment group are represented by 
different letters (those with different letters differed significantly) and hashtags (# for those in 
CM+H89) respectively. 
 
CM+DMSO (0.02%)
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4.4.6 Inhibition of sGC does not Influence Total and Progressive Motility of Sperm 
Incubated under Non-capacitating Conditions  
 
To establish a role for soluble guanylyl cyclase (sGC) pathway in effecting the motility 
enhancing effects of compound #26, #30, #36, #37 and #38, production of cGMP was 
modulated by using ODQ (1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one) (10µM) to inhibit 
the  activity of sGC (Figure 4-8). 
 
 
 
 
 
 
 
 
Sperm cells were pre-incubated for 15 min, under non-capacitating conditions and with or 
without 10µM final concentration of ODQ, before exposure (20 min) to 100µM final 
concentration of compound(s) (1% DMSO: Vehicle Control and 500µM IBMX: Positive 
Control).  A two-way factorial ANOVA was conducted on percentage total and progressive 
motility, with pre-incubation conditions (with or without ODQ) and treatment conditions 
(PDEi treatment or 1%DMSO) as factors. Figure 4-9A showed that there is no significant 
difference between total sperm motility when cells incubated in NCM+DMSO and 
NCM+ODQ were compared (compare white vs black bar chart: Figure 4-9A). This result 
Figure 4-8: Modulation of sGC activity by ODQ (1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-
one) (10µM) to examine the role of cGMP production to influence human sperm motility. 
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indicates that pre-incubation of cells in ODQ (10µM), before exposure to compounds, does 
not affect total motility of sperm cells. Analysis of progressive sperm motility also showed 
that there is no significant difference when cells in NCM+DMSO were compared with those 
in NCM+ODQ (compare white vs black bar chart: Figure 4-9B). However, when treatment 
conditions (that is, effect of PDEi on sperm cells pre-incubated in NCM+DMSO or in 
NCM+ODQ) were considered, there was a significant increase in percentage of cells with 
progressive motility in comparison with respective controls. For cells in NCM+DMSO, post 
hoc analysis using Tukey’s procedure (α level = 0.05), revealed a significant increase in 
percentage of progressively motile cells in comparison to control (1% DMSO); (as indicated 
by letter b: #36: p ≤ 0.001), (as indicated by letter b: #26, #30, #37, #38 and IBMX: p ≤ 0.01) 
(compare white bar chart: Figure 4-9B). Similar pattern of significant increase in percentage 
of progressively motile cell over control was observed for cells in NCM+ODQ, (as indicated 
by double hashtag (##): #26, #36 and #36:  p ≤ 0.0001), (as indicated by double hashtag (##): 
#37, #38 and IBMX *** p ≤ 0.001) (compare black bar chart: Figure 4-9B). These results 
clearly suggest that pre-incubation of sperm cells in ODQ (10µM), which inhibits sGC 
activity, does not affect the motility enhancing effects of the compound(s). 
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Figure 4-9: Inhibition of sGC with ODQ (under non capacitating condition) does not 
affect total or progressive motility. (A) Total motility and (B) Progressive motility are 
not significantly different between ODQ (10µM) pre-treated cells and those in 
NCM+DMSO. Values shown were measured 20min after addition of compounds to 
cell pre-treated (15min) in NCM+ODQ and NCM+DMSO respectively. ±SEM n=4 
(independent experiments): Two Way ANOVA: Difference in a treatment group are 
represented by different letters (a-b for those in NCM+DMSO: those with different 
letters differed significantly) and hashtags (# for those in NCM+ODQ: those with 
double hashtag differed significantly from those with single hashtag.) respectively. 
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4.4.7 PDEi Stimulates Sperm Swimming Velocities in the Presence of Chemical 
Inhibitor of sGC under Non-capacitating Conditions. 
 
Here the effect of PDEi on sperm velocities is evaluated. When velocities of cells incubated in 
NCM+DMSO were compared with those in NCM+ODQ, there was no significant difference 
in average velocities for all the velocities analysed: VAP VSL and VCL respectively 
(compare white vs black bar chart: Figure 4-10).   
When treatment conditions (that is, effect of PDEi on sperm cells in NCM+DMSO or in 
NCM+ODQ) were considered, there was a significant increase in average VAP, VSL and 
VCL in comparison with respective controls. Particularly for cells incubated in 
NCM+DMSO, multiple comparison tests indicate that there is significant (*p <0.05) 
difference in average velocities: VAP - (as indicated by letter b) (#26 and #38: p ≤ 0.001), 
(#30, #36 and IBMX: p ≤ 0.01) (#37 * p ≤ 0.05) (compare white bar chart: Figure 4-10A), 
VSL - (as indicated by letter b) (#26 and #36: p ≤ 0.0001), (#30, #38 and IBMX: p ≤ 0.001) 
(#37: p ≤ 0.001) (compare white bar chart Figure 4-10B), VCL - (as indicated by letter b) 
(#26 and  #38: p ≤ 0.01) (#30, #36, #37 and IBMX: p ≤ 0.05) (compare white bar chart Figure 
4-10C) when control (DMSO) and PDEi treated samples are compared. 
For cells incubated in NCM+ODQ, similar pattern of significant increase in average 
velocities: VAP - (as indicated by double hashtag ##) (#26, #36 and #38: p ≤ 0.001), (#30, 
#37 and IBMX: p ≤ 0.01) (compare black bar chart: Figure 4-10A), VSL - (as indicated by 
double hashtag ##) (#26, #36 and #38: p ≤ 0.0001), (#30 and IBMX: p ≤ 0.001) (#37: p ≤ 
0.001) (compare black bar chart: Figure 4-10B), VCL - (as indicated by double hashtag ##) 
(#26 and  #38: p ≤ 0.001) )  (#36 and IBMX : p ≤ 0.01) (#30 and #37: p ≤ 0.05) (compare 
white bar chart: Figure 4-10C), over control sample were observed for cells incubated in 
NCM+ODQ.   
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Figure 4-10: Inhibition of sGC with ODQ (under non capacitating condition) does not affect sperm velocity parameters. (A) 
Average path velocity (B) Straight-line velocity and (C) Curvilinear velocity are not significantly different (p > 0.05) in 
ODQ (10µM) pre-treated cells in comparison to cells in NCM+DMSO. Values shown were measured 20min after addition 
of compounds to cell pre-treated (15min) in NCM+ODQ and NCM+DMSO respectively. ±SEM n=4 (independent 
experiments): Two Way ANOVA: Difference in a treatment group are represented by different letters (a-b for those in 
NCM+DMSO: those with different letters differed significantly) and hashtags (# for those in NCM+ODQ: those with double 
hashtag differed significantly from those with single hashtag.) respectively. 
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4.4.8 Inhibition of sGC Activity by ODQ does not Affect Motility of Sperm Cells 
Incubated under Capacitating Conditions 
 
Result shown in Figure 4-9 and Figure 4-10 unequivocally show that under non-capacitating 
conditions, pre-incubation of cells in ODQ prior to exposure to compounds does not affect the 
motility enhancing effects of compounds. Under this condition, exposure of cells to PDEi 
significantly enhances progressive motility and sperm velocities; there is no significance 
difference between cells incubated in NCM+DMSO vs NCM+ODQ. 
In this section, the effects of ODQ on sperm incubated under capacitating conditions were 
assessed. Sperm cells were pre-incubated with inhibitor (ODQ) in non-capacitating media for 
15 min prior to resuspending the cells in capacitating media that contains ODQ (10µM) 
(CM+ODQ) and incubation for 3hrs. Alternatively, sperm cells were resuspended in 
capacitating media that contains 0.02% DMSO (CM+DMSO) and incubated for 3hrs. After 
3hrs incubation, cells from each incubation conditions were exposed to compounds for 20 
min. 
Figure 4-11A and B imply that exposure of sperm cells to ODQ under capacitating condition 
has no significant (p >0 .05) effect on total and progressive sperm motility (compare white vs 
black bar chart: Figure 4-11A and B). Comparison of treatment conditions (that is, effect of 
PDEi on sperm cells pre-incubated in CM+DMSO or CM+ODQ ), also indicates that there is 
no significant difference between control and compound treated samples- total motility 
CM+DMSO: p = 0.7437 (compare white bar chart: Figure 4-11A), CM+ODQ: p =0.9901 
(compare black bar chart: Figure 4-11A); progressive motility CM+DMSO: p = 0.0657 
(compare white bar chart: Figure 4-11B), CM+ODQ: p =0.2485 (compare black bar chart: 
Figure 4-11B) respectively. 
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Figure 4-11: Inhibition of sGC with ODQ (under capacitating condition) does not 
affect total or progressive motility. (A) Total motility and (B) Progressive motility 
are not significantly different between ODQ (10µM) pre-treated cells and those in 
CM+DMSO. Values shown were measured 20min after addition of compounds to 
cell in CM+ODQ and CM+DMSO respectively. ±SEM n=4 (independent 
experiments): Two Way ANOVA.  
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Figure 4-12: Inhibition of sGC with ODQ (under capacitating condition). (A) Average path velocity 
(B) Straight-line velocity and (C) Curvilinear velocity are not significantly different (p > 0.05) in 
ODQ (10µM) pre-treated cells in comparison to cells in CM+DMSO. Values shown were measured 
20min after addition of compounds to cell in CM+ODQ and CM+DMSO respectively. ±SEM n=4 
(independent experiments): Two Way ANOVA. 
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4.4.9 Inhibition of sGC Activity by ODQ does not Affect Velocities of Sperm Cells 
Incubated under Capacitating Conditions. 
 
Sperm velocities showed a general trend: sperm cells incubated in CM+DMSO are not 
significantly different (p >0.05) to those incubated in CM+ODQ for VAP, VSL and VCL 
respectively. Specifically for VAP, when comparing CM+DMSO vs CM+ODQ, there is no 
statistically significant difference in average VAP (compare white vs black bar chart: Figure 
4-12A). Multiple comparison tests also revealed that cells incubated in CM+DMSO or in 
CM+ODQ are not significantly (p >0.05) different from their respective controls (compare 
compounds vs DMSO). 
There is no significant difference in VSL for each treatment conditions when comparing 
CM+DMSO vs CM+ODQ (compare white vs black bar chart: Figure 4-12B). The effects of 
PDEi on the basis of incubation conditions indicated that, for cells in CM+DMSO, only cells 
treated with compound #30 are significantly (p <0.05) different in VSL when compared with 
control, other PDEi treated cells are not statistically different to control (compare white bar 
chart: Figure 4-12B). For cells incubated in CM+ODQ, there is no significant difference 
between control and PDEi treated samples: p =0.3078 (compare black bar chart: Figure 
4-12B). 
For curvilinear velocity, sperm cells incubated in CM+DMSO are not significantly different 
to those in CM+ODQ (p > 0.05) respectively (compare white vs black bar chart: Figure 
4-12C). However, when effect of PDEi on cells incubated in CM+DMSO was compared with 
control samples and each other, there is no significant (p=0.0787) increase in mean VCL was 
found (compare white bar chart: Figure 4-12C). The mean VCL of sperm cells incubated in 
CM+ODQ, are not significantly different (p=0.8852) to control (compare black bar chart: 
Figure 4-12C). 
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4.4.10 Inhibition of sGC Activity by ODQ does not Affect Hyperactivated Motility of 
Sperm Cells Incubated under Capacitating Conditions. 
 
The effect of PDEi on hyperactivated motility of cells pre-incubated with or without ODQ 
was examined under capacitating conditions. Figure 4-13 showed that there is no significant 
difference in percentage of hyperactivated cells between cells incubation in CM+DMSO or 
CM+ODQ (p ≥ 0.05). Multiple comparison tests of cells incubated in CM+DMSO or 
CM+ODQ also indicates that there is no significant (p ≥ 0.05) difference in percentage of 
hyperactivated cells when control and compound treated samples are compared respectively 
(compare white or black bar chart: Figure 4-13). 
 
  Figure 4-13: Inhibition of sGC with ODQ (under capacitating condition) does not affect 
percentage of hyperactivated cells. Values shown were measured 20min after addition of 
compounds to cells in CM+ODQ and CM+DMSO respectively. ±SEM n=4 (independent 
experiments): Two Way ANOVA 
Hyperactivation 
CM+DMSO (0.02%)
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4.4.11 Inhibition of PKG Activity by KT5823 does not Affect Total and Progressive 
Sperm Motility under Non-capacitating Conditions  
 
In order to characterise the involvement of PKG pathway in effecting the motility enhancing 
effects of compound #26, #30, #36, #37 and #38, KT5823 (10µM) was used to modulate PKG 
activity  (Figure 4-14). 
 
 
 
 
 
 
 
 
 
 
 
Similar experimental conditions to cells treated with ODQ was also used, that is, sperm cells 
were pre-incubated for 15 min, under non-capacitating conditions and with or without 10µM 
final concentration of KT5823, before exposure (20 min) to 100µM final concentration of 
compound(s) (1% DMSO: Vehicle Control and 500µM IBMX: Positive Control) (see Figure 
4-15).  A two-way factorial ANOVA was conducted on percentage total and progressive 
Figure 4-14: Modulation of PKG activity by KT5823 (9S,10R,12R)-2,3,9,10,11,12-
Hexahydro-10-methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-
fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl ester 
(10µM). 
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motility, with incubation conditions (with or without KT5823) and treatment conditions 
(compound treatment) as factors. Figure 4-15A and B showed that there is no significant 
difference between total and progressive sperm motility when cells incubated in 
NCM+DMSO and NCM+KT5823 were compared (compare white vs black bar chart: Figure 
4-15A and B). This result indicates that pre-incubation of cells in KT5823 (10µM), before 
exposure to compounds, does not affect total and progressive motility of sperm cells. 
However, when incubation conditions (that is, effect of compound on sperm cells in 
NCM+DMSO or in NCM+KT5823) was considered, there is a significant increase in 
percentage of cells with progressive motility in comparison with respective controls. For cells 
in NCM+DMSO, post hoc analysis using Tukey’s procedure (α level = 0.05), revealed a 
significant increase in percentage of progressively motile cells in comparison to control (1% 
DMSO); (as indicated by letter b:  #26, #30, #36, #37, #38 and IBMX:  p ≤ 0.0001) (compare 
white bar chart: Figure 4-15B). Similar pattern of significant increase in percentage of 
progressively motile cell over control was observed for cells in NCM+KT5823, (as indicated 
by double hashtag (##): #26, #30, #36, #37, #38 and IBMX:  p ≤ 0.0001) (compare black bar 
chart: Figure 4-15B). With these results, it is clear that pre-incubation of sperm cells in 
KT5823 (10µM) does not affect the motility enhancing effects of the compound(s). 
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Total Motility 
Progressive Motility 
Figure 4-15: Inhibition of PKG with KT5823 (under non capacitating condition) does not 
affect total or progressive motility. (A) Total motility and (B) Progressive motility are not 
significantly different between KT5823 (10µM) pre-treated cells and those in NCM+DMSO. 
Values shown were measured 20min after addition of compounds to cell pre-treated (15min) in 
NCM+KT5823 and NCM+DMSO respectively. ±SEM n=3 (independent experiments): Two 
Way ANOVA. There is no significant difference between cells pre-treated with or without 
KT5823). Difference in a treatment group are represented by different letters (a-b for those in 
NCM+DMSO: those with different letters differed significantly) and hashtags (# for those in 
NCM+KT5823: those with double hashtag differed significantly from those with single 
hashtag.) respectively. 
B 
A 
NCM+DMSO (0.02%) 
NCM+DMSO (0.02%) 
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4.4.12 Inhibition of PKG Activity by KT5823 does not Affect Velocities of Sperm Cells 
Incubated under Non-capacitating Conditions. 
 
When velocities of cells incubated in NCM+DMSO were compared with those in 
NCM+KT5823 for each treatment conditions, there was no significant difference in average 
velocities for all the velocities analysed: VAP VSL and VCL respectively (compare white vs 
black bar chart: Figure 4-16).   
Comparison of incubation conditions (that is, effect of compound on sperm cells in 
NCM+DMSO or in NCM+KT5823) showed that there was a significant increase in average 
VAP, VSL and VCL in comparison with respective controls. For cells incubated in 
NCM+DMSO, multiple comparison tests indicates that there is significant (p <0.05) 
difference in average velocities: VAP - (as indicated by letter b) (#26, #36, #37, #38 and 
IBMX : p ≤ 0.01), (#30: p ≤ 0.05) (compare white bar chart: Figure 4-16A); VSL - (as 
indicated by letter b) (#26 and #38: p ≤ 0.001), (#30, #36, #37 and IBMX: p ≤ 0.01) (compare 
white bar chart: Figure 4-16B), VCL - (as indicated by letter b) (#26 and  #38: p ≤ 0.05) 
(compare white bar chart: Figure 4-16C) when control (DMSO) and PDEi treated samples are 
compared. 
For cells incubated in NCM+KT5823, similar pattern of significant increase in average 
velocities: VAP - (as indicated by double hashtag ##) (#26, #30 and #36:  p ≤ 0.01), (#30, 
#37, #38 and IBMX :  p ≤ 0.05) (compare black bar chart: Figure 4-16A), VSL - (as indicated 
by double hashtag ##) (#26, #30 and #36:  p ≤ 0.001), (#38 and IBMX: p ≤ 0.01) (#37: p ≤ 
0.05) (compare black bar chart: Figure 4-16B), VCL -(as indicated by double hashtag ##) 
(#26 and  #36: p ≤ 0.05) (compare white bar chart: Figure 4-16C), over control sample were 
observed for cells incubated in NCM+KT5823.  
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Average Path velocity Straight-line Velocity 
  
Curvilinear Velocity 
Figure 4-16: Inhibition of PKG with KT5823 (under non capacitating condition). (A) Average path velocity (B) Straight-line 
velocity and (C) Curvilinear velocity are not significantly different (p > 0.05) in KT5823 (10µM) pre-treated cells in comparison 
to cells in NCM+DMSO. Values shown were measured 20min after addition of compounds to cell pre-treated (15min) in 
NCM+KT5823 and NCM+DMSO respectively. ±SEM n=4 (independent experiments): Two Way ANOVA. Difference in a 
treatment group are represented by different letters (a-b for those in NCM+DMSO: those with different letters differed 
significantly) and hashtags (# for those in NCM+KT5823: those with double hashtag differed significantly from those with 
single hashtag.) respectively. 
A 
B 
C 
NCM+DMSO (0.02%) 
NCM+DMSO (0.02%) 
NCM+DMSO (0.02%) 
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4.4.13 Inhibition of PKG Activity by KT5823 does not Affect Total and Progressive 
Motility of Sperm Cells Incubated under Capacitating Conditions 
 
In this section, the effects of KT5823 on sperm incubated under capacitating conditions were 
assessed. Sperm cells were pre-incubated with inhibitor (KT5823) in non-capacitating media 
for 15 min prior to resuspending the cells in capacitating media that contains KT5823 (10µM) 
(CM+KT5823) and incubation for 3hrs. Alternatively, sperm cells were resuspended in 
capacitating media (CM+DMSO) and incubated for 3hrs. After 3hrs incubation, cells from 
each incubation conditions were exposed to compounds for 20 min. 
 
Figure 4-17A and B shows that exposure of sperm cells to KT5823 under capacitating 
condition has no significant (p >0 .05) effect on total and progressive sperm motility 
(compare white vs black bar chart: Figure 4-17A and B). Additionally, comparison of 
incubation conditions (that is, sperm cells in CM+DMSO or CM+KT5823), also indicates that 
there is no significant difference between control and compound treated samples- total 
motility CM+DMSO (p = 0.6633 compare white bar chart: Figure 4-17A), CM+KT5823 (p 
=0.9714 compare black bar chart: Figure 4-17A); progressive motility CM+DMSO (p = 
0.6356 compare white bar chart: Figure 4-17B), CM+KT5823 (p =0.8197 compare black bar 
chart: Figure 4-17B) respectively. 
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  Total Motility 
Progressive Motility 
Figure 4-17: Inhibition of PKG with KT5823 (under capacitating condition) does 
not affect total or progressive motility. (A) Total motility and (B) Progressive 
motility are not significantly different between KT5823 (10µM) pre-treated cells 
and those in CM+DMSO. Values shown were measured 20min after addition of 
compounds to cell in CM+KT5823 and CM+DMSO respectively. ±SEM n=3 
(independent experiments): Two Way ANOVA.  
A 
B 
CM+DMSO (0.02%)  
CM+DMSO (0.02%) 
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Average Path velocity Straight-line Velocity 
 
  
Curvilinear Velocity 
Figure 4-18: Inhibition of PKG with KT5823 (under capacitating condition). (A) Average path 
velocity (B) Straight-line velocity and (C) Curvilinear velocity are not significantly different (p > 
0.05) in KT5823 (10µM) pre-treated cells in comparison to cells in CM+DMSO. Values shown 
were measured 20min after addition of compounds to cell in CM+KT5823 and CM+DMSO 
respectively. ±SEM n=3 (independent experiments): Two Way ANOVA. 
A B 
C 
CM+DMSO (0.02%) 
CM+DMSO (0.02%) 
CM+DMSO (0.02%) 
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4.4.14 Inhibition of PKG Activity by KT5823 does not Affect Velocities of Sperm Cells 
Incubated under Capacitating Conditions. 
 
Sperm velocities showed a general trend: sperm cells incubated in CM+DMSO are not 
significantly different (p >0.05) to those incubated in CM+KT5823 for VAP, VSL and VCL 
respectively. Specifically for VAP, when comparing CM+DMSO vs CM+KT5823, there is no 
statistically significant difference in average VAP for each treatment conditions (compare 
white vs black bar chart: Figure 4-18A). Multiple comparison tests also revealed that cells 
incubated in CM+DMSO or in CM+KT5823 are not significantly (*p >0.05) different from 
their respective controls (compare compounds vs DMSO). 
 
There is no significant difference in VSL for each treatment conditions when comparing 
CM+DMSO vs CM+KT5823 (compare white vs black bar chart: Figure 4-18B). The effects 
of compounds on the basis of incubation conditions indicated that, for cells in CM+DMSO, 
cells treated with compound #30 are significantly (*p <0.05) different in VSL when compared 
with control, other compound treated cells are not statistically different to control (compare 
white bar chart: Figure 4-18B). For cells incubated in CM+KT5823, there is no significant 
difference between control and compound treated samples: p =0.3078 (compare black bar 
chart: Figure 4-18B). 
 
For curvilinear velocity, sperm cells incubated in CM+DMSO are not significantly different 
to those in CM+KT5823 (p > 0.05) respectively (compare white vs black bar chart: Figure 
4-18C). However, when effect of compound(s) on cells incubated in CM+DMSO was 
compared with control samples and each other, no significant (p=0.0787) increase in mean 
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VCL was found (compare white bar chart: Figure 4-18C). The mean VCL of sperm cells 
incubated in CM+KT5823, are not significantly different (p=0.8852) to control (compare 
black bar chart: Figure 4-18C). 
 
4.4.15 Inhibition of PKG Activity by KT5823 does not affect Hyperactivated Motility of 
Sperm Cells Incubated under Capacitating Conditions. 
 
The effect of compound(s) on hyperactivated motility of cells incubated with or without 
KT5823 was examined under capacitating conditions. Figure 4-19 shows that there is no 
significant difference in percentage of hyperactivated cells between cells incubation in CM or 
CM+KT5823 (p ≥ 0.05). Multiple comparison tests of cells incubated in CM or CM+KT5823 
also indicated that there is no significant (p ≥ 0.05) difference in percentage of hyperactivated 
cells when control and compound treated samples are compared respectively (compare white 
or black bar chart: Figure 4-19).  
  
Figure 4-19: Inhibition of PKG with KT5823 (under capacitating condition) does not 
affect percentage of hyperactivated cells. Values shown were measured 20min after 
addition of compounds to cells in CM+KT5823 and CM+DMSO respectively. ±SEM 
n=3 (independent experiments). Two Way ANOVA. 
 
Hyperactivation 
CM+DMSO (0.02%) 
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4.5 Discussion 
 
This present study serves to determine the intracellular pathway(s) involved in the motility 
stimulating effects of the compounds with reported phosphodiesterase inhibitor activity 
identified in Chapter 3. The effects of PDEi’s on sperm motility and velocities were assessed 
in the presence of chemical compounds capable of inhibiting PKA, sGC and PKG activity 
respectively. Sperm cells were pre-incubated with or without H89, ODQ and KT5823, under 
capacitating and non-capacitating conditions respectively, before exposure to PDE inhibitors 
(1% DMSO: Vehicle Control and 500µM IBMX: Positive Control).  
The non-capacitating conditions used in this study support basal but constitutive activation of 
sAC since media constituent contains Ca2+ (1.8mM) and low concentration of Mg2+ (0.8mM).  
Study by Litvin et.al 2003, shows that in the absence of HCO3
-, activity of recombinant 
human sAC is only inhibited at high ATP-Mg2+ (substrate) concentrations (>6mM)  and 
presence of HCO3
- intensifies the reaction rate of sAC (30-fold stimulation of activity); 
thereby increasing the rate of converting ATP to cAMP (Litvin et al., 2003).  Therefore, the 
components of the medium  in  which  the  sperm  are  incubated  can  have  different  effects  
on  intracellular  enzymes,  and  so  affect  motility.   
Under non-capacitating conditions and in the absence of PKA inhibitor (H89), PDEi’s were 
effective in enhancing progressive motility and all velocity parameters analysed when 
compared with their relative controls (compare white bar chart: Figure 4-3B and Figure 4-4). 
Considering the sAC-cAMP/PKA signalling pathway, these results mean that addition of 
PDEi’s prevents the degradation of cAMP produced as a result of basal activity of sAC. In 
effect, increase in intracellular cAMP concentration leads to enhanced activation of PKA 
activity and the resultant enhancement in progressive and motility parameters. 
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However, pre-incubation of spermatozoa with H89 (50 µM) results in a significant decrease in 
progressive motility and velocities and addition of PDEi’s could not rescue the inhibitory 
effects of H89 under this condition (Figure 4-3B and Figure 4-4). The inhibitory effects of 
H89 were not due to non-speciﬁc effects on the viability of the spermatozoa, because this 
reagent had no signiﬁcant effect on total motility (Figure 4-3A). Additionally, concentrations 
of H89 ranging from 10 to 100 µM have been used by other studies to assess the role of PKA 
in sperm motility and capacitation and these studies have shown that H89 is not toxic to 
human sperm (Aitken et al., 1998a, Bajpai and Doncel, 2003, Battistone et al., 2013). Thus, 
the decrease in motility is most likely due to an antagonistic effect on PKA; and since 
addition of PDEi did not rescue decrease in motility and velocities, it indicates that PKA is 
working downstream of PDEi activity. Additionally the results presented here showed that 
overall; cAMP/PKA pathway is crucial for basal motility of human sperm.  
Interestingly, however, when sperm were resuspended in capacitating media and incubated in 
the presence of H89 (CM+H89), progressive motility was restored (Figure 4-5B).  This result 
could possibly suggest that there is an alternative pathway in spermatozoa, independent of 
PKA, which supports progressive motility under capacitating conditions even if cells were 
pre-treated / exposed to PKA inhibitor: H89. In many cellular systems, there are often 
complex signal transduction pathways: involving cross-talk between effector feedback 
inhibition mechanisms, and compensatory mechanisms that are vital for the dynamic and 
adaptive nature of cellular responses (Bajpai and Doncel, 2003, Logue and Morrison, 2012). 
Indeed, regulation of mammalian sperm motility is a complex process involving activation 
and/or down regulation of different signal transduction pathways (Thundathil et al., 2002, 
Turner, 2005). In addition to PKA activities, stimulation of sperm motility by Ca2+/CaM/CaM 
Kinase signalling pathway has been reported by many studies (Lasko et al., 2012, 
Schlingmann et al., 2007, Ignotz and Suarez, 2005, Marin-Briggiler et al., 2005). In human 
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and stallion sperm, CaM kinase IV and II has been found to be localised in the principal piece 
of the flagellum (Marin-Briggiler et al., 2005) and its been suggested to achieve some of the 
effects of Ca2+ on the flagellum; since inhibition of CaM decreases sperm motility (Si and 
Olds-Clarke, 2000, Ignotz and Suarez, 2005, Lasko et al., 2012). Although not investigated in 
this study, it is probable that Ca2+/CaM/CaM Kinase signalling pathway might be involved in 
the restoration of progressive motility of sperm cells incubated in the presence of PKA 
inhibitor: H89. 
An alternative argument could be that, resuspending cells in capacitating media that contains 
HCO3
- leads to increased sAC activity (30-fold stimulation of activity) and a massive cAMP 
increase leads to pronounced activation, by inducing dissociation of the catalytic domain from 
its regulatory subunits, of PKA activity that overcomes H89 inhibitory effect. Indeed, while 
several studies have used H89 as potent and specific inhibitor of PKA, H89 is a reversible 
competitive inhibitor of PKA. H89 works through competitive blockade of ATP binding site 
on PKA catalytic subunit. Thus, increase in the release of PKA catalytic subunit, as a result of 
rise in cAMP, means H89 and ATP are competing at higher concentration of PKA catalytic 
subunit and there are chances that ATP binds to some PKA catalytic subunits and then 
phosphorylate appropriate serine or threonine residues on target proteins that supports 
progressive motility under this condition of treatment.  
In this study, inhibition of PKA activity by H89 suppresses hyperactivated motility; a 
movement pattern characterised by asymmetrical, high amplitude beats of the ﬂagellum 
(Figure 4-7) and addition of PDEi was unable to restore hyperactivated motility. This result is 
in keeping with the proposed role of PKA in sperm; PKA has been shown to phosphorylate 
several proteins on Ser and Thr residues, activating, either directly or indirectly, several 
protein kinases and/or inhibiting protein phosphatases, which will finally produce an increase 
in the total protein tyrosine phosphorylation (Okamura et al., 1985, Bajpai and Doncel, 2003, 
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Luconi et al., 2005). Therefore, PKA inhibition by H89 blocks the onset of tyrosine 
phosphorylation which is important for the development of hyperactivation (Visconti et al., 
1995b, Nolan et al., 2004a, Naz and Rajesh, 2004, Leclerc et al., 1996a). Additionally, all 
velocity parameters analysed were found to be significantly reduced when cells were exposed 
to H89, under capacitating conditions (Figure 4-6).  This could be as a result of decreased 
tyrosine phosphorylation of flagellar proteins which probably leads to decreased flexibility of 
the fibrous sheath of the sperm tail (Si and Okuno, 1999). Consequently, this result highlights 
the participation of PKA pathway in enhancing sperm velocity and modulation of 
hyperactivated motility in human sperm. Additionally, since treatment with PDEi cannot 
rescue the inhibitory effects of H89, it can be concluded that PKA activity is acting 
downstream of PDEi’s in the signalling pathway. 
To establish a role for sCG-cGMP/PKG signalling pathways in human sperm motility and to 
determine if this pathway is involved in the motility enhancing effects of the PDEi’s, activity 
of sGC and PKG were modulated by ODQ and KT5823 respectively. In the literature, there 
are still controversies regarding the role of sGC in relation to human sperm motility. Although 
immunoblotting confirms a low but functional presence of sGC in human sperm, presence of 
PKG has not been detected in human sperm (Willipinski-Stapelfeldt et al., 2004). Assessment 
of functional activity of sGC in intact and membrane fraction of human sperm cells, showed 
that sGC has a relatively low activity in comparison to sAC and atrial natriuretic peptide and 
related peptides: brain natriuretic peptide and C-type natriuretic peptide are ineffective in 
elevating sperm cGMP; only sodium nitroprusside (SNP), a nitric oxide (NO) donor, induces 
a 2.8-fold increase in the relatively low cGMP concentration in human sperm (Revelli et al., 
2001, Wang et al., 2014). As a free radical, many investigators support the notion that 
physiological concentration of NO (<1µM) is beneficial to some sperm functions and 
increased level of NO is detrimental to sperm cells (Salvolini et al., 2012, de Lamirande et al., 
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1997a, Balercia et al., 2004, Lewis et al., 1996, Zini et al., 1995). In a recent study by 
Miraglia et. al, it was suggested that NO stimulates human sperm through activation of PKG 
pathway (Miraglia et al., 2011). This study is in contrast to study that suggested that there is 
no PKG in human sperm (Willipinski-Stapelfeldt et al., 2004). A careful consideration of the 
incubation conditions used in this study shows that sperm cells were isolated through swim-
up technique (for 2hr) in a sperm wash media that contains HCO3
- (Miraglia et al., 2010). 
Thus, for this study, the activity of sAC-cAMP/PKA driving the observed effect cannot be 
ruled out since incubation of cells for 2hrs in media that contains HCO3
- will lead to 
activation of this pathway.  
In other studies, Sildenafil a type-specific inhibitor of PDE5 that blocks degradation of cGMP 
has been used to stimulate sperm motility. Both Lefièvre et. al and Cuadra et. al suggested 
that addition of Sildenafil enhances sperm motility in vitro (Lefièvre et al., 2000, Cuadra et 
al., 2000). However, sperm preparation methods used by both studies also involves exposure 
of sperm cells to conditions that could stimulates sAC-cAMP/PKA pathways (Lefièvre et al., 
2000). In the study by Lefièvre et. al, a concomitant increase in cAMP level was also reported 
when Sildenafil (at 100-200µM) is added to sperm. The concomitant increase in cAMP and 
cGMP highlights a possible cross-talk with cAMP and cGMP signalling pathways. 
Alternatively, this could suggest that Sildenafil might be non-specific in its action at high 
concentration used in this study. 
Data from this study shows that inhibiting the activity of sGC (ODQ 10µM) and PKG 
(KT5823 10µM) has no effect on sperm motility.  Under non-capacitating conditions (in the 
absence of HCO3
-) and in the presence of chemical inhibitor of sGC and PKG, PDEi’s were 
effective in enhancing progressive motility (Figure 4-9B and Figure 4-15B) and there is no 
difference between cells pre-incubated with or without chemical inhibitor of sGC and PKG 
respectively. In the same way, PDEi’s strongly increase the individual parameters of sperm 
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velocities (Figure 4-10 and Figure 4-16). This results are totally in contrast to what was 
observed when cells were pre-incubated with PKA inhibitor (H89), were addition of H89 
significantly reduces progressive motility and sperm velocities; and addition of PDEi’s could 
not rescue the inhibitory effect of H89 (see above).  
Also, under capacitating conditions (in the presence of HCO3
-), there was no difference 
between ODQ and KT5823 treated and untreated sperm cells; addition of compounds resulted 
in similar motility and velocity pattern for both treated (ODQ and KT5823) and untreated 
cells: progressive motility (compare white vs black bar chart: Figure 4-11and Figure 4-17), 
sperm velocities (compare white vs black bar chart: Figure 4-12 and Figure 4-18) and 
hyperactivated motility (compare white vs black bar chart: Figure 4-13 and Figure 4-19). 
Since inhibition of sGC and PKG activity did not blunt or abolish the effects of PDEi on 
sperm motility, it can be concluded that sGC and PKG do not participate in the overall 
signalling pathway involved in the motility enhancing effects of PDEi identified. 
In conclusion, this experimental strategy indicated that PKA signalling pathway is mediating 
the intracellular pathway(s) involved in the motility stimulating effects of PDEi identified 
Chapter 3. Furthermore, test of sGC and PKG inhibitors showed that motility enhancement by 
PDEi was independent of sGC and PKG activity. Also, for the first time, data from this study 
shows that PKA activity is essential for the maintenance of basal progressive motility of 
human sperm under non-capacitating conditions. In addition, this study also suggested that 
there might be an alternative pathway independent of PKA that supports progressive motility 
under capacitating conditions. Finally, data presented here also showed that continuous 
activation of PKA is necessary for hyperactivated motility. 
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Chapter 5.  
Ibudilast enhances in vitro fertilization rate of in vitro mature 
porcine oocytes 
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5.1 Introduction 
 
The overall goal of screening for new compounds in this study is to identify compounds that 
could be used clinically: as a result of enhancement in sperm motility and functionality in 
relation to in vitro fertilization. Thus, to build on chapters 3 and 4, animal IVF system was 
developed in this study as a proof of concept model that demonstrates that addition of PDEi’s 
could enhance IVF. Current ethical approval preclude the use of human oocyte for research, 
thus, porcine IVF system was used. 
Advances in in vitro maturation (IVM) and in vitro fertilization (IVF) of porcine oocyte 
means use of this model for basic biomedical research purposes is gaining popularity. It has 
been demonstrated that cells harvested from unused organs from slaughterhouses, such as 
oocyte, oviductal epithelial cells, cumulus cells (CCs), and granulosa cells, can be grown in 
culture conditions (Areekijseree, 2003, Areekijseree and Vejaratpimol, 2006, Areekijseree 
and Veerapraditsin, 2008).  These cells have also been shown to be an excellent model for the 
biological toxicity study of mammalian reproductive system (Sanmanee and Areekijseree, 
2009, Sanmanee and Areekijseree, 2010).  
Historically, addition of phosphodiesterase inhibitor (such as caffeine) is known to increase 
the ability of spermatozoa to fertilize porcine oocytes (Niwa, 1993). Previous research has 
shown that addition of caffeine (concentration ranging from 1- 5mM) to fresh or frozen-
thawed ejaculated boar spermatozoa significantly influence oocytes penetration in vitro 
(Abeydeera and Day, 1997b, Funahashi et al., 2000, Wang et al., 1991, Funahashi and 
Romar, 2004). By stimulating capacitation and/or acrosome reaction related events during in 
vitro co-culture of sperm-oocytes, caffeine is thought to increase the chance of more 
spermatozoa binding to the zona pellucida, thus more sperm cells achieve penetration within 
a narrow window (Funahashi et al., 2000).  However, a high incidence of polyspermic 
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penetration (the penetration of an oocyte by more than one spermatozoon) remains a 
persistence problem to porcine IVF systems when caffeine is added to culture media 
(Machatkova et al., 2007, Niwa, 1993, Funahashi and Day, 1997, Day, 2000). 
Examining the effect of caffeine (1mM), fertilization-promoting peptide (FPP) (100nM), and 
adenosine (10µM) on fertilization parameters of in vitro matured oocytes, Funahashi and 
colleagues report that a significantly higher proportion of oocytes were penetrated when IVF 
medium contained caffeine (98%) in comparison with FPP (75%) and adenosine (71%) 
respectively (Funahashi et al., 2000). Nevertheless most of the oocytes were polyspermic in 
the presence of caffeine (87%) when compared with FPP (25%) or adenosine (21%) 
(Funahashi et al., 2000). In another study comparing in vitro fertility of boars with high field 
fertility (Machatkova et al., 2007), it was reported that treatment of spermatozoa with 
caffeine leads to significant polyspermic rate ( range: 50-92%) in comparison to  untreated 
samples (range: 61-75%). This high incident of polyspermic penetration has been attributed 
to slow zona reaction as well as simultaneous penetration by a number of spermatozoa with 
induced acrosome reaction as a result of caffeine in fertilization medium (Wang et al., 1998, 
Han et al., 1999, Funahashi and Nagai, 2001). Thus, an ideal compound that will 
support/enhance in vitro porcine IVF system would: (1) enhance capacitation related events 
without significant induction of acrosome reaction, (2) not increase polyspermy rate or affect 
subsequent development and (3) be non-toxic to both sperm and oocyte respectively. 
 
 
5.2 Aims and Experimental Design 
 
The aim of this chapter is to determine if addition of compound #26 (Ibudilast) during in vitro 
fertilization will promote penetration of ejaculated spermatozoa into oocytes.  To achieve 
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this, in vitro matured porcine oocytes were fertilized in vitro and rate of fertilization 
determined. Additionally, the effect(s) of this compound on boar sperm motility and velocity 
will be investigated using CASA, to determine if the compound produced the same effect as 
shown in human in Chapter 3 and Chapter 4. 
 
5.3 Materials and Methods 
 
5.3.1 Chemicals and Media 
 
The oocyte maturation media (OMM) was a TCM 199- based medium consisting of TCM 
199 salts (TCM-199  with Earle′s salts and L-glutamine, without sodium bicarbonate,  Sigma-
Aldrich, UK) supplemented with 26.2mM NaHCO3, 0.9mM Sodium pyruvate, 1% BSA (heat 
inactivated), 0.1µg/ml luteinizing hormone (LH), 0.1µg/ml Follicle stimulating hormone 
(FSH), 4ng/ml Epidermal growth factor (EGF), 10% (v/v) porcine follicular fluid (pFF), 
50µg/mL streptomycin sulphate, and 50 IU/mL penicillin. The follicular fluid was the pooled 
aspirate of healthy follicles, 6–8 mm diameter; the pooled fluid was centrifuged at 2500 g for 
20 min to remove cell debris, filtered through 0.22 mm membrane filters and stored at -20 
degrees Celsius until needed.  The oocyte collection media (OCM)  was a TCM 199 medium 
(TCM 199- With Hanks′ salts and L-glutamine, without sodium bicarbonate,  Sigma-Aldrich, 
UK), supplemented with 4.2 mM NaHCO3, 10 mM HEPES and 1 mg/mL polyvinyl alcohol 
(PVA) and it was used for washing the oocytes. Media’s pH was adjusted to 7.4 with 1M 
NaOH and was filtered through 0.22 mm disposable filtration unit under sterile conditions.  
The in vitro fertilization media (IVF-m) was based on a modified Tris-buffered media 
described by (Ye et al., 2007) with slight modifications. IVF-m consist of 113 mM NaCl, 3 
mM KCl, 7.5 mM CaCl2.2H2O, 20 mM Tris-base, 11 mM glucose, 5 mM sodium pyruvate, 
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0.3% (w/v) BSA, 0.2 mM freshly prepared reduced glutathione (antioxidant), but free of 
antibiotics (pH 9.9 at 4oC, balanced to pH 7.4 at 39oC in 5% CO2 for 12–24 h). All media 
used in this study were equilibrated beforehand to the gas phase and temperature at which 
they were to be used.  
5.3.2 Ovary Collection and In Vitro Maturation of Oocytes 
 
Pre-pubertal pig ovaries were collected from a local commercial abattoir. They were removed 
within 30 min of slaughter and transported to the laboratory within 1 hour. Selected ovaries 
were washed thrice in sterile phosphate buffered saline (PBS). Ovaries were then placed in a 
sterile Petri dish containing 3ml of OCM. The follicular contents of selected healthy (with a 
translucent appearance and extensive vascularisation) follicles with diameter of about 3–8 
mm were released into the OCM, in the Petri dish, by making an incision (with a scalpel) in 
the follicles. Cumulus oocyte complexes (COCs) with more than three intact and compact 
cumulus layers were selected, under a stereomicroscope, for culture after washing in fresh 
OCM. Then, groups of 25–40 COCs were transferred into OMM (500µl) and incubated under 
an atmosphere of 5% CO2 in humidified air at 39 °C for 48h. All culture containing oocytes 
were covered with a thin layer of pre-equilibrated (5% CO2 in humidified air at 39 °C) 
mineral oil (500µl). Incubator temperatures and gas remained constant of their expected 
values except for short periods when doors were opened to access cells. 
5.3.3 Preparation of Spermatozoa and In Vitro Fertilization (IVF) 
 
Fresh extended pig semen (Pig Improvement Company UK Limited) stored up to 2 day at 16-
17oC in TRIXCell extender (IMV technologies) was washed twice by centrifugation (5 min, 
500 g) in IVF-m. The sperm pellet was resuspended in IVF-m and sperm concentration and 
motility characteristics determined by CASA. The sperm suspension was pre-incubated for a 
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short period (10 min) at 39oC before co-incubation with oocytes. At the end of maturation, 
COCs were denuded of cumulus cells by brief vortexing (1–2 min) in warm OMM (balanced 
at 39oC in 5% CO2), washed in the same media and transferred to fresh dish containing 500µl 
IVF-m which were covered with mineral oil and pre-incubated for 2-3 h. To fertilize the 
oocytes, 10 µl aliquot of sperm cells (1×105 sperm cells/ml) was added to OMM culture 
media containing in vitro matured oocytes. After addition of DMSO (Vehicle control) and 
compound #26 (1% v/v and 100µM final concentration respectively), oocyte–sperm co-
incubation was carried out for 3 h at 39oC under 5% CO2 in humidified air. After a brief wash 
in IVF-m, putative fertilized oocytes were cultured in IVF-m for 18h. 
 
5.3.4 Fixing and Staining of Fertilized Oocytes 
 
To ensure fertilized oocytes can be observed at the pronuclei (2PN) stage, the inseminated 
oocytes were (after 18h) washed by gentle pipetting in fresh IVF-m to remove loosely 
attached spermatozoa and cumulus cells. The oocytes were then permeablized in 100% ice-
cold methanol solution (-20oC) for 1h. The nucleic acid of permeablized oocytes was then 
stained with Hoechst stain (Hoechst 33342 Sigma: 3µg/ml) for 30-45min at 4oC.  
Fertilization was independently assessed and the number of fertilized oocytes (oocytes with 
2PN) was scored using a fluorescent microscopy. 
5.3.5 Fertilization Assessment 
 
Fertilization stage of oocytes was assessed using a fluorescence microscope. Oocytes were 
determined to be penetrated when male pronucleus (pronuclei) were found. Oocytes with 
more than one male pronucleus were assessed as polyspermic. Only oocytes with one male 
and one female pronucleus were determined as monospermic.  
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5.3.6 Boar Sperm Treatment and Motility Analysis  
 
The CASA analysis was performed by using a commercial system (SCA® Microptic version 
5.1.0.1, S.L., Barcelona, Spain). In this procedure, compound (#26: 100µM) and DMSO (1% 
v/v) was added to samples that were previously warmed at 37oC for 10 min. 5 µL aliquots of 
these samples were then placed on a warmed (39oC) microscope and covered with a 25- mm 
x 25-mm coverslip slides (glass slides and coverslips were coated with 0.4% agarose). Sperm 
motion analysis was based on the examination of 30 consecutive, digitalized images obtained 
from a single field using a 10× positive phase contrast objective. Images were taken with a 
time lapse of 1s - the image capture speed was therefore one every 33 millisecond. Three to 
four separate fields were taken for each sample.  With respect to the setting parameters for 
the SCA® program, a sperm cell with a VAP < 20 μm/s was considered static or immotile, 
while objects with a velocity >20 μm/s were considered motile. Sperm cells with >45% STR 
(Straightness coefficient: (VSL/VAP) x100) and with velocities between 30 and 45 μm/s 
were considered as sperm with slow progressive motility speed; those with a velocity 
>45μm/s were considered as sperm with fast progressive motility (Ramio et al., 2008, 
Broekhuijse et al., 2011).  
5.3.7 Statistics 
 
The data were expressed as mean percentages ± SEM of penetrated oocytes from inseminated 
oocytes, and polyspermic and monospermic oocytes from penetrated oocytes. For motility 
analysis, all data are presented as means ± SEM. The statistical analysis was carried out using 
GraphPad Prism 6 (GraphPad Software, California, USA). The data were analysed by One-
way ANOVA on paired observations. Differences were considered significant at a P < 0.05. 
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5.4  Results 
 
5.4.1 In Vitro Maturation (IVM) of Porcine Oocyte 
 
The presence of cumulus cells is considered a significant element of the cumulus oocyte 
complex that supports in vitro nuclear and cytoplasmic maturation necessary for successful 
male pronuclear (MPN) formation and developmental competence of oocytes. In this study, 
oocytes selected for in vitro maturation are based on the characteristic of the cumulus cells 
surrounding the oocytes. Oocytes with no cumulus cells (denuded oocytes) or those with 
partial cumulus cell layers were not selected for IVM (Figure 5-1A and B). Oocytes with 
intact-cumulus, with ≥ 5 layers of compact cumulus cells, and/or those with multi-layered 
cumulus, with 2–3 incomplete layers of CCs, were matured in vitro, in the presence of 10% 
(v/v) pFF, EGF, FSH and LH, to produce oocytes with expanded cumulus cell layer (Figure 
5-1C and D).   
5.4.2 Effects of Ibudilast (Compound #26:100µM)) on Fertilization during Co-
incubation 
 
Boar sperm and in vitro matured oocytes were co-incubated in IVF-m in the presence or 
absence of compound #26 (100 µM) for 3hrs and then putative fertilized oocytes were 
transferred into fresh sperm free IVF-m for 18h. The presence of 100µM compound #26 
during the 3hrs co-culture period significantly improved the rates of sperm penetration (39 
±4% vs 8 ±3%; p<0.005) (Table VII). Considering the effect of compound on the rate of 
monospermic and polyspermic penetration, in total penetrated oocytes examined, 94 ±4% of 
penetrated oocyte showed monospermic penetration, presence of two pronuclei (2PN) (Table 
VII) (Figure 5-2A), and 6 ±4% polyspermic penetration, presence of three or more pronuclei 
(Figure 5-2C), respectively. Oocytes with one pronucleus (PN) were considered unfertilized 
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(Figure 5-2B). For oocytes in control condition (i.e. treated with DMSO), all eight penetrated 
oocytes showed monospermic penetration (Table VII). 
 
 
 
 
   
Figure 5-1: Micrographs of an oocyte with a completely denude oocyte (A), an 
oocyte with partial cumulus cell layers (B), an oocyte with expanded cumulus cell 
layers (lower magnification) (C), an oocyte with expanded cumulus cell layers 
(higher magnification) (D). Micrographs are representation of different oocytes 
assessed using light microscope. The scale bar represents: A and B: 60 μm, C and 
D 150 and 100 μm respectively. 
A B 
C D 
128 
 
Data are from four replicates. 
Percentage of penetrated oocytes is relative to the number of examined oocytes. 
Percentage of monospermic oocytes is relative to the number of penetrated oocytes. 
a,b Values with different superscripts within each column are significantly different (p<0.05). 
n=4(independent experiments) 
   
Figure 5-2 Micrograph of hoechst stained porcine oocytes 18 h after the addition of 
sperm to the oocytes for IVF. In A) a normally fertilized oocyte is seen, with two polar 
bodies. In B), an oocyte with one pronucleus. In C), polyspermic fertilization has taken 
place and multiple decondensed sperm head can be seen. PN: Pronuclei. 3PN: 3 
Pronuclei. DC:Decondensed Nuclei. CC: Cummulus cell. SH: Sperm Head. 
Micrographs are representation of different oocytes assessed using fluoresnce 
microscope. The scale bar represents 40 μm. 
Table VII: Effect of Ibudilast (compound #26) on sperm penetration into oocytes in vitro 
A B 
C 
         
Treatment 
    % of Oocytes ± SEM 
No. of oocytes 
examined Penetrated Monospermy Polyspermy 
DMSO 86 8 ±3 100 - 
#26 159 39 ±4 94 ±4 6 ±4 
 
a 
b 
129 
 
5.4.3 Effect of Ibudilast (Compound #26: 100 µM)) on Boar Sperm Motility 
 
To determine the effects of the compound on boar sperm motility, compound was added to 
samples that were previously warmed at 37oC for 10 min and motility was assessed at t0, t10 
and t20 respectively.  As shown in Figure 5-3A, there is no significant difference between 
total motility, at each time point analysed, when cells incubated in compound #26 (100µM) 
and DMSO were compared (compare white vs black bar chart: Figure 5-3A). With respect to 
progressive motility, addition of compound caused a significant increase in the percentage of 
progressively motile sperm at cells t0 (p< 0.005); however, no significant difference was 
found at other time points (that is t10 and t20) when cells treated with compound #26 and 
DMSO were compared (compare white vs black bar chart: Figure 5-3B). When velocities of 
cells treated with compound were compared with those treated with DMSO, there is no 
significant difference in average velocities for all the velocities analysed and at each time 
points: VAP: (p>0.05) Figure 5-4A; VSL: (p>0.05) Figure 5-4B and VCL: (p>0.05) Figure 
5-4C respectively. 
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* 
A 
B 
Figure 5-3: Effect(s) of compound (#26) on sperm motility: Boar spermatozoa were treated 
for 20min at 37oC with 100µM of compound #26 or DMSO (1% v/v). (A) Total motility is 
not significantly different between DMSO and compound (#26) treated cells at all time-
points (t0, t10 and t20 respectively). (B) Progressive motility is significantly increased at t0, 
however, there is no significant difference between DMSO and compound (#26) treated 
cells at t10 and t20 respectively. n=7 (7 independent experiments), mean ±SEM. Two Way 
ANOVA: *p≤0.05.  
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A 
B 
C 
Figure 5-4: Effects of compound (#26) on swimming velocities of boar 
spermatozoa. (A) Average path velocity (VAP).  (B) Straight-line velocity 
(VSL). (C) Curvilinear velocity. (DMSO: 1% v/v) mean:  ±SEM. Two Way 
ANOVA. 
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5.5 Discussion 
 
Addition of phosphodiesterase inhibitors, such as caffeine and theophylline, during sperm-
oocyte co-incubation is generally employed in many porcine IVF systems (Suzuki et al., 
2005, Yoshioka et al., 2003, Abeydeera and Day, 1997a). These compounds are considered to 
inhibit the degradation of cyclic nucleotides, resulting in an increase in intracellular 
nucleotide, as well as affect various aspects of sperm capacitation and acrosome reaction. 
Addition of caffeine to boar spermatozoa during in vitro fertilization promotes sperm 
penetration; however, this is usually accompanied by an increase in polyspermic penetration 
(Abeydeera and Day, 1997b, Funahashi and Nagai, 2001). In this present study, it is 
demonstrated that compound #26 at 100µM could stimulate the ability of spermatozoa to 
penetrate in vitro-matured porcine oocytes without being accompanied by high rate of 
polyspermic penetration. 
In this present study, the proportion of oocytes penetrated in the presence of compound #26 
were low (39%), but incidence of monospermic penetration was high (96%). The low rate of 
oocyte penetration may be due to the concentration of sperm cells used (1x 105cells/ml). In 
many porcine IVF systems, sperm concentration ranging from 106-107cells/ml has been used 
during sperm to oocyte co-incubation and the mean number of penetrated oocyte tends to 
increase with increasing sperm concentration (Nagai et al., 1984, Funahashi and Day, 1997, 
Funahashi et al., 2000, Wang et al., 1991). However, presence of a large number of 
spermatozoa has been associated with high polyspermy rates (Funahashi and Nagai, 2001). 
Here, concentration of 1x 105cells/ml was used: 1) to ensure that addition of compound #26 
during sperm-oocyte co-incubation is what potentiates oocyte penetration; 2) in order to rule 
out confounding effects relating to addition of large number of spermatozoa during sperm-
oocyte co-incubation.  
133 
 
Use of optimal sperm-oocyte co-incubation time interval is crucial in porcine IVF systems in 
order to allow sufficient sperm-oocyte interaction and prevent high incidence of polyspermic 
penetration. Data presented here suggest that sperm-oocyte co-incubation interval of 3hrs, in 
the presence of compound #26, followed by post-incubation in fertilization media without 
sperm and compound, is efficient for sperm-oocyte interaction and promotion of high 
monospermic penetration rate. Gamete co-incubation of 16-21hrs has been reported 
(Martinez et al., 1996), however, the deleterious effect of reactive oxygen species (ROS) 
during prolonged gamete co-incubation has been extensively documented (Guérin et al., 
2001). Although, ROS may originate from oocyte metabolism, as a result of enzymatic 
activity, it is plausible that prolonged interval of gamete co-incubation may result in an 
excess of dead sperm leading to generation of ROS in culture. A recent study demonstrate 
that ROS levels generated by spermatozoa significantly increases after 18 h in culture 
(Enkhmaa et al., 2009). Therefore, 3hrs gamete co-incubation time used in this study could 
potentially mean reduction in the level of ROS in culture media. 
In most porcine IVF systems (Grupen, 2014, Abeydeera and Day, 1997a, Funahashi and 
Romar, 2004), caffeine is frequently used as an additives to sperm suspensions in order to 
improve sperm characteristics and stimulates induction of capacitation. Caffeine is generally 
assumed to work by inhibiting phosphodiesterase activity, resulting in elevation of 
complementary adenosine monophosphate levels in spermatozoa.  Results presented here 
showed that there is no significant effect of compound #26 on sperm velocities (VAP, VSL 
and VCL) and the percentage of total motile spermatozoa over the time interval analysed (t0-
t20). However, a significant increase in progressive motility was observed at t0, when the 
compound was added to sperm suspension, but not at t10 and t20 respectively. The lack of 
effect of compound #26 on boar sperm motility is particularly notable, since this differs from 
human studies (Chapter 3 and Chapter 4) in which addition of compound #26 leads to an 
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increase in the percentage of total and progressively motile sperm respectively. In 
mammalian cells, multiple PDE types and subtypes, including splice variant do exist and they 
differ in relation to their sensitivity to activators/inhibitors. Particularly in sperm cells, 
relatively little is known about PDE types/subtypes, their specificities/affinities and their 
cellular sub localisation/distributions. This result could highlight a possible species-specific 
difference in the effect of compound #26 with respect to human and boar sperm motility.   
 Since, in this present study, compound #26 was found not to have any significant effect on 
boar sperm motility; the observed increase in oocytes penetration rate  may be due in part to 
enhancement of capacitation related events. Although effects of compound #26 in relation to 
capacitation related events was not analysed in this study, other studies have shown that 
addition of phosphodiesterase inhibitor or cell permeable cAMP analogue to  boar sperm 
could induce a rapid and major change in the lipid architecture of sperm plasma membrane 
(Harrison et al., 1996). These surface changes are crucial because it enables sperm cells to 
bind to the extra cellular matrix of the oocyte (zona pellucida) during fertilization. Evidence 
has been provided over the years to show that, among other molecular changes, capacitation 
involves a transition in the plasma membrane from a stabilized to a destabilized state and 
only capacitated sperm cell can bind to the ZP, leading to fertilization of oocyte (Flesch and 
Gadella, 2000, Gadella et al., 2008). Alternatively, since compound #26 was added during 
gamete co-incubation, it is plausible that the compound is also exerting its effects on the 
oocyte; thereby leading to an enhanced penetration rate. While there are no studies analysing 
the effects of PDE inhibitors on oocytes during gamete co-incubation, previous studies have 
reported that addition of PDE inhibitors during in vitro maturation of oocytes improved 
nuclear maturation by regulating meiotic and cytoplasmic maturation (Nogueira et al., 2005, 
Rose et al., 2013, Gharibi et al., 2013, Huang et al., 2013).  
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In conclusion, the result presented in this chapter has shown that compound #26 has no 
significant effect on boar sperm motility and velocity characteristics analysed. However, 
addition of this compound in fertilization media during gamete co-incubation can promote 
penetration of in vitro matured porcine oocytes. The 3hr interval of gamete co-incubation was 
found to be efficient for sperm-oocyte interaction and a remarkable proportion of fertilized 
oocyte, using this short incubation time, resulted in monospermic fertilization. Nevertheless, 
further study is needed to determine if increasing sperm concentration and gamete co-
incubation time will increase penetration rate. Additionally, although the primary aim of this 
chapter is to determine the effect of compound #26 on porcine IVF system, a direct 
comparison with caffeine is needed using exact protocols described in this chapter. 
Furthermore, the effect of the compound on capacitation related events of boar sperm, such as 
plasma membrane modification, needs to be characterised. 
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Chapter 6.  
 
Optimisation and validation of HPLC technique for the 
quantification of cAMP in boar sperm
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6.1 Introduction 
 
Adenosine 3´, 5´-cyclic monophosphate (cAMP), is a ubiquitous intracellular second 
messenger that is involved in the regulation of numerous physiological functions in 
mammalian sperm cells (De Jonge, 2005, De Jonge et al., 1991, Visconti et al., 1995b, 
Visconti et al., 2002). Cyclic AMP stimulates activation of protein kinase A (PKA) which in 
turn, by indirect action through SRC (Lawson et al., 2008, Baker et al., 2006), leads to the 
phosphorylation of tyrosine residues on other proteins. The central role of cAMP-PKA 
pathways in regulating numerous physiological functions in sperm has been established by 
many studies (Buffone et al., 2014, Liu et al., 2013, Buffone et al., 2009, Munire et al., 2004). 
Evidence from mouse models and human data – including those presented in Chapter 3 and 
Chapter 4 – is that cAMP-PKA pathway is involved in sperm capacitation, motility and 
hyperactivated motility and loss or diminished capacity of any of these processes is 
associated with infertility (Burton and McKnight, 2007). Consequently, based on its central 
role,  the  determination  of  cAMP levels in mammalian sperm cells  has  great practical  
importance  for  pharmaceutical  and  biomedical  research.  
However, measurement of cyclic nucleotides from sperm cells is often a challenging task, 
(characterised by low concentration, instability of nucleotides, post-extraction hydrolysis), 
thus, experimental limitations have impeded our ability to routinely and efficiently detect 
cyclic nucleotide in mammalian sperm. Currently, there are few /no studies examining the 
intracellular dynamics of a wide range of molecules in mammalian sperm; in order to 
generate a biochemical profile of the effects that physiological processes and 
pharmacological agents have on sperm cells. Additionally, the two main methods currently in 
vogue for the detection of cyclic nucleotides in mammalian sperm cells are expensive, labour 
intensive, have low detection levels/range, as in the case of enzyme-linked immunosorbent 
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assay (ELISA), and involve the use of radio activity ( radio immunoassay). In  this  regard, a  
highly  sensitive  and  selective  method  is  required  for routine quantification of cyclic 
nucleotides  changes in mammalian sperm. 
 
For non-germinal cell types, determination of cyclic nucleotide pool by high performance 
liquid chromatography is a well-established procedure (Lorenzetti et al., 2007, Ohba et al., 
2001, Prado et al., 2013). HPLC is an analytical technique based on the separation of 
molecules due to differences in their structure and/or composition (Malviya et al., 2010, 
Dahimiwal et al., 2013). In HPLC, separation is accomplished by injection of a small amount 
of dissolved sample into a moving stream of liquid (called the mobile phase) that passes 
through a column packed with particles of stationary phase. Separation of a mixture into its 
components depends on the differences in specific chemical or physical interactions of each 
component with the column. In many analytical chromatography procedures involving 
nucleotide analysis, ion-pairing reversed phase HPLC (RP-HPLC) is often a method of 
choice due to its ability to provide stable and reproducible results. Additionally, a 
combination of UV and fluorescence detection mechanism enhances the detection of low 
concentration cyclic nucleotides.  This method of separating components of miscible solute in 
solution will be innovative and instructive for the assessment of sperm biochemical 
dynamics; therefore needs validation and standardisation.   
 
6.2 Aims and Experimental Design 
 
In the present work, an isocratic HPLC method with ion–pair system was optimised and 
validated for the determination of cellular nucleotide (cAMP) concentrations in extracts from 
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boar sperm cells. Boar sperm was used as a surrogate model to human sperm due to cost and 
ease of availability of sperm sample. Additionally, the effect of phosphodiesterase inhibitors 
on the level of cAMP in boar sperm was examined. On the basis of results from previous 
chapters, it is hypothesised that PDEi compounds will enhance cAMP levels in boar sperm 
cells. 
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6.3 Materials and Methods 
6.3.1  Chemicals and Reagents  
 
Adenosine 3´, 5´-cyclic monophosphate (cAMP) sodium salt, KH2PO4 and HPLC grade: 
acetonitrile, methanol and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich, 
UK. The deionised water used for standard and mobile phase preparation and dilution were 
from a Millipore water purification system.  
  
6.3.2 Capacitating Conditions 
 
Capacitating media (CM) was composed of 5mM KCl, 1mM KH2PO4, 95mM NaCl, 5.55mM 
glucose, 25mM NaHCO3, 2mM CaCl2, 0.4% BSA and 2.5mM pyruvate (pH 7.4). Non-
capacitating media (NCM) lacked calcium, bicarbonate and BSA and consisted of 2.7mM 
KCl, 1.5mM KH2PO4, 8.1mM Na2HPO4, 137mM NaCl, 5.55mM glucose and 2.5mM 
pyruvate (pH 7.4). 3x107 cells were pelleted and resuspended in 1ml of either CM or NCM 
and incubated at 39°C for 3hours. Cells in CM were kept in CO2 incubator with the lids off 
while those in NCM with lids closed. 
 
6.3.3 Preparation of Standard Solution 
 
Adenosine 3´,5´-cyclic monophosphate  (cAMP)  sodium  salt (Molecular Weight: 
369.20g/mol) standard was prepared by dissolving precisely weighed 1mg of cAMP-
salt(HPLC grade (≥98.5%) in 10mL of deionised water in volumetric flask and this was then 
serially diluted (x5) in deionised water (See below). All calibration procedures and 
experiments were performed using freshly made standards.  
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Table VIII: cAMP concentration and serial dilutions of cAMP standard solution 
Serial 
Dilution 
No 
Amount of 
cAMP 
(g/10ml) 
Initial No 
of  Moles 
Conc. of 
Solution 
(M) 
Injection 
Volume 
(µl) 
Amount of 
cAMP per 
Injection 
(g) 
Final No 
of Moles 
1 1x10-3 2.71x10-6 2.7x10-4 50µl 5x10-6 1.35x10-8 
2 1x10-4 2.71x10-7 2.7x10-5 50µl 5x10-7 1.35x10-9 
3 1x10-5 2.71x10-8 2.7x10-6 50µl 5x10-8 1.35x10-10 
4 1x10-6 2.71x10-9 2.7x10-7 50µl 5x10-9 1.35x10-11 
5 1x10-7 2.71x10-10 2.7x10-8 50µl 5x10-10 1.35x10-12 
6 1x10-8 2.71x10-11 2.7x10-9 50µl 5x10-11 1.35x10-13 
 
 
n= moles of pure substance. m= mass of substance in grams. M= Molar mass in g/mL. 
L= Litres 
n =
 
M
 ,    Molarity =
     
L
 
 
For Serial dilution No 1:  
                                                                              n =
   
   .  /  
     = 2.71x10-6 moles in 
10ml (or 10000µl) 
 
Concentration of Solution:    
 .  ×           
 .   
  = 2.7x10-4 M 
 
Number of mole in 50 µl injected volume:  
 .  ×           ×    
       
  = 1.35x10-8 moles or 
13500 pmoles 
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6.3.4 Chromatographic Equipment and Conditions 
 
The HPLC system (see Figure 6-1) consists of Waters: 1525 Binary HPLC pump, 2487 Dual 
λ Absorbance Detector, 2475 Multi λ Fluorescence Detector and 717 plus Autosampler. The 
chromatographic separation was accomplished on a Synergi™ 4µm Fusion – RP80A 
(Phenomenex, Cheshire, UK) C18 analytical column (150mm× 4.6mm Internal Diameter 
(I.D), 4µm particle size) Column temperature: ambient temperature; Flow rate: 1.0 ml/min; 
Injection volume: 50 µl. The detection wavelength for cyclic nucleotide was set at 260 nm 
and the system was controlled and data analyses were performed on Water’s Breeze Version 
3.20 software.  
 
 
  
Figure 6-1 Diagram of the general structure of a HPLC system 
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6.3.5 Mobile Phase 
 
The  mobile  phase  consisted  of  Buffer  A, 20 mM  KH2PO4,  pH  2.5. This is prepared by 
dissolving 2.7218g of HPLC grade KH2PO4 in ultrapure water (in a volumetric flask) and pH 
adjusted with 2.5% phosphoric acid solution (Final volume of buffer: 1L).  Buffer B, is  
ultrapure water supplemented with 0.1% TFA  and 0.1%  acetonitrile (ACN) and Buffer C, 
20mM Phosphate buffer supplemented with 0.1%TFA and 0.1%ACN (final pH 2.08). All 
buffers used were filtered through a 0.22 µm Millipore membrane filter before use.  
6.3.6 Sperm Preparation and Treatment 
 
Boar sperm, (Pig Improvement Company UK Limited) stored up to 2 day at 16-17oC in 
TRIXCell extender (IMV technologies), was pelleted by centrifugation (15 min, 1500 rpm). 
The sperm pellet was resuspended  in CM and incubated for 3hrs under capacitating 
conditions (39oC and 5% CO2 humidified atmosphere) after sperm concentration was 
determined by haemocytometer count (Sperm concentration: 3x107/ml). After incubation, 
sperm cells were exposed to compounds (PDEi) for 20min before extraction of cytosolic 
content of the cells. 
 
6.3.7 Cell Extraction of Cyclic Nucleotides 
 
For the extraction of cyclic nucleotides, two alternative techniques were attempted; methanol 
extraction and sonication.  Methanol is routinely used during cells extraction (Rose and 
Oklander, 1965, Ferrer et al., 2011) and sonication (Ijiri et al., 2011, Han et al., 2011) 
involves mechanical disruption of cells without introduction of other compounds in the cell 
extract. 
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6.3.7.1 Methanol 
 
After incubation and treatment (see above), cell pellet (3x107/ml) was formed by 
centrifugation (15 min, 1500 rpm) and cells were lysed, after removing supernatant, by 
resuspending in 500µL ice-cold 100% HPLC grade methanol (-20oC, 10min). To separate the 
particulate and soluble fractions, lysed samples were centrifuged (30 min, 3000 rpm), the 
supernatant was taken and vacuum centrifuged (~1.5hr at 60oC; Eppendorf Concentrator 
5301) to evaporate the methanol and the lyophilised soluble fractions was resuspended in 
500µL of Buffer A. This is then transferred into labelled vials and loaded onto the HPLC 
system. 
6.3.7.2 Sonication 
 
After incubation and treatment (see above), cell pellet was formed by centrifugation (15 min, 
1500 rpm) and after removing supernatant, cells were resuspended in 500µL Buffer C (see 
above). Mechanical disruption of cell membrane was achieved by sonication using a Micro 
tip (Sonics & Materials Model: V1A). Sonication experiments were conducted at 10 s, 15s, 
20s, 25s and 30s at 95% power and amplitude of 4 (samples were kept on ice at all time). 
After sonication, the particulate and soluble fractions were separated by centrifugation (15 
min, 1500 rpm at 4oC; Eppendorf Centrifuge 5417R). The soluble fractions were then 
transferred into labelled vials and loaded onto the HPLC system. 
 
6.3.8 Derivatization of cAMP Standards and Cell Extract 
 
In liquid chromatography analysis, fluorescent derivatives; such as UV chromophores and 
fluorophores, are often introduced into sample to increase their sensitivity to UV absorption 
and fluorescence detection. For the conversion of nucleotides into fluorescent derivative, 
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500µl of freshly prepared cAMP standard samples and 500µl of cell extract (lyophilised 
soluble fraction in Buffer A) were mixed with 50µl of chloroacetaldehyde (ClCH2CHO) and 
500µl of 2.5% phosphoric acid in capped 1.5ml Eppendorf tubes.  These mixtures were 
vortex mixed and kept at 80ºC for 30 minutes. After the reaction (Figure 6-2), the tubes were 
immediately placed in a 4oC refrigerator to stop the reaction (Zhang et al., 2006). These 
solutions were transferred into labelled vials and loaded onto the HPLC system. 
 
 
 
 
 
 
 
 
 
 
 
6.3.9 Assay Validation and Statistical Analysis 
 
The analytical method was validated by evaluating linearity through the calibration curve 
obtained with six concentration levels of cAMP standard solutions. By analysing the linear 
regression of the peak-height versus concentration, the determination coefficient, the 
intercept and the slope were calculated. The limits of quantification (LOQ) and limits of 
80oC, 30min 
ClCH2CHO, pH 2.5 
Figure 6-2: Derivatization reaction of cAMP by 2-chloroacetaldehyde 
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detection (LOD) was determined based on the standard deviation of the response and the 
slope of the calibration curve as recommended by ICH guidelines (Guideline, 1997). 
LOQ =
   
 
   ,   LOD =
 .  
 
 
Where  σ = the standard deviation of the response  
    S = the slope of the calibration curve 
Statistical analysis of the effects of different compound treatment conditions and sonication 
time on the level of cAMP in boar sperm was conducted using analysis of variance 
(ANOVA). The statistical analysis was carried out using GraphPad Prism 6 (GraphPad 
Software, California, USA). Differences were considered significant at a P < 0.05. 
6.4 Results 
 
6.4.1 Effect of Mobile Phase on Retention Time of Standard  
 
The separation of organic compounds in reverse phase chromatography is due to the different 
binding properties of the solutes present in the sample as a result of the differences in their 
hydrophobic properties. Thus, by manipulating the hydrophobic properties of the mobile 
phase, through the addition of organic modifiers to lower the polarity of the solution, 
separation of solutes can be fine-tuned and the retention time (the time between injection and 
detection) modified. Here, the effect of three mobile phases on retention time of cAMP 
standard was assessed.   
 Figure 6-3A showed that by using Buffer A, 20mM phosphate buffer (pH 2.5), the retention 
time of cAMP standards was at ~17 min. A linear calibration curve is demonstrated in Figure 
6-3B and this showed that for Buffer A, the lower limits of quantification (LOQ) of cAMP, 
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that is, the lowest concentration of cAMP that can be reliably detected, is at 1.494x10-6M 
(0.55µg/mL) with r2 = 0.9707 (Figure 6-3B).  With Buffer B, ultrapure water supplemented 
with 0.1% TFA (ion-pairing agent) and 0.1% ACN (organic solvent) (pH 2.2), the retention 
time of cAMP standards was reduced to ~11min (Figure 6-4A), however, the limit of 
quantification (LOQ) while using this buffer was at 1.27x10-6M (0.46 µg/mL) with r2 = 1 
(Figure 6-4 B). The retention time of cAMP standards when using Buffer C, 20mM 
Phosphate buffer supplemented with 0.1%TFA and 0.1%ACN (pH 2.08), was at ~ 7min 
(Figure 6-5A) and the limit of quantification of cAMP is at 1.56x10-6M (0.57µg/mL) with r2 
=0.996 (Figure 6-5B); and there is no significant difference between the LOQ of the three 
buffers (See APPENDIX 2 for calculation of LOQ). For the three buffers, the lower limit of 
detection (LOD), that is, the lowest concentration of cAMP that can be reliably distinguished 
from blank or background noise is: Buffer A: 4.930 ×10-7M (0.18 µg/mL); Buffer B: 4.199 
×10-7 M (0.15 µg/mL) and Buffer C: 5.153 ×10-7 M (0.19 µg/mL) respectively. 
For each mobile phase, the method of cAMP separation and the precision of the system 
showed good repeatability and reproducibility. The percentage of relative standard deviation 
(% R.S.D), which is a measure of precision and repeatability of an assay in analytical 
chemistry, was calculated from the peak area ratios for each concentration of cAMP standard 
injected. The % R.S.D is similar for the three mobile phase tested; and for each concentration 
of standard injected; it was within 2%.  
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Figure 6-3: Effect of Buffer A (20mM Phosphate buffer) on retention time of cAMP standard. 
(A)  Chromatogram of cAMP standard peak. 1.35×10 -8 to 1.35×10 -13 moles of cAMP standard 
prepared in ultrapure water were injected into HPLC. The retention time was ~ 17min. (B) 
Linear relationship of cAMP concentration vs. UV peak area. Area under the curve of peaks 
were normalized by taking Log10 and plotted versus given cAMP concentrations. (n=3, r
2 = 
0.9707). 
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Mobile phase 
Ultrapure water supplemented  with 0.1% TFA  and 0.1%  
acetonitrile (ACN) 
Flow rate 1.0 mL/minute 
Temperature 25 °C 
Detection 260 nm 
Retention time ~11min 
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Figure 6-4: Effect of Buffer B (Ultrapure water supplemented with 0.1% TFA and 0.1% 
(ACN)) on retention time of cAMP standard. (A)  Chromatogram of cAMP standard peak. 
1.35×10 -8 to 1.35×10 -13 moles of cAMP standard prepared in ultrapure water were injected 
into HPLC. The retention time was ~ 11min. (B) Linear relationship of cAMP 
concentration vs. UV peak area. Area under the curve of peaks were normalized by taking 
Log10 and plotted versus given cAMP concentrations. (n=3, r
2 = 1). 
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Figure 6-5: Effects of Buffer C (20mM Phosphate buffer supplemented with 
0.1%TFA and 0.1%ACN) on retention time of cAMP standard. (A)  Chromatogram 
of cAMP standard peak. 1.35×10 -8 to 1.35×10 -13 moles of cAMP standard 
prepared in ultrapure water were injected into HPLC. The retention time was ~ 
7min. (B) Linear relationship of cAMP concentration vs. UV peak area. Area under 
the curve of peaks were normalized by taking Log10 and plotted versus given 
cAMP concentrations. (n=3, r2 = 0.996). 
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6.4.2 Effect of Cell Extraction on Cyclic Nucleotide Detection by HPLC 
 
Two approaches were adopted for the extraction of cAMP from boar sperm cells. The initial 
approach involves the use of 100% methanol (-20oC for 10min) to lyse cell pellet of 
capacitated boar sperm. The sample is then centrifuged to separate membrane and cytosolic 
supernatant. The supernatant is vacuum centrifuged to evaporate the methanol and the 
lyophylised cytosolic pellet is resuspended in 500µl of Buffer A. However, when this sample 
was run on the HPLC system, using the exact same conditions used for the detection of 
cAMP standards in Buffer A (Figure 6-3), no peak was identified (n=3) at the retention time 
seen in Figure 6-3. In order to improve sensitivity and quantification of cAMP in cell extract, 
both sample and cAMP standard solutions were derivatized and detected using a fluorescence 
detector. Figure 6-5A showed a chromatogram with distinct peak of derivatized cAMP 
standard, with retention time at ~14min. However, in derivatized cell extract, no peak similar 
to those found with derivatized cAMP standard could be identified (n=3). 
The second approach uses sonication technique to lyse boar sperm cells.  With this approach, 
cell pellet of capacitated boar sperm were resuspended  in 500µl Buffer C, while keeping 
sample tubes on ice, cells were sonicated at various times (10s 15s, 20s, 25s and 30sec). 
Since sperm cells were resuspended in Buffer C, the exact same condition used for the 
detection of cAMP standards in Buffer C was used on the HPLC system. Using this approach 
cAMP extract from boar sperm cells can be quantified. 
 Figure 6-7, showed the peak area of cAMP from boar sperm cells. Using the linear 
regression equation, that is y= 0.4421ln(x) + 2.8593 the mass of cAMP in boar sperm for 
each sonication time was calculated (10s: 5.75 ± 1.15µg; 15s: 4.68 ± 0.95µg; 20s: 4.59 ± 
0.84µg; 25s: 4.19 ± 1.07µg and 30s: 4.85 ± 0.61µg) and there is no significant difference in 
peak area when various sonication times were compared p= 0.7965 (n=4). To ensure 
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sonication does not lead to degradation of cAMP during cell lysis, solutions of cAMP 
standards were sonicated, for 30s each, using the exact same conditions used for cell lysis. 
Figure 6-8A and B showed that exposure of the cAMP standards to 30s sonication time does 
not leads to degradation of cyclic nucleotides or alter the sensitivity of the system, moreover, 
this data is comparable to non-sonicated sample in Figure 6-5B. 
 
 
 
 
 
B 
A 
Figure 6-7: Effect of various sonication times on cyclic nucleotide detection on HPLC.  
Pellet of capacitated boar sperm cells were re-suspended in buffer C and cell lysis was 
achieved through sonication. There is no significant difference in peak area between 
sonication times. Peak area of cyclic nucleotides was determined by HPLC absorbance 
detector ±SEM n=4 One Way ANOVA. 
Figure 6-6: (A) Chromatogram of a derivatized cAMP standard. (B) A comparative 
view of derivatized and non derivatized cAMP standards. 
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Mobile phase 20mM Phosphate buffer + 0.1%TFA+0.1%ACN 
Flow rate 1.0 mL/minute 
Temperature 25 °C 
Detection 260 nm 
Retention time ~7min 
Figure 6-8: Effect of 30s sonication on solutions of cAMP standards. (A) Chromatogram of cAMP 
standard peak. 1.35×10 -8 to 1.35×10 -13 moles of cAMP standard were injected into HPLC using 
Buffer C as eluent. The retention time was ~ 7min. (B) Linear relationship of cAMP concentration 
vs. UV peak area. Area under the curve of peaks were normalized by taking Log10 and plotted 
versus given cAMP concentrations. (n=4, r2 = 0.9999). 
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Figure 6-9: The effect of PDE inhibitors on cAMP level in boar sperm. (A) 
Capacitated and (B) non-capacitated boar sperm were exposed to PDEi for 
20min. Cells were lysed by 30s sonication. Mobile phase buffer C. Peak area of 
cyclic nucleotides was determined by HPLC absorbance detector ±SEM n=3 
One Way ANOVA 
6.4.3 Effects of Phosphodiesterase Inhibitor on cAMP Level in Boar Sperm 
 
To assess the effects of phosphodiesterase inhibitors (PDEi) on the level of cAMP, 
capacitated and non-capacitated boar sperm cells were exposed to PDEi (No drug (Control), 
#26, #36, #37, #38, IBMX, and DMSO (vehicle control)) for 20min. Figure 6-9A and B 
showed that there is no statistically significant difference in peak area when each treatment 
conditions were compared with each other. Thus, this data suggests that there is no significant 
difference in in the level of cAMP between treated and non-treated cells; both in capacitating 
and non-capacitating conditions.  
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6.5 Discussion 
 
Adenosine 3´, 5´-cyclic monophosphate (cAMP), is an important molecule that is involved in 
the regulation of numerous physiological functions in mammalian sperm cells (De Jonge, 
2005, De Jonge et al., 1991, Visconti et al., 1995b, Visconti et al., 2002). Inside the cell, 
cAMP activates PKA which then leads to phosphorylation of tyrosine residues on other 
proteins by an indirect action (Lawson et al., 2008, Baker et al., 2006) and this signalling 
pathway has been shown to be important for the process of sperm capacitation, motility and 
hyperactivated motility (Buffone et al., 2014, Liu et al., 2013, Buffone et al., 2009, Munire et 
al., 2004). However, in sperm cells, detection of cyclic nucleotides has proved difficult 
because the two main methods are expensive, labour intensive, low throughput, can only 
detect one subtype of nucleotide at a time and have either a very limited detection range, as in 
the case of enzyme-linked immunoabsorbant assay (ELISA), or involve the use of radio 
activity (radio immunoassay). With advancement in liquid chromatography technique, use of 
HPLC technique provides an alternative technology to classical ELISA assays and this 
technique is suitable for high throughput automated detection systems. 
In this study, HPLC technique was optimised and validated for the detection of cAMP. Using 
this technique, cAMP has been identified / quantified in boar sperm for the first time 
(Harrison, 2004, Harrison et al., 1996, Gadella and Harrison, 2002).  The initial analysis 
involves determination of the mobile phase buffer that provides optimal sensitivity and 
selectivity and the quickest retention time for cAMP in solution. Previous studies have shown 
that mobile phase pH and the concentration of organic modifiers are some of the most 
important factors that affect the retention of ionisable solutes (Tanaka et al., 1978, Al-Hamdi 
et al., 2006, Shibue et al., 2005, Heyrman and Henry, 1999, Zou et al., 1991, Zisi et al., 
2013). In this study, three mobile phase buffers (Buffer A, B and C) were tested to determine 
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their effects on cAMP retention. The concentration of the buffer (20 mM Phosphate) was 
chosen on the basis of column type as recommended by the manufacturer. While for each 
buffer there is high level of reproducibility regarding cAMP separation, the quickest total 
retention times, however, were associated with Buffer C: at ~ 7min followed by Buffer B 
(~11mim) and Buffer A (~17min) respectively. An explanation for this is that at increasing 
acidic pH, the basic groups of cAMP are protonated which results in an increase in polarity, 
thus the interaction between solutes and the stationary phase is altered, leading to decrease in 
retention time. Additionally, there is no significant difference between the limit of 
quantifications (LOQ) and detections (LOD) for all three buffers used; therefore, Buffer C 
was selected for the remainder of this study as it offered the quickest retention time for cAMP 
detection. 
 In this study, 100% methanol was used as the extraction agent to extract the intracellular 
content of boar sperm as methanol is frequently used for the extraction of cellular content 
during ELISA.  Here, methanol extract was evaporated to dryness and reconstituted in Buffer 
A. However, the reconstituted methanol extract from boar sperm cells gave no chromatogram 
when analysed on the HPLC system. The experimental conditions were scrutinized and 
several eventualities that might explain this unexpected failure to detect cAMP in methanol 
extract were entertained. The initial consideration was that the concentration of cAMP in 
lyophilised extract was too low for UV detection; therefore, in order to increase sensitivity, 
the samples were derivatized. While derivatized cAMP standards gave a chromatogram, on 
the contrary, no cAMP peak was detected from lyophilised methanol extract of boar sperm.  
The effect of temperature (60oC) to possibly cause degradation of cAMP during the process 
of lyophilising the methanol extract sample was also considered, however, cAMP standards 
incubated at 80oC during the process of derivatization gave a chromatogram which is 
comparable to underivatized sample; suggesting no degradation as a result of high 
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temperature. While it was concluded that cAMP from methanol extracts might be lost while 
the sample were being concentrated, the effect of temperature as a degradation factor was 
excluded as a possibility. 
A shift in retention time of cAMP standard was observed in the derivatized cAMP standard 
solutions (Figure 6-6). This may be due to change in the structure of the compound (Figure 
6-2); however, the quantification of cAMP does not change.  Contrary to what was observed 
with methanol extraction, mechanical disruption of boar sperm membrane using sonication 
techniques led to detection of cAMP peak; therefore an improvement on methanol extraction.  
Although, there is no significant difference in cAMP peak between the sonication times 
tested, 30sec sonication time was chosen for optimum cell lysis. Also, 30sec sonication does 
not lead to cAMP degradation (Figure 6-8). 
Several studies have shown that cAMP-dependent pathway plays a crucial role in regulating 
various sperm functional events associated with capacitation and motility in many species 
(Visconti et al., 1999c, Kalab et al., 1998, Galantino-Homer et al., 1997, Leclerc et al., 
1996a). Additionally, the intracellular levels of cAMP, the second messenger that activated 
PKA, can be modulated by treatment with activators or inhibitors that targets the cAMP-
dependent pathway. Here, boar sperm treatment conditions were set-up to mimic the 
conditions of treatment used in human sperm experiments (Chapter 3 and 4), that is, samples 
were exposed to the compounds for 20min then the effect of PDE inhibitor (PDEi), in this 
case on the levels of cAMP in boar sperm was assessed. For boar sperm under the 
experimental conditions described in this chapter, no significant difference was observed for 
the level of cAMP peak between PDEi treated and untreated boar sperms samples under 
capacitating and non-capacitating condition of treatment.  
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The lack of effect of these compounds on boar sperm cells, that is, to induce an increased 
level of cAMP is particularly notable and it does not match the initial hypothesis.  One 
explanation for this might be that on the basis of incubation time used in this experiment 
(20min exposure to compound), the time window for detecting an increase or significant 
difference has been missed. Several studies, both in human (Battistone et al., 2013, Brenker 
et al., 2012) and boar sperm (Harrison and Miller, 2000) have reported a rapid increase in 
cAMP levels (raising within 1 min) which then rapidly falls back to control levels within 10-
60min.  cAMP efflux could be another mechanism that could explain why no difference was 
observed in cAMP levels between PDE treated and untreated samples (Salut et al., 2013, 
Rodriguez et al., 2011, Lin et al., 2007). While inhibition of PDE activity is one means of 
modulating cAMP level, regulation of cAMP homeostasis within the cell can also be 
achieved by efflux proteins. Indeed, while it has not yet been identified in boar sperm, high 
affinity efflux pump for cAMP (MRP4) has been identified in other cell types (Godinho and 
Costa-Jr, 2003, Sassi et al., 2012, Hofer and Lefkimmiatis, 2007) and recently in bovine 
sperm (Salut et al., 2013). Presence of such efflux pump in human and boar sperm may 
account for the rapid decrease in cAMP levels that is often reported in literature. 
Fundamentally, it will be interesting to quantify cAMP levels in extracellular media during 
boar sperm capacitation or when cells are exposed to PDE inhibitors. Alternatively, it could 
be that these sets of PDEi have no effect on boar sperm motility. As discussed in chapter 5, it 
is possible that they are not targeting the PDE subtypes found in boar sperm thus no increase 
in cAMP levels. Another explanation in relation to the effects of PDE inhibitor on human 
sperm is that these set of compounds also target CatSper in addition to activation of 
cAMP/PKA signalling pathway. Indeed, preliminary patch clamp data from our research 
group, using another PDE inhibitor (Trequinsin hydrochloride a PDE3 inhibitor), shows that 
PDE inhibitor can target and stimulates CatSper activation.  
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Finally, the method described here, for the detection of cAMP from boar sperm, is 
reproducible, rapid to perform, and has good linearity and precision. While the primary aim 
of this section of study was to optimise HPLC technique in order to determine cAMP 
concentration in boar sperm, this technique can possibly be adapted to simultaneously 
measure array of intracellular nucleotides. Being able to simultaneously measure array of 
nucleotides will give an insight into the dynamics of nucleotide metabolism during in vitro 
incubation of sperm cells or when exposed to different pharmacological agents. This study 
has provided proof of concept that this technique is sensitive enough to detect cAMP in 
mammalian sperm, therefore justifies future use of HPLC technique for high throughput 
screening of cyclic nucleotides in human spermatozoa.  
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Chapter 7.  
 
                           General Discussion and Future Work 
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The aim of this thesis was to (1) examine the effect of phosphodiesterase inhibitors on 
spermatozoa in order to identify compounds that have clinically relevant enhancement of 
human sperm motility. (2) Identify the signalling pathway(s) involved in the motility 
enhancing effects of identified compounds by targeting modulator and mediator of cyclic 
nucleotides. (3) Develop an animal IVF model to assess effects of compound on fertilization 
and (4) Optimise HPLC techniques for routine detection of cyclic nucleotides in sperm cells. 
7.1 Key findings 
Sperm motility still remains one of the most important prerequisites for achieving fertilization 
and pregnancy. Under physiological conditions, in vivo, the sperm must travel through the 
female reproductive tract to the site of the ovulated oocyte before fertilization can occur. 
While the development and use of assisted reproductive technique has allowed many infertile 
couples to conceive, there is currently no clinically approved drug that can be added to 
spermatozoa in vitro or taken by a man in order to improve fertility. Although many 
substances have been proposed for the stimulation of human sperm motility (e.g. 
gonadotropin hormones FSH, and LH), however, advances in our knowledge means that 
targeting intracellular pathway(s) directly involved in sperm motility is the most attractive 
means of enhancing sperm motility.  
With respect to Chapter 3, using a two-phased drug discovery screening approach, 43 
compounds with reported phosphodiesterase inhibitor activity were systematically screened 
and from these; several compounds were found to have robust and effective stimulation of 
human sperm motility. Indeed, 6 compounds were found to have strong effect on poor 
motility samples; stimulating a significant increase in percentage of total and progressive 
motility both in capacitating and non-capacitating conditions respectively. Importantly, 
results presented in Chapter 3 showed that not only do these compounds stimulate and 
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enhance motility; their effects on progressive motility were sustained for a period of up to 
180min, when compounds were co-incubated with sperm samples. The clinical use of the 
compounds would involve washing and effective removal of compounds prior to use.  The 
data presented in this thesis showed that short (20min) exposure of sperm cells to compounds 
is still effective in enhancing both total and progressive motility even 300min after 
compounds were washed off. These findings are clinically relevant because they indicated 
that if these compounds were adopted for clinical use they could be added to sperm and then 
washed off, since their effects still persist after removal, before IVF insemination or 
intrauterine insemination (IUI). Indeed, data presented in this thesis showed that the 
enhancement of motility observed in poor motility samples can be replicated in patient 
samples. Particularly in ICSI patient samples, and with respect to compound #26, #37 and 38, 
≥79% of samples showed a significant increase in total motility and progressive motility 
respectively. Furthermore, ~63% of IVF samples showed a significant increase in total 
motility, the majority of sperm cells from this sample group have better swimming velocity; 
characterised by higher proportion of treated cells having VCL ≥120µm/s than control 
samples.  
Since sperm motility is still one of the main factors that determine the type of ART a patient 
is assigned (that is IUI for mild, IVF for moderate and ICSI for men with severe, sperm 
dysfunction (Barratt et al., 2011)), the findings from this thesis may have implications with 
respect to current clinical practice. Several studies have demonstrated a significant correlation 
between conception in vivo and the number/concentration of motile sperm and/or percentage 
motile cells in subfertile couples (reviewed in Tomlinson et al., 1999, 2013). In view of the 
above, that is, by boosting sperm motility of current crop of patient samples, hypothetically 
patients that are currently assigned for ICSI due to poor sperm motility could be assigned to 
IVF or IVF patients could be converted to IUI which is a cheaper option. From this 
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perspective, application of compounds; such as those identified in this study, to boost sperm 
motility could potentially increase the availability of fertility treatments to a global 
population, thus using IUI instead of IVF and making cost effective IUI available to a much 
wider patient population. Since many ART treatments are now commercially driven, the 
findings presented here could have profound economic benefits for private patients 
undergoing ART or policy makers that make recommendations on government funded 
patients. 
The ideal compound that can be used clinically to enhance sperm motility will affect motility 
without any detrimental effects on other sperm functions and physiology. The potential 
negative effects of these compounds on human sperm physiology were examined. While 
there is still controversy regarding the timing of acrosome reaction during sperm-oocyte 
interaction, the acrosome reaction is a crucial step in the process of fertilization. Thus it is 
acknowledged that premature induction of the acrosome reaction by compounds would be a 
negative effect. In this study, the acrosome of human sperm incubated with compounds 
remained intact. Additionally, to assess the effects of the compounds on steps leading to 
fertilization, the Kremer penetration test was used to establish whether sperm are more able 
to swim through viscous media when incubated with compounds. Viscous media 
(methylcellulose) was used to mimic the viscous environment encountered in the cervix 
during the journey of the sperm to the oocyte in vivo. Results demonstrate that there is a 
significant increase in the number of sperm at a marked distance when sperm have been 
incubated with compounds; the reason for this could possibly be due to an increased average 
sperm swimming velocity when incubated with the compounds. Further to this, plasma 
membrane translocation of phosphatidylserine, which is an indication of apoptosis, was 
examined. Tests such as this are crucial to establish the clinical benefits or detriment of using 
these compounds during ART procedures. The results presented in this thesis demonstrate no 
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negative effects of the compounds on the level of phosphatidylserine externalisation.  Pieced 
together, these results are very encouraging; since they show that compounds have positive 
effects on human sperm functions under the conditions of treatment. However, further studies 
are required to investigate the exact effects of compounds on sperm ion channels (such as 
CatSper) that are implicated in other fertilization processes.  
 
Evidence from this thesis clearly shows that compounds positively affect human sperm 
motility, enhance other sperm functions and they have no detrimental effects. Thus it was 
hypothesised that compounds could potentially enhance in vitro fertilization rate. Although, 
current ethical approvals preclude the use of human oocytes, an animal IVF system was 
developed to test this hypothesis. Using boar sperm and porcine oocyte as a model, the effect 
of co-incubating boar sperm and porcine oocyte with Ibudilast (compound #26) on 
fertilization rate was determined. Ibudilast was found to significantly enhance IVF rate. In 
porcine IVF system, high polyspermic rate is often reported as a result of using stimulant 
(such as caffeine) to aid IVF rate. On the contrary, the data presented in this thesis showed 
that the addition of Ibudilast during sperm-oocyte co-incubation leads to a significantly high 
monospermic rate under the experimental conditions used. While, Ibudilast was the only 
compound tested, other compounds identified in this study need to be tested so as to 
determine their effects on IVF rates. Additionally, experiments to investigate the effects of 
these compounds on human oocytes are still necessary to establish safety and clinical 
effectiveness before they are considered for use at a clinical level. 
 
In this thesis, the possible molecular signalling pathway mediating the motility stimulating 
effects of compounds were evaluated. In  spite  of  the  importance  of  sperm  motility  to  
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fertility  in  mammalian species, relatively little  is  known about  the  signalling  pathways  
that  regulate  motility. While there is evidence to suggest that cAMP-PKA pathways are 
involved in overall sperm motility, their role in specific aspects such as initiation and 
maintenance of progressive motility, and hyperactivated motility are not well characterised 
(Visconti et al., 1997). Furthermore, the major downstream targets of PKA are yet to be fully 
characterised. The results presented in chapter 4 showed that the compounds were working 
predominately through the cAMP-PKA pathway. Incubation of sperm cells with sGC and 
PKG inhibitors have no inhibitory effect on sperm motility, however, incubation of cells in 
the presence of PKA inhibitor significantly reduce basal progressive motility and 
hyperactivation respectively. Moreover, the design of the experiment in this study enables the 
delineation of the role of PKA regarding initiation and maintenance of progressive motility 
and ultimately stimulation of hyperactivated motility. Results presented here shows that PKA 
is critical for basal progressive motility and stimulation of hyperactivated motility in human 
sperm.  
 
Data presented in chapter 5 highlighted a possible species-specific difference in the effect of 
Ibudilast with respect to motility. Ibudilast, contrary to its motility enhancing effect on 
human sperm, seems not to affect boar sperm motility. Although in this study, boar sperm 
cells showed high sensitivity to microscope slides used for motility analysis by CASA, no 
significant improvement in motility was recorded when PDEi treated cells were analysed on 
agarose-coated microscope slides. This result could possibly mean Ibudilast is not affecting 
the PDEi targets in the tails of boar sperm; thus, this might highlight a difference in subtype 
of PDE present in human and boar sperm respectively. Alternatively, it could also mean that 
the compound is influencing capacitation related events in boar sperm.  
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Finally, an HPLC technique was optimised and validated for the detection of cyclic adenosine 
monophosphate (cAMP) in boar sperm. The use of HPLC provides a high throughput means 
of quantifying cAMP level in boar sperm extracts. Additionally, while the focus here was to 
detect cAMP, this technique can be used for the simultaneous detection of other nucleotides 
in cell extract, thus overcoming the limitations of single solute determination approach of 
ELISA technique. 
 
7.2 Future Work 
While the work carried out for this thesis has identified several compounds that have robust 
and effective stimulation of sperm motility however, data for IVF/ICSI patients were from 
one assessment. Thus further studies are required in order to establish the robustness of 
responses and to determine whether responses are repeatable.  This can be achieved by 
setting up a clinical trial that will test the effects of compounds on a bigger pool of IVF and 
ICSI patient sample. Furthermore, more studies are necessary to evaluate the effects of 
compounds on sperm Ca2+ ions and associated signalling pathways. Numerous studies 
(Tamburrino et al., 2014) have highlighted the importance of Ca2+ ion on overall sperm 
function in relation to sperm motility and other fertilization processes. Thus, work would 
need to be expanded upon regarding the effects of compounds on CatSper ion channel and 
calcium influx through CatSper and Ca2+ store mobilisation. With advances in patch 
clamping electrophysiology and single cell calcium imagining, these techniques can be used 
to explore the effects of PDE-I on sperm intracellular calcium ions and calcium source. 
Similarly, with regards to motility, the involvement of calcium regulated downstream 
pathways needs to be explored further. It was postulated in this thesis that Calmodulin-
CaMKII pathway might be involved in supporting progressive motility of H89 treated cells 
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under capacitating conditions, thus, this needs to be fully explored in other to determine 
whether this pathway can induce or supports progressive motility of PKA inhibited cells. 
The work presented in this thesis also shows that identified compounds have no detrimental 
effects on human sperm functions and physiology. Although to a large extent this suggests 
that the compounds are “sperm-safe”, the clinical safety and effectiveness of these 
compounds on human oocytes during human IVF and different stages of embryo 
development needs to be well established before they can be considered for clinical use.  
Also, while data from the animal IVF model used in this study suggest that Ibudilast might 
enhance penetration rate during porcine IVF the effectiveness of Ibudilast over caffeine and 
other related compounds currently in vogue needs to be tested using the experimental 
protocol used in this study so as to determine if Ibudilast is a better alternative to compounds 
which are currently in use.  
Finally, the HPLC technique described in this study serves as a proof of concept that this 
method can be used for the determination of low level of cyclic nucleotides found in 
mammalian sperm. The use of this technique needs to be expanded upon (and extended to 
human sperm analysis), that is, for the determination of other nucleotides. This high 
throughput technique could help improve our knowledge of the intracellular dynamics of 
cyclic nucleotides in mammalian sperm. An added advantage of the HPLC technique is that it 
can be coupled to a mass spectrometer, thereby aiding further analysis of unidentified 
intracellular compounds yet to be identified due to limitation of current methods (such 
ELISA and radioimmunoassay).  
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Fig 1: Effect(s) of compound(s) on sperm motility: Human spermatozoa were treated for 20 min at 
37
o
C with 100µM of Compound. (A) Compound tested (#b, #1 to #12). (B) Compound tested (#13 
to #24). (C) Compound tested (#25 to #36). (D) Compound tested (#37 to #43). 100% increase 
equal 2 fold increase in motility compare to 1% DMSO (i.e.: DMSO=15%-- treatment 30%). 
Green line indicates threshold for strong responder while red line is the threshold for background. 
Compound between green and red line indicates mild responder. n=3 (3 separate analysis on 
pooled sample) mean ±SD.  
D 
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APPENDIX 2 
 
Calculation of limit of quantification (LOQ) and limit of detection (LOD) 
 
Peak Area Concentration g/10mL 
Buffer A 11813979 0.001 
11813979 0.001 
11813979 0.001 
1186667 0.0001 
1186667 0.0001 
1186667 0.0001 
171994 0.00001 
171994 0.00001 
171994 0.00001 
11512 0.000001 
11512 0.000001 
11512 0.000001 
136 0.0000001 
136 0.0000001 
136 0.0000001 
SUMMARY OUTPUT 
Regression Statistics 
Multiple R 0.999990211 
R Square 0.999980423 
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Adjusted R 
Square 0.999978917 
Standard 
Error 21908.67737 
Observations 15 
ANOVA 
  df SS MS F Significance F 
Regression 1 3.18722E+14 3.19E+14 664018.7 5.40795E-32 
Residual 13 6239871875 4.8E+08 
Total 14 3.18729E+14       
  Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% 
Upper 
95.0% 
Intercept 14983.40652 6507.825867 2.302367 0.038489 924.1034935 29042.70954 924.1034935 29042.71 
X Variable 1 11798551487 14478998.5 814.8735 5.41E-32 11767271512 11829831462 11767271512 1.18E+10 
LOQ 5.51578E-06 
LOD 1.82021E-06 
RESIDUAL OUTPUT 
Observation Predicted Y Residuals 
1 11813534.89 443.8033241 
2 11813534.89 443.8033241 
3 11813534.89 443.8033241 
4 1194838.555 -8171.800262 
5 1194838.555 -8171.800262 
6 1194838.555 -8171.800262 
193 
 
7 132968.9214 39024.9429 
8 132968.9214 39024.9429 
9 132968.9214 39024.9429 
10 26781.958 -15270.03589 
11 26781.958 -15270.03589 
12 26781.958 -15270.03589 
13 16163.26167 -16026.91007 
14 16163.26167 -16026.91007 
15 16163.26167 -16026.91007 
Peak Area Concentration g/10mL 
Buffer B 11973342 0.001 
12029653 0.001 
12021529 0.001 
1237522 0.0001 
1236312 0.0001 
1232810 0.0001 
121084 0.00001 
121583 0.00001 
121758 0.00001 
12071 0.000001 
12143 0.000001 
12159 0.000001 
0 0.0000001 
0 0.0000001 
0 0.0000001 
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SUMMARY OUTPUT 
Regression Statistics 
Multiple R 0.999992899 
R Square 0.999985797 
Adjusted R 
Square 0.999984705 
Standard 
Error 18983.28259 
Observations 15 
ANOVA 
  df SS MS F Significance F 
Regression 1 3.29839E+14 3.3E+14 915290.7 6.71561E-33 
Residual 13 4684745233 3.6E+08 
Total 14 3.29843E+14       
  Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% 
Upper 
95.0% 
Intercept 8259.588492 5638.856941 1.464763 0.166748 -3922.421302 20441.59829 -3922.421302 20441.6 
X Variable 1 12002541293 12545664.7 956.7083 6.72E-33 11975438032 12029644554 11975438032 1.2E+10 
LOQ 4.69805E-06 
LOD 1.55036E-06 
RESIDUAL OUTPUT 
Observation Predicted Y Residuals 
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1 12010800.88 -37459.27137 
2 12010800.88 18852.45593 
3 12010800.88 10728.13186 
4 1208513.718 29008.60219 
5 1208513.718 27797.83876 
6 1208513.718 24295.99809 
7 128285.0014 -7201.461238 
8 128285.0014 -6702.416879 
9 128285.0014 -6527.027069 
10 20262.12979 -8191.521636 
11 20262.12979 -8118.851758 
12 20262.12979 -8102.949022 
13 9459.842621 -9459.842621 
14 9459.842621 -9459.842621 
15 9459.842621 -9459.842621 
Peak Area Concentration g/10mL 
Buffer C 19098941 0.001 
19250200 0.001 
19328191 0.001 
1891354 0.0001 
1912691 0.0001 
1916200 0.0001 
192660 0.00001 
193223 0.00001 
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194879 0.00001 
14274 0.000001 
18252 0.000001 
18874 0.000001 
2307 0.0000001 
1986 0.0000001 
2158 0.0000001 
457 0.00000001 
436 0.00000001 
446 0.00000001 
SUMMARY OUTPUT 
Regression Statistics 
Multiple R 0.999984205 
R Square 0.99996841 
Adjusted R 
Square 0.999966435 
Standard 
Error 41969.04487 
Observations 18 
ANOVA 
  df SS MS F Significance F 
Regression 1 8.92089E+14 8.92E+14 506465.6 1.94785E-37 
Residual 16 28182411641 1.76E+09 
Total 17 8.92117E+14       
  Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% 
Upper 
95.0% 
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Intercept -3010.091425 11085.50224 -0.27153 0.789453 -26510.30637 20490.12352 -26510.30637 20490.12 
X Variable 1 19227532462 27017713.79 711.6639 1.95E-37 19170257467 19284807456 19170257467 1.93E+10 
LOQ 5.76543E-06 
LOD 1.90259E-06 
RESIDUAL OUTPUT 
Observation Predicted Y Residuals 
1 19224522.37 -125581.0124 
2 19224522.37 25677.62573 
3 19224522.37 103668.3245 
4 1919743.155 -28389.01433 
5 1919743.155 -7052.06199 
6 1919743.155 -3543.060677 
7 189265.2332 3394.906913 
8 189265.2332 3957.314922 
9 189265.2332 5613.701034 
10 16217.44104 -1943.439923 
11 16217.44104 2034.144936 
12 16217.44104 2656.703601 
13 -1087.338179 3394.193688 
14 -1087.338179 3073.674896 
15 -1087.338179 3245.550834 
16 -2817.8161 3274.8161 
17 -2817.8161 3253.8161 
18 -2817.8161 3263.8161 
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APPENDIX 3 
Consent form for patient/donor participation in research 
 
ASSISTED CONCEPTION 
UNIT 
NHS TAYSIDE 
WARD 35 NINEWELLS HOSPITAL 
 DUNDEE DD1 9SY 
 
 Direct line (01382) 632111 
Fax (01382) 633853 
CONSENT FORM FOR PATIENTS/DONORS  
[producing extra semen samples]   
Title of research: Understanding the regulation of human sperm function and the development 
of novel treatments for male infertility. 
First of all we would like to thank you very much for taking part in our research project. 
The aim of this study is to understand how a sperm cell is activated in response to secretions 
from the female tract - progesterone and nitric oxide and to understand if this activation is 
abnormal in some men. In addition we would like to test enzyme inhibitors to see if we can 
enhance sperm motility and hope that in the future we may be able to develop drugs which may 
be able to improve IVF success. 
You may decline to take part, or withdraw at any time without this affecting, in any way, your 
treatment and care now or in the future. 
I have fully understood what will be involved in the project.  This study involves me producing 
a semen (sperm) sample by masturbation in the Assisted Conception Unit or by arrangement at 
home, for the research purposes of the project.  In the future there may be requests for further 
semen samples. 
 
Signed……………………………………………………………………………………. 
Name (block capitals)…………………………………………………………………….. 
Date………………………………………………………………………………………… 
Witnessed…………………………………(name)………………………………Signature 
 
If you have any further queries or questions you can contact either: Mr Steven Mansell (01382 
660111 ext. 33605) or Nurse Evelyn Barratt,  e.barratt@dundee.ac.uk 
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